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Abstract 
Colorectal cancer (CRC) is a significant cause of mortality. In the UK, 1 in 14 men 
and 1 in 19 women will develop CRC in their lifetime. Overall, five-year survival 
is 60% and this compares poorly to many countries in Western Europe. Survival is 
directly linked to stage at presentation. The majority present at Dukes stage B or 
above. Better methods of detecting CRC at an earlier stage are needed to improve 
survival figures.  
Published evidence on the two-week wait pathway (TWW) for detecting CRC was 
evaluated using a systematic review. This showed low CRC detection and no 
difference in stage at presentation in the TWW group compared with the non-TWW 
pathways of referral. These results indicate the emphasis on TWW targets is not 
justified and should prompt consideration of better methods of risk stratification for 
those with suspected CRC. 
Biomarkers have the potential to improve the positive predictive value of referral 
criteria in the symptomatic population and also increase the sensitivity of the faecal 
occult blood test when used as an adjunct in the bowel screening population. Two 
potential urinary biomarker groups in the detection of CRC were explored: one 
based on volatile organic compounds (VOCs) and one on peptide markers. Analysis 
demonstrated that CRC could be correctly classified from control using a VOC or 
peptide biomarker-based test with a high degree of accuracy in pilot work. Further 
protein analysis using immunohistochemistry explored the role of Meprin alpha in 
the pathology of CRC with possible implications in aggressive disease. 
There is a need for better ways of detecting CRC and biomarkers hold huge 
potential. But there must be a culture change from the current fragmented approach 
to elucidating diagnostics in CRC. Collaborations between research groups and 
data-sharing is essential to validate pilot studies and share knowledge on 
methodology and results.   
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1.1 Clinical Scope 
Colorectal cancer (CRC) is a leading cause of cancer-related deaths in the Western 
world with highest rates in North America, Europe and Australia  (1, 2). It 
represents the fourth most common cancer in England and Wales and is the second 
leading cause of cancer-related deaths(1). There were 41,265 new cases in 2014, 
and it makes up over 10% of all cancer diagnoses in the England and Wales 
population. Like many cancers, CRC predominantly affects older age groups, 
especially people aged 60 years or older, with peak rates of 85-89 years (3). The 
incidence has remained relatively consistent over the past 20 years, although there 
has been a downward trend in mortality for both males and females (figure 1.1) (4). 
Figure 1.1. CRC incidence and mortality. Directly age-standardised rates per 
100,000 population of newly diagnosed cases of CRC and deaths from cancer (4). 
 
 
Currently, the overall five-year survival is approximately 50% (5, 6). Survival is 
high for early stage disease but declines sharply with advancing stage at diagnosis 
as shown in table 1.1 (3).  
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Table 1.1. Five year relative CRC survival by stage for adults in England, 2002-
2006 (3). 
Stage Men Women 
Stage I 94.6 100.2 
Stage II 83.5 85.9 
Stage III 62.6 62.7 
Stage IV 6.9 8.1 
All Stages 58.2 61.1 
Stage Not Known 18.7 15.1 
 
Despite rising awareness of CRC, the majority of patients present at Dukes stage 
B/stage ii or above, this is represented graphically in figure 1.2. The United 
Kingdom (UK) survival figures fall short of many of our Western European 
counterparts (5, 7, 8). Wales has the poorest survival in the UK with figures similar 
to Estonia and Croatia rather than Germany and Switzerland (figure 1.3). It has been 
estimated that 10,000 deaths could be avoided each year if the cancer mortality 
figures were similar to the lowest rates in Europe (6).  
 
 
 
 
 
 
 
 
26 
 
Figure 1.2. Proportion of CRCs Diagnosed at Each Stage, All Ages, England 2014 
(3) 
 
Figure 1.3. Age-Standardised CRC Five-Year Relative Survival, Adults in 
European Countries, 2000-2007 (9) 
 
Although it is a complex issue, the UK’s poor performance in Europe is thought, in 
part, to be related to a disproportionately high number of patients presenting at an 
advanced stage or as an emergency and possibly due to delays in treatment (10). 
Approximately 25 % of patients with CRC present as an emergency: this proportion 
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rises in the elderly and is higher than in many other common cancers (3). This has 
a direct effect on one-year survival rates: 48% in those presenting as emergencies 
compared with 73% through other routes of presentation (5). The early recognition 
of symptoms and prompt diagnosis are essential in reducing mortality (11). 
The financial burden associated with CRC is significant. It is estimated that total 
CRC cost amounts to £1.6 billion per year in the UK. This includes the economic, 
healthcare and the unpaid care costs provided by family and friends (12). 
In view of the impact of CRC and the need to address survival figures, this thesis 
re-evaluates the referral pathways for CRC, using a systematic review and meta-
analysis. The emerging advances in the diagnosis of CRC, are investigated through 
a series of practical experiments. This work is intended to demonstrate progression 
in the understanding of the diagnostic options in this disease and set the foundations 
for further experimental work in bio-marker diagnostics.  
 
1.2 Research Aims 
1. To comprehensively evaluate the evidence reported on CRC detection using 
the two-week wait (TWW) referral pathway. 
2. To perform a detailed analysis of the methods used for urinary volatile 
organic compound (VOC) detection in CRC.  
3. To evaluate the utility of urinary VOC detection-based technology as a 
diagnostic tool in CRC applied to both the symptomatic and asymptomatic 
population. 
4. To evaluate the utility of urinary peptide markers as a diagnostic tool in 
CRC and evaluate the role of target proteins in the pathogenesis of the 
disease.  
 
1.3 Thesis structure 
Chapter Two is a literature review which explains the pathophysiology, diagnosis 
and treatment of CRC as this disease is central to the thesis. The current UK routes 
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to diagnosis of the disease are highlighted to provide the background for the work 
carried out in Chapter Three. The later part of the literature review focusses on the 
theory and research into the two areas of CRC biomarker development that form 
the experimental work in this thesis, namely VOCs and peptide markers.  
In Chapter Three the results of a systematic review and meta-analysis are presented. 
This chapter investigates, for the first time, the key outcome measures in the fast-
track referral of patients with possible CRC. The impact of these results is explored 
and recommendations for improvement and development of the pathway are 
detailed 
Chapter Four is the first of two chapters investigating the volatile content of urine 
headspace for VOCs. This chapter provides an in-depth analysis of the 
methodology used in this relatively new technology with a series of experiments 
that contributed improvements in urine sampling and analysis. It provides a hands-
on guide for other researchers also utilising this technology. 
The experimental work on VOCs is continued in Chapter Five with focus on CRC 
cases. Several experiments involving symptomatic and asymptomatic patients with 
the disease are presented. These are the first results to present data on the bowel 
cancer screening population.   
Another relatively new and exciting technology in CRC diagnosis using urine is 
evaluated in Chapter Six. Firstly, capillary electrophoresis coupled to mass 
spectrometry is used to detect peptide markers unique to CRC and a peptide-based 
diagnostic test is proposed. Following sequencing of these peptides, the role of the 
corresponding proteins are considered in the pathology CRC.  
The results of the tested technologies and diagnostic pathways and the impact these 
have on CRC diagnosis are debated in the concluding chapter and suggestions are 
made for ongoing research.   
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1.4 Conclusion 
 
The impact of CRC on morbidity and mortality is significant. Research into more 
effective ways of diagnosing patients, particularly at an earlier stage, is vital to 
improving the survival figures. The following four results chapters aim to approach 
different aspects of CRC diagnosis. From pathway development, for streamlining 
symptomatic patients, to advances in laboratory based biomarkers using the newest 
emerging techniques that could have a direct benefit to patients.  
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CHAPTER 2:  
Literature review 
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2.1 The anatomy of the colon 
The colon, or large intestine, is situated in the lower abdomen. It is the final part of 
the digestive tract and forms the connection between the small intestine and the anal 
canal. It is comprised of the following sections; Caecum, Ascending colon, 
Transverse colon, Descending colon, Sigmoid colon and Rectum (figure 2.1) and 
measures around 150cm in length (13). Blood supply arises from the Superior 
Mesenteric Artery and Inferior Mesenteric Artery. The colonic wall is composed of 
four layers: the mucosa, submucosa, muscularis and adventitia. The surface 
epithelium is simple columnar cells (14). The colon functions mainly to absorb 
water and acts as a storage compartment for faeces prior to evacuation. 
Figure 2.1 Anatomy of the colon with labelled constituent parts (15).  
 
2.2 Colonic polyps 
Polyps are a mass of tissue that protrudes into the colonic lumen. The 
characterisation of polyps relates to their size, whether they have a stalk 
(pedunculated) or are flat (serrated) and their overall appearance (figure 2.2). In 
general terms polyps can be divided into neoplastic (adenomas and carcinomas) and 
non-neoplastic (hyperplastic, juvenile,Peutz-Jeghers and Inflammatory) (13).  Most 
polyps are asymptomatic, although due to their protuberance, they can ulcerate, 
causing pain or bleeding.  
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Figure 2.2 A picture of a pedunculated adenomatous rectal polyp (patient 
permission granted).  
 
 
 
Adenomas are the most common neoplastic polyp and are by definition dysplastic 
(16). Dysplasia is defined as an alteration in size, shape, and organization of 
an adult cell. Most CRC arises from adenomas, but most adenomas have a benign 
course, with only five percent progressing to cancer (13, 16). Adenomas are more 
common in men and with increasing age, affecting up to 50% of those over 70 years 
of age (16, 17). They are commonly categorised by size into three groups: less than 
1cm, 1-2cm and greater than 2cm. Most are less than 1cm in size, increasing size is 
associated with a higher risk of progression to cancer. Other factors determining the 
potential to progress to cancer are histological type and degree of dysplasia (18). It 
is thought that progression from adenomatous polyp to carcinoma in susceptible 
individuals takes at least five years (18).  
Adenomatous polyps are thought to arise due to a disruption in the usual process of 
cell proliferation and cell death. It is uncontested that most carcinoma arises from 
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adenomas (19). The adenoma-carcinoma sequence describes the progression from 
normal epithelium to dysplastic and then subsequent carcinoma (figure 3).  
 
Figure 2.3. The adenoma-carcinoma sequence (adapted from Fearon and 
Vogelstein) (20) 
 
Developed by Fearon and Vogelstein (20), there is a robust body of clinical, 
epidemiological, pathological and molecular genetic evidence to support the 
adenoma-carcinoma sequence:  
 
1. The prevalence of adenomas in a population parallels the incidence of CRC 
(19).   
2. The anatomical distribution of adenomas and cancers appears to be similar, 
with the majority found distal to the splenic flexure, in the left colon (21). 
3. Patients with polyposis syndromes such as Familial Adenomatous Polyposis 
(discussed later) will develop CRC. Also studies have shown that if 
adenomas are removed then the rate of colon cancer declines (22-24). 
4. Pathological investigations show it is very unusual to find a focus of cancer 
in otherwise normal colonic mucosa, secondly there is often a degree of 
adenomatous tissue residing in a CRC (19).  
5. It is well-known that genetic abnormalities play a key role in cancer 
development. Support from molecular genetic evidence has mapped the 
series of genetic alterations in the evolution of adenoma to carcinoma. In 
normal circumstances oncogenes stimulate cell growth, however 
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uncontrolled cell growth can result if mutation or overexpression of the 
genes occurs (19). In opposition to oncogenes, tumour suppressor genes 
work to inhibit cell cycle progression or promote apoptosis: disruption of 
these genes results in loss of normal inhibitory control. Another important 
gene type are Deoxyribonucleic acid (DNA) repair genes which control the 
rate of genetic mutation. Damage to these means mutations can occur in an 
uncontrolled manner (18). The key genetic abnormalities related to CRC 
are: 
a) Mutation in the K-ras oncogene (25).  
b) Inactivation of tumour suppressor genes: The most important of which 
is thought to be APC (adenomatous polyposis coli). Other genes thought 
to play a key role include DCC (deleted in colon cancer), TP53, SMAD2 
and SMAD 4 (26).  
 
The detection of adenomas is mainly achieved via endoscopy (specifically 
colonoscopy or flexible sigmoidoscopy) which is considered to be the gold standard 
(27). Targeted bowel imaging such as Computed Tomography Colonography 
(CTC) can also detect polyps with accuracy (28). However, this method is limited 
to detection only as polyps need to be removed using endoscopy.  Due to the clear 
link between adenomas and cancer, there are stringent guidelines both in the UK 
via the British Society of Gastroenterology (BSG) and internationally, to advise on 
endoscopic follow up of patients found to have adenomatous polyps on 
colonoscopy. The larger a single polyp and/or the higher the number of polyps, the 
more frequently they will be recalled for follow-up colonoscopy, as shown in figure 
2.4.  
 
 
 
 
 
 
 
35 
 
Figure 2.4. The BSG CRC screening and surveillance flowsheet (27). 
 
 
2.2.1 Colonic polyposis syndromes and Lynch syndrome 
Colonic polyposis is the term given to multiple polyps present throughout the colon. 
They are classified based on histological type and certain characteristic features 
(29). Polyposis syndromes are thought to contribute to between 5-15% of all CRCs 
(30). Most are inherited, cancer risk is higher in almost all of these syndromes.  
The most common inherited polyposis syndrome is Familial Adenomatous 
Polyposis (FAP). It is caused by a germline mutation in the APC gene, located on 
chromosome 5q21-922 (31). It is inherited in an autosomal dominant manner and 
has between 80-100% penetrance (32). It affects both sexes in equal proportion with 
a prevalence of 1 in 5000 to 7500 (29). Multiple mutations have been identified. 
FAP is characterised by the development of hundreds of adenomas in the second 
and third decade of life; without treatment almost all those affected will develop 
CRC (33, 34), with average age at developing malignancy of 39. Other extra-
colonic features include upper gastrointestinal polyps, thyroid nodules and brain 
tumours (35). The diagnosis is made using colonoscopy, where multiple polyps are 
visualised. The treatment involves surgery to remove the entire colon and rectum 
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(total proctocolectomy). There are several variants of FAP that form syndromes, 
characterised by the presence of colonic adenomas and specifically defined 
extracolonic manifestations, for example CHRPE (congenital hypertrophy of the 
retinal pigment epithelium) (36) and Gardner’s syndrome (osteomas, fibromas and 
sebaceous cysts) (37). Genetic testing of relatives is essential as stringent bowel 
surveillance is required in all those affected. 
MUTYH polyposis results from mutation of the MUTYH gene, which is 
responsible for repair of genetic mutations.  It is recessively inherited and 
characterised by multiple adenomas but usually fewer than 100 (33). The affected 
individuals have a 60-70% risk of developing CRC (33).  
Hamartomatous polyposis syndromes include Peutz-Jeghers syndrome, juvenile 
polyposis syndrome, hamartoma tumour syndromes and other rare syndromes (13). 
Most confer an increased risk of developing CRC (34). 
Serrated polyposis syndrome (SPS) is a more recent discovery and is defined by the 
World Health Organisation (WHO) as either a) at least five histologically diagnosed 
serrated polyps proximal to the sigmoid colon, with at least two larger than 10mm 
b) any number of serrated polyps proximal to the sigmoid in a person with a first-
degree relative with SPS; or c) more than 20 serrated polyps of any size distributed 
throughout the colon (38).  In general they are more difficult to detect than 
pedunculated polyps as they lie flat on the colonic mucosa. The previous 
understanding was that small serrated (flat) polyps were thought to be most likely 
hyperplastic and therefore run a benign course. However it has been increasingly 
recognised that CRC can develop from serrated lesions with the 5-year cancer risk 
reported as high as 7% (38, 39).  
The most common cause of inherited CRC is not a polyposis syndrome. Hereditary 
nonpolyposis colorectal cancer (HNPCC) or Lynch syndrome is an autosomal 
dominant condition caused by germline mutations in one of the DNA mismatch 
repair (MMR) genes (40). MMR genes function to repair errors occurring during 
DNA replication. Interruption in this repair process leads to microsatellite 
instability (MSI) which is a key feature of this syndrome (34). It accounts for 3-5% 
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of newly diagnosed CRC (19, 40). Sufferers have up to 47% lifetime risk of 
developing CRC (41), they are also at an increased risk for synchronous (second 
cancer occurring at or within six months of surgical resection from index cancer) 
and metachronus (CRC occurring more than 6 months after surgery for index case) 
CRCs  and are predominantly located in the right colon. The average age at CRC 
development is 45 years (30), with the progression from adenoma to carcinoma 
occurring much more rapidly in Lynch syndrome (34).  Extracolonic manifestations 
include endometrial cancer and malignancies of the pancreas, breast and cervix. 
Current UK colonic screening guidelines recommend at least biennial colonoscopy 
(27) and have been found to decrease mortality (42). 
Hereditary CRC syndromes are being increasingly identified due to better 
awareness, clear screening guidelines as outlined in by the British Society of 
Gastroenterology and the investigation for MSI by histology departments routinely 
on identification of a colonic tumour to detect previously unrecognised Lynch 
syndrome. Timely identification allows early screening and cancer detection both 
in the colon and in other high risk sites such as the upper GI tract, but also pre-
emptive planning for preventative surgery where appropriate.  
Following on from the previous sections on pathological and genetic pathways to 
CRC, the disease will now be discussed in detail. 
2.3 Colorectal cancer  
2.3.1 Pathology 
Colorectal (bowel) cancer affects any part of the colon or rectum and cancers are 
most commonly found distal to the splenic flexure with around 25% affecting the 
sigmoid colon and 30% affecting the rectum, depending on the patient’s sex.  
Carcinogenesis is a multistep process, which results in the uncontrolled growth of 
cells. More than 90% are adenocarcinomas and as discussed above, most of these 
arise from adenomatous polyps (43) (figure 2.5).  
A cancer starts as an intramucosal epithelial lesion. Advancement results in 
penetration of the muscularis mucosae with subsequent invasion into the lymphatics 
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and vasculature. The pattern of spread depends on the cancer site. Due to the portal 
venous system, the liver is the most common site of haematological spread (13).  
Figure 2.5. A picture of a colonic adenocarcinoma detected at colonoscopy 
(patient permission granted) 
 
2.3.2 Staging  
Two staging systems are widely used to classify affected individuals. In 1929, 
Cuthbert Dukes proposed a staging classification. Following several modifications, 
the Astler and Coller classification described in 1954 is most readily used and 
divides cases into one of three categories: Dukes A –the tumour is limited to the 
mucosa, Dukes B – Invasion through to muscle layer without lymph nodes 
involved. Dukes C – Involvement of lymph nodes. Dukes D was added in the 1970s 
by Whittaker and Goligher and describes the presence of distant metastases (44). 
The American Joint Committee on Cancer (AJCC) introduced the TNM staging 
classification for CRC (45), this gives information on the primary tumour (t), the 
status of regional lymph nodes (n) and the presence or absence of distant metastases 
(m). Using the TNM information cases are then grouped into one of five stages. 
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Staging is an important way to categorise cases for prognostication, to guide 
treatment and to group patients for clinical trial purposes.    
2.3.3 Aetiology 
Environmental factors appear to play a large role in cancer development. This is 
evidenced by the regional variations across the world but also variations seen within 
the UK (46). As mentioned, CRC is predominantly a disease of the elderly and is 
the result of environmental, dietary and genetic factors coupled with other as yet 
un-explored susceptibility factors. It is thought sufferers require an accumulation 
of multiple cell defects with mutational activation of oncogenes together with 
inactivation of tumour-suppressor genes in order to develop malignancy (43). In 
this section the factors that have been thought to influence CRC will be discussed.  
2.3.3.1 Diet 
Diet seems to play a significant role in the development of CRC, as evidenced by 
higher disease rates in areas where total fat consumption is high such as the UK and 
the US. Data suggests that obesity is associated with a small increased risk of CRC 
(47). It is proposed that dietary fat enhances hepatic cholesterol and bile acid 
synthesis, increasing the amount of sterols in the colon. This increase in sterol 
metabolites and bile acids seems to damage the colonic mucosa and increase 
proliferative activity of the epithelium (13). There has been enough evidence of a 
link between consuming processed red meat and CRC that the WHO’s international 
agency for research on cancer have classed them as Group one carcinogens, albeit 
with a low risk association (48). Risk seems to be highest with left sided tumours 
and high cooking temperature is associated with the greatest risk, perhaps due to 
the production of carcinogens during the charring process. A multitude of evidence 
has linked dietary fibre to reduced levels of CRC, however, high dietary fibre is not 
associated with an additional drop in risk (49). It is not clear which fibres hold the 
most benefit, but it has been suggested that whole grains are particularly beneficial 
(50). Dietary fibre resists digestion, its protective role is not completely understood 
but theories include increasing stool bulk, dilution of colonic carcinogens together 
with promoted elimination which serves to minimise contact with mucosa. Finally, 
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the fermentation process of fibre by gut bacteria to short chain fatty acids is 
protective (13, 50). Coffee, fish oil and selenium have also been suggested to 
provide benefit in CRC development, but this has not yet been substantiated by high 
quality evidence. 
Epidemiological studies have shown a link between dietary fruit and vegetable 
intake with a risk reduction (51, 52), the relative risk is 0.5 when comparing those 
with  the highest intake to those with the lowest (53). It is postulated that the cancer 
protection is due to the antioxidant plus other anticarcinogenic components of fruit 
and vegetables (51). 
2.3.3.2 Lifestyle factors 
There is a clear link between smoking and alcohol consumption and the 
development of CRC. Tobacco is associated with an increased risk of and mortality 
from CRC. Smoking is also a risk factor for all types of polyps (54). Several studies 
have linked moderate to high alcohol consumption with CRC (55). Alcohol is 
broken down into acetaldehyde and this has a toxic effect on the colonic epithelium 
(51). The effect of alcohol on cancer risk seems most pronounced in the distal colon. 
Finally, physical activity has an inverse relationship with CRC risk. 
In summary diet and lifestyle factors hold significance in the development and 
progression of CRC and our understanding of the mechanisms behind this is 
growing. Multiple research groups are continuing to investigate these factors and 
enhance our current understanding further.   
2.3.3.3 The microbiome 
The human microbiome is the aggregate of the entire community of microbes in the 
body. There are approximately 100 trillion microbial cells in the human body, 
which outnumbers human cells ten to one (56). The skin and gut are the primary 
sites of microbe colonisation. Given the number of microbes present, it is no 
surprise that the microbiome has a significant effect on human physiology. The 
body’s relationship with it’s own microbial community is a delicate balance and 
alterations or ‘dysbiosis’ have been linked to diseases such as inflammatory bowel 
disease (IBD), bile acid malabsorption, diabetes and asthma (57-59).  
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Several decades ago, it was recognised that CRC not only alters gut flora, but also 
as a consequence, bodily excretions such as breath, urine and blood. Haines et al 
published a small study in 1977 measuring the methane concentrations of patients 
breath with and without CRC and found a much higher proportion with CRC had 
detectable levels of methane on their breath (60). The surface of the colonic 
epithelium is exposed to intricate and complex bacterial communities and it has 
long been suggested that gut microbiota are an important contributor to the health 
and disease of the gut. Protection occurs by way of preventing overgrowth of 
pathogens, influencing the development of the innate and adaptive immune system 
and also provides energy and nutrition to the host.  
The identification of key bacteria has developed over the last few years. 
Understanding of the gut bacterial community comes from stool testing and 
evaluation of colonic biopsy specimens. Increases in Escherichia coli levels have 
been linked to IBD and also colitis-associated CRC (61, 62) as have reduced levels 
of Faecalibacterium prausnitzii or Clostridium clusters; both changes lead to a link 
between dysbiosis and increased risk of CRC. Enterococcus faecalis is thought to 
release extracellular superoxide which can convert to hydrogen peroxide with 
subsequent DNA damage and chromosome instability (63, 64).   
 
Ongoing work into this vast microbial community will improve our understanding 
of the role of bacteria in health and disease, as the primary function of the majority 
of the gut bacteria remain largely unclear.  
 
2.3.3.4 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) encompasses Ulcerative colitis and Crohn’s 
Disease and increases the risk of CRC, accounting for approximately 2% of CRC 
cases (65). The latest evidence suggests a cancer or dysplasia risk of 7.7% at 20 
years and 15.8% at 30 years (27). Risk is linked to duration of colitis and the extent 
and location of the inflammation, as right sided involvement is associated with a 
higher risk of developing cancer. There is a well-established endoscopic 
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surveillance programme in the United Kingdom last updated by the BSG in 2009. 
This involves a colonoscopy at 8-10 years from diagnosis (27). The interval to next 
endoscopic assessment is dictated by a combination of endoscopic and histological 
evidence of inflammation coupled with individual patient risk factors (those with 
family history or concomitant Primary Sclerosing Cholangitis (PSC) are screened 
more frequently). 
2.3.4 Chemoprevention 
Chemoprevention refers to the use of natural or synthetic chemical compounds to 
reverse, suppress or prevent progression to invasive cancer (66). The results from 
trials using Aspirin and NSAIDS have shown the most promise. Case-control and 
cohort studies have demonstrated reductions in incidence of CRC of up to 50%, 
together with reduction in mortality also observed (67). Although the mechanism is 
not fully understood, COX-2 has been found to be overexpressed in colonic 
adenomas and carcinomas. It is thought that these drugs induce apoptosis, and via 
blockage of cyclo-oxygenase-2 (COX-2) tumour cell growth is inhibited (68). 
Indeed there has been some more recent trial evidence of a role of COX-2 inhibitors 
in the reduction of number and size of colonic adenomas; Celecoxib, a COX-2 
inhibitor is now approved as an adjunct to standard therapy in patients with FAP 
(13).  
Use of  5- Aminosalicylic acid (5-ASA) therapy has been found to be protective in 
some studies (69). 5 ASA’s are a derivative of aspirin and seem to have both 
molecular and genetic effects on cancer prevention (70). 
Several trials have seen a benefit of calcium supplementation in the prevention of 
CRC, with a relative risk (RR) 0.80 (71). The American College of 
Gastroenterology have recommended calcium supplementation for the primary and 
secondary prevention of colonic adenomas (72). Opinion on the effect of vitamin D 
supplementation is inconsistent (73).  
Folic acid supplementation has gained popularity in the prevention of CRC, but 
results are conflicting and it may depend if intake is increased by dietary sources or 
through tablet form. Folate is essential for a number of critical cellular metabolic 
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pathways, deficiency may contribute to DNA damage, instability of chromatin, 
impaired DNA repair or aberrant patterns of genomic and/or gene-specific DNA 
methylation. All these processes can promote carcinogenesis (51). Observational 
data suggesting a protective effect has not been substantiated by large-scale 
randomised studies therefore it cannot be recommended as a routine supplement, in 
fact paradoxically, there has been some evidence that supplementation can be 
harmful (74). 
Other drugs under investigation include the ornithine decarboxylase inhibitor 
difluoromethylornithine (DFMO) (75)(meyskens), the bile acid ursodiol, epidermal 
growth factor receptor (EGFR) inhibitors and 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) inhibitors, which are commonly known as statins (76, 
77).  
The next section will cover the treatment of CRC. Diagnosis will be explored in the 
subsequent section as it links directly with the review of novel diagnostic markers 
that features towards the end of this chapter. 
2.3.5 Treatment 
2.3.5.1 Surgery 
Treatment is heavily dependent on stage at diagnosis. Surgical resection is usually 
the treatment of choice in those with non-metastatic disease. A wide resection of 
the affected colon is made with removal of lymphatic drainage. Resection margins 
are dependent on the blood supply and regional lymph node distribution (78). 
Where possible laparoscopic resection is recommended as it is associated with a 
faster recovery without any detrimental affect on recurrence or survival (79, 80). 
Even in patients with metastatic disease it is common practice to remove the 
primary tumour to prevent complications such as bowel obstruction and bleeding 
(13).  
There is an increasing role for surgery in treating hepatic metastases in carefully 
selected individuals who have no evidence of extra-hepatic spread. Now 7% of 
patients with liver metastases are being considered for hepatic resection (81). Less 
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common is resection of pulmonary metastases, however there has been 
demonstration of improved survival (82).  
2.3.5.2 Chemotherapy 
There are a number of chemotherapy regimes, the most convincing evidence of 
benefit is seen in those with stage III disease. It remains controversial in stage II 
disease but should be considered in those with high-risk features (81). Drug regimes 
are frequently superseeded by more efficacious combinations based on new trial 
evidence. Both adjuvant therapy (chemotherapy used in addition to surgery) and 
neoadjuvant therapy (given prior to surgery) are both used. Neoadjuvant therapy is 
commonly used for rectal cancer, but it is not fully clear which of those in the non-
rectal CRC group would benefit, therefore the traditional approach would be en-
bloc resection followed by adjuvant chemotherapy (81). Chemotherapy has a 
significant role in metastatic disease too but with modest effects on survival, with 
one meta-analysis demonstrating 3.7 months additional median survival compared 
to no treatment (83). 
Future advances in the understanding of CRC may allow a more individualised 
approach to treatment based on anatomical and biological features (84). For 
example: histological features such as poor-differentiation, signet ring or colloid 
tumours which are associated with poorer prognosis may be associated with more 
favourable outcomes in stage ii disease if adjuvant chemotherapy is used.  
2.3.5.3 Radiotherapy 
Radiotherapy is used to decrease local recurrence of rectal cancers that have 
penetrated the bowel wall or are associated with regional lymph node involvement. 
It can also be used for symptomatic relief of rectal bleeding in palliative cases (85).  
2.3.5.4 Other therapy 
Monoclonal antibodies have been used to disrupt tumour growth and are used in the 
treatment of advanced CRC. Examples include Bevacizumab that targets VEGF 
and Cetuximab which targets EGFR (86, 87).  
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Treatment for CRC is continuously under review and subject to the latest evidence 
that guides changes. The path to diagnosis of CRC is varied depending on many 
factors including whether the patient has symptoms or not and encompasses correct 
utilisation of current biomakers in clinic practice. The next section will discuss the 
main pathways, and sets the scene for the subsequent discussion on evolving 
biomarker research.  
2.4 Diagnosis of colorectal cancer  
CRC’s are slow growing and can often go unnoticed by the patient for several years. 
Asymptomatic patients may have occult blood loss and develop anaemia. Some 
with anaemia may develop constitutional symptoms such as shortness of breath or 
fatigue. Common symptoms include change in bowel habit which is more common 
with left sided tumours, bleeding per rectum (37%) or vague abdominal discomfort 
(34%) (88). Symptomatic patients tend to have a poorer prognosis. More advanced 
cases may present as emergencies with obstructive symptoms, such as abdominal 
pain, distention, vomiting and absence of bowel movements as the tumour affects 
a large proportion of the bowel lumen. Approximately 25 % of patients with CRC 
present as an emergency (3). All symptoms associated with CRC can be found in 
other, more common bowel conditions, making the diagnosis notoriously difficult 
based on clinical symptoms alone. 
Endoscopic investigation of the bowel with flexible sigmoidoscopy or colonoscopy 
is generally accepted as the test of choice for CRC. It is the only means of obtaining 
a tissue diagnosis through biopsy and can also diagnose concurrent adenomas, with 
the potential for them to be removed during the procedure. Imaging of CRC’s has 
progressed over the last few decades, a Barium enema which was once used 
routinely in the investigation of bowel symptoms has almost completely been 
superseded by the more sensitive CT Colonography (CTC) (89). In contrast to a 
traditional CT, the Colonography provides an endo-luminal perspective of the colon 
and is highly accurate with CRC detection rates over 95% (90) and polyp detection 
rate is also very good. Patient acceptability for CTC is high (91) and it can be used 
as an alternative to colonoscopy in more frail, elderly patients. However full bowel 
46 
 
preparation is still required, there is radiation exposure and there is a chance of 
requiring an endoscopy following this test if an abnormality is found.  
Laboratory tests are a useful adjunct in assessing for anaemia and liver function 
where metastatic disease may be suspected, but have little diagnostic ability in 
isolation and lack sensitivity (13).  
2.4.1 Tumour and biomarkers 
According to the National Institute of Health, ‘a biomarker is a biological molecule 
found in blood, bodily fluids or tissue that is a sign of a normal or abnormal process, 
or of a condition or disease’ (92). Biomarkers are being increasingly used in the 
diagnosis and monitoring of disease. Although biomarkers generally refer to DNA, 
ribonucleic acid (RNA), microRNA epigenetic changes or antibodies, tumour 
markers can be considered as biomarkers attributed to the development of 
carcinogenesis 
Tumour-associated antigens (TAAs) are molecules produced by both normal and 
neoplastic cells but at much higher levels in tumour cells. Carcinoembryonic 
Antigen (CEA) is the most well-known tumour marker associated with CRC. It was 
discovered over 50 years ago and is still the only tumour marker recognised to have 
efficacy in monitoring patients with CRC. It is an oncofoetal protein that rises in 
the serum of patients with a number of cancers such as pancreas, stomach, lung, 
breast and bladder. It has no role in the diagnosis of CRC due to low sensitivity and 
specificity (93, 94), sensitivity ranges between 32% and 69% and is highly 
dependent on tumour stage (13). CEA is useful in the monitoring of patients with 
metastatic disease. Rising levels are likely to indicate disease progression and 
should prompt re-evaluation and possible treatment change (94). CEA monitoring 
following curative resection has been shown to detect recurrent disease earlier than 
would be found at routine follow up (95, 96).  
Cancer antigen 19-9 ( CA 19-9) is a glycoprotein found in serum that currently has 
no role in the monitoring of CRC, it has inferior sensitivity to CEA and there is no 
published literature to support its use in any aspect of CRC diagnosis or surveillance 
(94, 97). Many other protein biomarkers have been and are currently under 
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investigation for their use in CRC diagnosis, but none are recommended for current 
use, these are discussed in more detail in section 2.7.1. CA-72 also has poor 
sensitivity and currently has no use in clinical practice in isolation (97). It may be 
in future a combination of tumour antigens can be used to provide a tumour antigen 
profile for the patient which may improve diagnostic accuracy, but this is still work 
in progress (97). 
Faecal calprotectin (FCP) is excreted in excess into the intestinal lumen when 
inflammation is present (98). Its use in IBD is now well established, as evidenced 
by its role in both European and American IBD guidelines but more recently there 
has been interest in the potential clinical application of FCP as a diagnostic adjunct 
in other pathologies of the GI tract such as microscopic colitis (99), but most 
prominently in CRC. FCP levels have been found to be elevated in neoplasia, yet a 
meta-analysis found no significant difference in FCP levels between CRC and 
controls (100).  
Tests involving DNA, RNA and protein biomarkers in stool and blood are being 
investigated. Biomarker stool tests work on the principle that colorectal neoplasms 
shed surface cells into the stool. DNA can then be isolated from these cells and 
tested for mutations and genetic alternations that occur during carcinogenesis (101).   
For example, detection of methylated SEPT9 DNA in blood yielded a CRC 
sensitivity of 48% (102), although this does not compete with the sensitivity of the 
FIT or even the FOBT, ongoing research means newer blood and stool biomarkers 
with better sensitivity and specificity are likely to emerge in the future (103) and 
work in this area forms the basis of the majority of experimental work in this thesis.   
Microsatellite instability (MSI) describes the changes in coding and non-coding of 
repeated DNA sequences. These sequences can be exposed to errors in the mutation 
repair system resulting in the loss of, or multiplication of nucleotide sequence 
repetitions. Mismatch Repair Genes (MMR) serve to eliminate mutations causing 
these sequencing errors. Microsatellite instability can be classed as high (MSI-H) 
or low (MSI-L). Studies have demonstrated a protective effect if MSI-H was present 
in tumour cells in CRC stage ii and iii with improved survival (104-106). However 
results when looking at MSI status and chemotherapy regime have demonstrated 
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mixed results, with studies showing both a better and worse response to 5-FU based 
chemotherapy with MSI-H (107, 108). As mentioned previously, following analysis 
of clinical and cost effectiveness, in 2017 NICE recommended universal testing for 
MMR status for all colonic tumours with the purpose of detecting Lynch syndrome 
(109). 
Loss of heterozygosity on chromosome 18q (18qLOH) in the coding place of 
SMAD 4 proteins specific to CRC has been a factor of interest as a prognostic 
marker particularly in CRC stage ii and iii. A systematic review by Popat has 
demonstrated poorer survival in those with 18q chromosome deletion(110). 
Research groups have also looked at the role of 18qLOH in predicting response to 
chemotherapy (111), but there has not been strong enough evidence to date, to base 
therapeutic decisions on.  
Mutation of the p53 tumour suppressor gene is present in 50-70% of all CRC and 
is associated with a worse outcome. An international collaborative study found p53 
mutations present in 34% of proximal tumours, and 45% of all distal and rectal 
cancers with overall worse survival (112).  
Several biomarkers have demonstrated promise when used to predict efficacy to 
certain treatments. For example the KRAS mutation on the short arm of 
chromosome 12 is associated with non-response to Cetuximab and Panitumumab.  
Uridine diphosphate glucuronosyl transferase 1A (UGT1A1) gene polymorphism 
is associated with higher Irinotecan toxicity and knowledge of its presence can aid 
in dosing decisions (113, 114).  
CRC is a heterogeneous disease with survival outcomes heavily influenced by cell 
type and stage at diagnosis. It is hoped in the future, with greater understanding of 
the genetics and biomarker profile of CRC, that treatment can be personalised based 
on a patient’s own tumour profile using genomic and proteomic approaches. The 
expanding research into biomarkers in CRC diagnosis, prognosis and treatment is 
an exciting development into the understanding of CRC and will hopefully lead to 
more individualised therapy with improved outcomes where a prognostic panel of 
biomarkers are available. Tumour phenotyping with chemotherapy matched 
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accordingly is perhaps the next step in therapy. Bowel cancer screening using faecal 
tests will be discussed in detail below.  
2.5 Diagnostic pathways in colorectal cancer 
Two strategies are widely used to improve CRC prognosis and to optimise the 
health resources consumed: Population-based CRC screening programs and early 
diagnosis pathways in symptomatic patients. The criteria for these strategies vary 
between countries, here in the UK the current system involves: 
 Asymptomatic patients over 60 years of age are entering into the bowel 
cancer screening programme. 
 Symptomatic patients of any age meeting referral criteria, being seen via 
the two-week wait (TWW) scheme.  
As discussed above, patients with a risk greater than that of the general population, 
such as those with IBD, polyposis syndromes and strong family history of CRC are 
entered into targeted surveillance programmes.   
2.5.1 Bowel cancer screening  
In 1968 Wilson and Junger’s seminal work on screening principles devised criteria 
for mass screening programs (115). These ten principles, 50 years later, still form 
the basis of preventative medicine and are followed by the WHO. In essence, for a 
disease to benefit from screening, it should be important, be detectable at an early 
stage using a method that is acceptable to patients and have an effective treatment. 
The screening test should be both sensitive (have the ability to correctly identify 
those with the disease) and specific (have the ability to correctly identify those that 
don’t have the disease). The natural history of CRC makes it a suitable target for 
population based screening; it is a relatively common disease with significant 
mortality associated with it (116, 117) . As discussed in detail above, in most cases 
it arises from a benign polyp which takes several years to undergo neoplastic 
transformation. This window of opportunity allows for early detection which is 
directly associated with improved survival.  
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Screening for CRC was proposed decades ago, but took subsequent years of robust 
research before it was rolled out into clinical practice. Several, large randomised 
controlled trials demonstrated mortality reduction using CRC faecal occult blood 
(FOB) screening by between 15 and 33% (118-121). Although the technique 
differed between studies, all demonstrated that screening was better that no 
screening. Two subsequent systematic reviews have found a pooled mortality 
reduction in the region of 16% (122, 123). All of these studies used screening based 
on the detection of blood in stool. Screening for CRC is offered in many countries 
all over the world but protocol differs between countries and even within the UK. 
Two UK pilots, one in England and one in Scotland were carried out between 2000 
and 2002 to determine the feasibility of CRC screening in the UK population and 
confirmed the acceptability of FOBT for population screening with response rates 
of around 60% (124).   
Following a funding agreement by the Department of Health, from 2007 the bowel 
cancer screening programme was implemented nationally. As 80% of bowel cancer 
cases affect those over 60 year of age this was the age selected for initiation of 
screening. Initially the upper limit of screening age was 69, this has since been 
extended to 74 (125).  
 
2.5.1.1 The screening process 
In England, from the age of 60, subjects identified for screening are sent an 
invitation letter. A second letter containing the FOB kit is then sent out a week or 
two later. Each kit contains six windows and patients collect a stool sample every 
day for 3 days, using two windows for each sample (figure 2.6 ) (126). Guaiac 
FOBTs detect the haem moiety of haemoglobin molecules by making use of the 
pseudoperoxidase activity of haem; haem will be present if a stool sample contains 
blood. When a developing agent (hydrogen peroxide) is applied to the stool sample, 
haem releases oxygen from the hydrogen peroxide which then reacts with the 
colourless guaiac to form a blue dye. The number of sample windows that turn blue 
(positive result) is recorded by a technician and further action is determined by the 
number of positive results. Screening is offered biennially. Kits are sent and 
received at one of five testing laboratories, called hubs, situated throughout 
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England. Depending on the outcome of test one, the patient may have a repeat 
screen, a colonoscopy, or just continue along the screening pathway and repeat the 
test in two years (127). Those who have a positive test on the first or indeterminate 
second test will be referred to their local screening hospital to see a specialist 
screening practitioner within 14 days. The vast majority of patients will be offered 
a colonoscopy, in less than three percent of cases they will be deemed unfit for 
colonoscopy and a CT colonography may be offered (126).  
 
Figure 2.6. A picture of the guaiac faecal occult blood test with one panel open 
showing two windows. 
  
 
 
Colonoscopies are only undertaken at centres accredited by the Joint Advisory 
Group (JAG) on GI endoscopy. Screening colonoscopists undertake dedicated 
training culminating in a formal assessment. If the patient has a normal 
colonoscopy, they enter back into the standard screening programme and will 
complete another FOBT in two years time provided they are still within screening 
age range. Those with adenomas that are deemed intermediate or high risk are 
entered into a screening surveillance programme until they reach the age where 
screening stops, those with low risk adenomas are not surveyed within the screening 
programme. Those with cancer are managed via the hospital multi-disciplinary 
team.  This process is standardised across the country and comprehensive data 
collection regarding all aspects (e.g. demographics, uptake of test and colonoscopy, 
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diagnosis, outcome) is collected for the bowel cancer screening database which is 
audited at regular intervals.  
 
2.5.1.2 The drawbacks of using the guaiac FOBT  
As already discussed CRC screening reduces mortality but the current UK FOBT 
screening has several drawbacks which affect overall sensitivity and specificity of 
screening: 
1. The guaiac test method is not specific to human haemoglobin, therefore 
consumption of meat can mean animal haemoglobin is detected in the faeces 
and will result in a false positive result. Also fruits and vegetables high in 
peroxidase activity may also create false positives (129).  
2. The current technique relies on a technician to detect positivity therefore 
human error can occur resulting in both erroneously false negative and 
positive tests (129). 
3. Faecal testing is unpopular with patients, and this is reflected in generally 
low uptake rates. Uptake is around 60%, although this varies markedly 
between regions (130) with lower uptake in more deprived areas and those 
with a higher proportion of ethnic minorities. The requirement for three 
different stool samples on different days is inconvenient for patients and can 
deter uptake (129, 131).  
4. Due to the relatively low sensitivity and specificity, a large proportion of 
patients unnecessarily undergo a colonoscopy, which is considered an 
invasive test (129). 
Around 2% of FOBT’s are positive and approximately 10% of those with a positive 
test will have cancer. Cancer plus intermediate or high risk adenoma pick up rate 
collectively has been reported at around 40% (126). Latest regional figures for 
Coventry and Warwickshire are an 8.8% CRC rate and 50.8% adenoma detection 
rate in 2017. This compares with the 2014 national figures of 9.4% cancer detection 
and 59.9% (this includes low risk polyps). 
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Since the introduction of CRC screening in the UK, two major developments have 
occurred in an attempt to improve screening techniques and ultimately diagnose 
more cancer.   
2.5.1.3 Faecal immunochemical testing  
In January 2016 the UK National Screening Committee (NSC) published a 
recommendation that FIT should be implemented to replace the current FOBT. This 
was decided based on published evidence that FIT:  
a) Was easier to use and more reliable given that it does not require human 
detection and can be measured using machinery  
b)  Demonstrated increased sensitivity to a much smaller amount of blood than 
FOBT 
c)  Is superior to FOBT at detecting advanced adenomas 
d) FIT requires a single faecal sample and showed increased participation rates 
e) Is as cost effective as FOBT 
 
Implementation of the FIT, which is an immunoassay specific to human 
haemoglobin within the next few years, will provide a one-stop stool test which has 
been demonstrated to improve uptake by as much as 25% (126, 130). 
Immunochemical FOBTs are said to be more sensitive because they use monoclonal 
or polyclonal antibodies raised against the globin moiety of human haemoglobin, 
detecting intact human haemoglobin or its very early degradation products. When 
globin antigen is present, labelled antibodies attach to it, equating to a positive test. 
FIT collection involves a single sample collected using a wand which is inserted 
into the stool and then placed in a container (figure 2.7). The process is simpler than 
the traditional FOBT suggesting that ease of completion is a major contributor to 
return rates (132). FIT is a quantitative test, the cut off value for screening differs 
between the countries where it is currently being used as a screening tool. It does 
allow cut-off levels to be tailored to available resources and colonoscopy capacity; 
a lower cut-off increases the detection of advanced neoplasia but in turn lowers the 
positive predictive value and thus results in more demand for colonoscopies. 
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Figure 2.7. A picture of the faecal immunochemical test kit: this involves a single 
sample with applicator within device lid, allowing easier sampling (used with 
permission from Steve Smith). 
 
 
 
Between 2009 and 2011 the FIT was piloted in the NHS to 66,000 people in 
Scotland, return rates were significantly higher than for the FOBT (58-61% vs 52-
56%) (133). A recent study comparing FOBT with FIT found a 20% higher FIT 
completion rate, with particular improvement in uptake amongst the lower socio-
economic groups(131). However, as this test still relies on faecal sampling, lack of 
completion by up to 40% of the eligible population means a large proportion remain 
unscreened (134, 135). FIT is the CRC screening method in many European 
Countries and the aim is to roll this out to the UK within the next 12 months. 
 
2.5.1.4 Endoscopic population screening 
A large randomised controlled trial demonstrated the effectiveness of a one-off 
flexible sigmoidoscopy in reducing CRC incidence by 23% and mortality by 31% 
(136). The authors estimated that 489 patients would need to be screened to prevent 
one death from CRC. Further studies in Italy (137), Norway (138, 139) and the 
United States (140) confirmed a reduction in incidence and mortality from CRC. 
The hypothesis that flexible sigmoidoscopy could reduce cancer incidence and 
mortality is based on observations suggesting that most people who develop a distal 
colon cancer will have developed an adenoma by 60 years of age (141). The United 
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States have been using endoscopic evaluation as a screening method for CRC for 
some time, with consensus that the accrued cost is offset by the reduction in 
morbidity and mortality from CRC. As discussed earlier in this chapter, distal 
(below splenic flexure) CRC makes up the majority of CRC seen in the UK (3).  
In the UK, since 2013 bowel scope screening has been piloted and from 2015 it has 
been offered at around two-thirds of screening centres. Currently a one-off flexible 
sigmoidoscopy is offered to men and women at age 55 in England, this age differs 
in other parts of the UK. Current randomised controlled trials assessing screening 
using colonoscopy are ongoing and may well change the face of screening again in 
the future; results are expected between 2025 and 2034 (142, 143).  
2.5.2 The two-week wait (TWW) referral system  
Following recognition by the Government and health bodies that patients were 
facing unacceptable waiting times for assessment, diagnosis and treatment of 
cancer, a new rapid access strategy was introduced through the Department of 
Health NHS Cancer plan in 2000 (144). The TWW referral pathway was devised 
to streamline referral for those with symptoms suggestive of cancer in order to allow 
diagnosis at an earlier stage, reduce cancer survival inequality around the country, 
and, ultimately reduce cancer related mortality(144). 
By 2001 the Government pledged that those with suspected breast cancer would 
wait no more than 32 days from referral to diagnosis and this would extend to all 
cancer by 2005. Targets then focussed not only on diagnosis but treatment, meaning 
a wait no longer than 62 days from referral to cancer treatment as shown in Figure 
11. The government plan to reduce the diagnostic timeframe from 32 to 28 days by 
2020(6).   
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Figure 2.8. A flow diagram of the TWW pathway (145))  
 
Patients with symptoms suggestive of cancer predominantly present to primary 
care, but although cancer is common, in the primary care setting it is still 
infrequently seen: for example, a GP working in an average size practice with a list 
size of around 2000 patients will only see eight or nine new cancers per year, and 
only one CRC (146) . Thus in collaboration with The National Institute for Health 
and Care Excellence (NICE), a set of referral criteria to enable standardisation 
between practices were devised and rolled out alongside the Government referral 
targets for each suspected cancer site. The criteria include a combination of signs, 
symptoms and laboratory tests to be used in primary care which have been regularly 
updated with the latest version published in 2017(147). Patients fulfilling any of 
these criteria are eligible to be seen by a specialist within 14 days of referral.   
The decisions regarding which symptoms should be included, were based on a risk 
threshold, correlating to positive predictive value (PPV) i.e., if the risk of symptoms 
being caused by the specific cancer was above a pre-defined level then further 
investigations are indicated (147). The current NICE guidelines are based on PPV 
threshold of 3% for symptoms being caused by cancer and this has decreased from 
the previous guideline from 5%. Recommendations are made based on the best 
available evidence, prediction models and collaborator expert opinion. In the 
recently updated guidance, there has been new emphasis placed on faecal occult 
blood testing using FIT. Although the context of its use is likely to need further 
clarification as currently ‘unexplained symptoms’ are an indication to carry out FIT 
testing and if positive then a TWW referral is required (147).  
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There has been little documentation on specific cancer diagnostic targets via the 
TWW or any benchmark for numbers of referrals made by primary care trusts. 
According to the Department of Health (DOH) the original target was to ‘identify 
up to 90% of patients with bowel cancer’(144). This statement now only features 
in an archived DOH document and does not feature in the most recent publication 
on the strategy for cancer (5).  
The suspected cancer TWW pathway is subject to nine operational standards which 
detail waiting time measures along with corresponding percentage targets for 
compliance. Performance data is regularly collected at NHS trusts and national data 
is available for public viewing. The 2016-2017 annual report shows eight of the 
nine targets have been met nationally (148). For example, at least 93% of patients 
referred via this route must be seen within 14 days of referral. According to recent 
DOH figures, compliance is high with over 95% of patients being seen within 2 
weeks (6).  
This pathway is not without controversy. A recent study gauging clinician opinion 
demonstrated significant concern over the disproportionate utilisation of services 
due to the TWW system, often to the detriment of patients who do not fit this 
criteria, but make up a greater proportion of total referrals (149).  
In summary, methods of improving CRC detection in both the symptomatic and 
asymptomatic population are in constant development with aims to improve 
detection at an earlier and more treatable stage. There could be huge benefit gained 
from devising more efficacious ways to screen and detect CRC via non-invasive 
methods and without such reliance on symptom-based prediction models. A large 
proportion of experimental work in this thesis focusses on novel biomarkers in CRC 
using Volatile Organic Compound (VOC) analysis and are discussed in the next 
section. 
2.6 Volatile Organic Compounds (VOCs) 
VOCs are organic chemicals that have a high vapour pressure at room temperature, 
i.e. that evaporate or sublimate readily under ambient conditions. They have a role 
in both health and disease in the human body.  
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2.6.1 The origin of VOCs 
VOCs are present in every environment: where people live, work and play. For 
example, householders may have seen the VOC rating of their paint which gives an 
indication of the degree of noxious fumes they may be exposed to. The detection 
and identification of VOCs has been well established in certain areas of industry 
for years. In waste disposal sites VOC data gives vital information about pollution, 
providing health and safety information for workers and nearby residents, where 
exposure to noxious odours is possible (150, 151). Animals utilise VOC 
information to detect food sources and to distinguish enemies.  
Odours omitted from human bodies give information about the metabolic and 
psychological status of an individual and are recognised by other humans, often 
without thought; for example, starvation stimulates the production of ketones that 
can be smelt on the breath and stressed individuals can often emit odourous 
perspiration. Healthy individuals emit a wide array of VOCs daily depending on 
their diet, medication, genetics and physiological status (152, 153). This can be 
considered as the ‘odour-fingerprint’. It is not just the more obvious waste products 
such as exhaled breath and sweat that emanate VOCs, blood is an important source 
of body odours as many VOCs are derived from blood and are eventually emitted 
into the external environment via a variety of sources such as breath and urine (154).  
The concept of smelling disease was documented by Hippocrates in around 400 BC 
when he talked of the odour associated with liver disease ‘the fetor hepaticus’, and 
many other medical practitioners since have appreciated that disease could change 
the odour of bodily waste (155, 156). Odour recognition formed the basis of 
Chinese traditional medicine hundreds of year ago. There has also been significant 
interest in the use of canines for smelling disease (157, 158). The concept of dogs 
smelling disease seems logical considering dogs have at least twenty times as many 
olfactory receptors as humans (159). In 1989, Williams and Pembroke detailed the 
case of a patient who grew concerned about a mole on her leg due to her dog’s 
persistent interest in it. Indeed the mole turned out to be a malignant melanoma and 
it was postulated the dog was able to detect the unique smell exuded from the 
malignant tissue. Even now it is common to see news articles featuring dogs that 
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have detected disease in small case-control studies (160). However the feasibility 
of utilising this animal technology as a point of care test in clinical practice is 
unlikely.  
It is only in the last few decades, since the 1980s, that advances in the knowledge 
of metabolomics and VOCs, together with improved analytical technology, has the 
concept of smelling disease been studied in more depth using a range of diagnostic 
techniques (161-163). Consequently, there has been an explosion of interest in 
researching the use of analytical technology to electronically smell a unique odour 
exuded from bodily waste products, in order to detect disease by mimicking human 
olfaction (164-167). 
VOC gas phase biomarkers emitted from multiple bodily products (breath, urine, 
stool, sweat) are an attractive prospect as potential biomarkers of disease. They 
reflect metabolic processes arising from complex interactions between the gut 
lining, microflora and invading pathogens (the fermentome). These signatures are 
altered in disease states (154). But metabolic profiling is complex, as VOC 
signatures found in blood reflect cellular processes in the liver, kidneys, muscles, 
fat and airways, including bacterial and inflammatory processes (168). Therefore 
teasing out the disease-specific markers is a big challenge. In order to understand 
the analysis methodologies for detection of VOCs, a summary of the various 
techniques is provided below.  
2.6.2 Instruments used in VOC analysis 
 
Despite the wide range of studies involving VOC analysis which are discussed 
below, and the variety of analytical techniques employed, there is no real consensus 
amongst researchers on which are superior. The decisions regarding instrument 
choice are usually based on practical factors such as availability and cost together 
with prior experience. An overview of the commonly used devices is provided here.  
 
Field Asymmetrical Ion Mobility Spectrometry (FAIMS) 
The FAIMS is discussed in detail in Chapter Four. This technology was originally 
developed for the detection and identification of chemical warfare agents in spiked 
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food products (169), but has been applied to the detection of disease in several 
recent studies (170, 171). It is a highly sensitive method of detecting ions based on 
their mobility, but cannot identify individual chemical compounds.  
 
Electronic nose (e-nose) 
First developed in the 1980s in Warwick (172) in an attempt to replicate the human 
olfactory system, the electronic nose is an umbrella term describing an instrument 
formed from an array of sensors with overlapping sensitivity. It has the ability to 
identify a sample based on the composite chemicals triggering sensors within the 
e-nose (akin to olfactory receptors in the nose). It is composed of chemical sensors 
that are tuned to different chemical groups with sensitivities in the parts-per-million 
to parts-per-billion. Figure 2.9 shows the process of sample detection by the 
electronic nose and how this compares to the human olfaction system. As with the 
human nose, the electronic nose has the ability to learn through repeated exposure 
to the same chemical composition (smell), combining these elements to distinguish 
between different types of sample (170). Samples can be analysed quickly but the 
e-nose does not have the ability to identify specific chemicals, rather it can 
distinguish between different classes of samples with distinctive patterns.  GC-MS 
analysis would be required to identify specific chemicals. 
 
Figure 2.9. Schematic of the comparison between the human and electronic nose 
(reproduced by permission from Professor James Covington) 
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Gas Chromatography – Mass Spectrometry (GC-MS) 
This method of VOC analysis can be broken down into its two constituent parts. 
Gas Chromatography (GC) is a method used to separate the constituent molecules 
within the sample, according to a combination of their molecular weight and 
polarity (173). Using long, thin columns with a retentive coating along the inside 
wall, the sample is passed through a column using an insert carrier gas such as 
Helium. Gases pass through the column at a mobility determined by the polarity 
and weight of the molecules within the sample. The column temperature is 
gradually increased allowing chemicals with lower mobility to pass through. Once 
chemicals have passed through the column they hit a detector producing a 
chromatograph based on molecular count and time. This technology can be 
combined with mass spectrometry (MS).  
 
MS operates by first ionising and breaking the molecules into constituent ion 
species, they are then accelerated into a right angle bend. At the bend, an 
electromagnetic field is applied which determines the path of the ions depending on 
their molecular weight. The ionic mass within the spectrometer when the magnetic 
deflection is applied, is almost completely unique to an individual chemical 
compound, a schematic is shown in figure 2.10. GC-MS allows the identity of gases 
and compounds present within a sample (173). Libraries of compounds and their 
corresponding mass spectra have been built up and sold commercially by analytical 
chemical companies. One such library is the National Institute of Standards and 
Technology (NIST).  
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Figure 2.10: Schematic of a GC-MS instrument. 1-5: GC separates the analytes. 
The column is flooded with inert gas and the analytes travel along it with speeds 
dependent on their physical and chemical properties. 7-11: MS is used to identify 
and quantify the separated substances. Ionisation occurs causing analyte 
fragmentation. Masses are analysed and the chemical formula can be determined 
(128). 
 
 
 
 
 Gas- capillary column ion mobility spectrometry (GC-IMS)  
This method has been mainly used in the food industry for freshness quality control 
and authentication of ingredients but it has recently gained interest as a method of 
disease detection albeit in only a handful of cases to date (174, 175). It is a two-
stage analysis of compounds: firstly a gas column provides initial separation, and 
secondly ionisation of the sample occurs and detection of ions based on their 
individual mobility as they pass through a drift tube, a further explanation can be 
found in Chapter Four. Information collated from both steps results in a highly 
sensitive analytical modality. Its portability, ease of use and low running costs make 
it attractive for use in the detection of disease. A recent pilot study found 60% 
sensitivity and 80% specificity in detecting bacterial respiratory tract infections 
using breath capture (176), but sample numbers were small and more work needs 
to be done to explore the feasibility of this technique further.  
 
There are multiple other analytical instruments used by different research groups, 
discussion in this review has been limited to those used in experimental work in this 
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thesis and an overview of the more frequently used alternatives. The choice of 
instrument used is a balance between affordability, access and experience in use. 
Currently, there is no consensus or guideline as to which holds superiority  
 
2.6.3 VOC detection in non-gastrointestinal disease 
There is a wide breadth of research into detection of diseases outside of the gi tract 
using VOCs, these are summarised according to the biological medium used.  
Breath 
Exhaled breath contains hundreds of VOCs which are derived from both exogenous 
and endogenous sources. Exogenous volatiles are those that are inhaled from the 
external environment, those produced following the ingestion of food and those 
from recreational activities such as smoking, chewing gum and teeth-brushing. 
Endogenous volatiles are blood-borne, stored in fat and released via the lungs. The 
basis of disease detection rests on the principle that endogenous VOCs reflect the 
condition of the cells at the site of disease. As the compounds detected in breath are 
present in tiny concentrations it can be difficult to distinguish endogenous products 
from contaminants in the external environment. However, breath collection is very 
tolerable for the patient and of course is always readily available. 
The utilisation of VOCs for disease detection in human breath was described in the 
1971 by Pauling and colleagues where a chromatogram of exhaled breath was 
created (177). Little development occurred for several years after this, mainly 
hindered by the lack of technical progress of analytical methods until the 1980s.  
 
Some of the earliest and largest volumes of work on VOCs in the detection of 
disease have focussed on the respiratory system. The majority of work in the 
respiratory field has been carried out on breath capture, not only using sensor 
detection but also in isolating chemicals of interest. Breath is mainly made up of 
nitrogen, oxygen, carbon dioxide and water. The remaining small fraction will 
consist of tiny concentrations of compounds such as ethane, pentane, acetone and 
isoprene (178). Most recently in 2018 Pizzini et al isolated four VOCs which were 
able to distinguish acute exacerbations of COPD from chronic disease with an Area 
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Under the Curve (AUC) of 0.92 (161) . Separation has also been demonstrated when 
looking at COPD and controls, with significant differences in hexanal aldehyde 
concentrations between groups. This may represent oxidative stress in the airways 
precipitated by smoking (179). Besa et al also isolated six key volatiles which were 
able to discriminate COPD cases from healthy controls with 70% accuracy, body 
mass index (BMI), C-reactive protein (CRP) and forced expiratory volume (FEV1) 
all seemed to affect the breathprint though (180). Despite the number of 
observational studies conducted with promising results, a systematic review of 
COPD breath analysis revealed heterogeneity amongst studies with no marker 
present in all 12 studies included (181).  
 
Other groups have also showed separation in non-malignant respiratory disease 
including asthma. Using an electronic-nose, asthma has been distinguished from 
controls (182), and from COPD with an accuracy of >90% (183) but separation of 
mild from severe asthmatics was not demonstrated (182). Tuberculosis has also 
been studied with success using e-nose: 100% accuracy was reported by Pavlou et 
al (184) and with a sensitivity of 84% by Van de Schee and colleagues(185). Studies 
involving mesothelioma, cystic fibrosis and sarcoidosis have also been published 
(186).  
 
In malignant disease, O’Neill and colleagues identified 28 breath VOCs as potential 
markers of lung cancer (187). Similar results were found by Phillips et al who 
identified 22 potential VOCs associated with lung cancer. These were 
predominantly alkanes, alkane derivatives and benzene derivatives with 100% 
sensitivity and 81.3% specificity for cancer detection (188). Schallschmidt and 
colleagues discuss the limitations of breath capture with low and variable VOC 
levels detected at times despite high separation of lung cancer from control, albeit 
on small patient numbers (189). 
 
Other malignancies have been studied using breath capture, in particular breast and 
urological cancers have attracted interest (190).  A recent study using GC-MS found 
test accuracy of 90% for detecting breast cancer in 54 patients from 124 controls 
65 
 
(191). Others have demonstrated that the breath VOC profile differs in melanoma, 
mesothelioma and head and neck cancer: many are pilot or proof-of-concept studies 
(192-195). To date, hundreds of breath VOCs have been identified with a proposed 
link to various cancers, however no consensus on those key to identifying 
malignancy has been made (196). Finally, another area that has gained interest for 
breath VOC profiling are liver diseases such as hepatocellular carcinoma and 
cirrhosis (197, 198). 
 
Breath analysis raises a number of important challenges despite some obvious 
advantages in disease detection. It is not clear what the relationship is between 
alveolar concentration of a compound and that found in exhaled breath, also the 
stability of these compounds is limited and repeatability seems to be a particular 
issue (199). Breath is the most vulnerable detection source to the effects of 
environmental factors and overcoming this will be the major challenge for this 
method of VOC capture.  
 
Urine 
Urinary metabolites are the end products of many metabolic pathways, the use of 
urine in the diagnosis of a number of metabolic disorders such as diabetes, carcinoid 
syndrome and porphyria is well established. Urine contains a complex mix of 
components that could be significantly influenced by food and drink ingestion, this 
can prove challenging when trying to separate compounds of interest. However, 
urine is readily available, collection is usually acceptable to patients and it has the 
potential to be stored long-term with relative stability. It is the second most 
investigated modality of VOC detection after breath. Although the focus of urinary 
analysis has largely been on gastrointestinal disorders, investigation into a diversity 
of urological disease and other malignancies has also taken place and is summarised 
below.  
Using a model based on four VOCs prostate cancer was separated from control with 
modest accuracy of 63-65%, this increased to a maximum of 74% when VOC 
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profile was combined with prostate-specific antigen (PSA) (200). Bernabei also 
looked at prostate cancer and bladder cancer comparing with healthy controls 
before and after surgery. The differentiation of both cancers from control was 
demonstrated pre-surgery, but this was not replicated when post-surgical cancer 
samples were compared with controls (201). A study of 22 patients with renal cell 
carcinoma (RCC) were compared with healthy controls using solid phase 
microextraction (SPME) followed by GC-MS. They found 11 elevated VOC 
markers and 3 decreased in the RCC group compared with controls (202), but 
acknowledged these results would need to followed up with a larger study.  
Detection of urinary tract infections (UTI) has been attempted by five research 
groups (203), most recently by Roine et al in 2014 where the detection of four 
common pathogens responsible for UTI were tested against sterile plates (204), 
sensitivity was 95% and specificity was 97% for detecting the correct bacteria.  
In order to investigate a faster method of Tuberculosis detection, a study was 
conducted to identify urinary V0OCs in those with tuberculosis versus controls. 
Results showed a significant (p < 0.05) increase in the abundance of o-xylene (6.37) 
and isopropyl acetate (2.07) and decreased level of 3-pentanol (0.59), 
dimethylstyrene (0.37), and cymol (0.42), the authors felt this information could 
form the basis of a diagnostic test (205). In pilot work, the FAIMSHED research 
group has used VOC detection to differentiate control samples from inflammatory 
bowel disease, liver cirrhosis, diabetes and obesity (154, 206, 207) and most 
recently pancreatic cancer where pancreatic adenocarcinoma was detected from 
health controls with 91% sensitivity and 83% specificity with 81 patients in each 
group (208).  
Urine definitely holds promise for VOC diagnostics, perhaps particularly in 
urological conditions and gastrointestinal given the promising pilot work carried 
out to date. The ease of collection and storage is certainly attractive, but 
repeatability of much of the work mentioned has not been demonstrated on a larger 
scale.  
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Blood 
Blood VOCs are an attractive prospect as they directly reflect the internal 
environment and are not altered by external environmental factors. There is also the 
potential to store samples for prolonged periods. However collection is relatively 
invasive for patients, plus sample centrifuging is time consuming therefore this may 
seem a less appealing option. Consequently there has not been a large body of 
research conducted using VOC blood markers. Blood VOCs in the diagnosis of 
CRC and other GI disease are discussed below. 
Faeces 
Stool samples in theory may seem the most logical way of detecting VOCs 
particularly in gastrointestinal disease, as they represent the dietary end-products of 
digestion and intestinal bacterial metabolism. However the patient’s microbiome is 
known to significantly influence faecal VOC profile and as demonstrated by the 
modest uptake in bowel screening, patients do not like providing faecal samples. 
Also samples are unlikely to be produced at the time of a clinic, thus rely on the 
patient returning the sample at a later date. These factors all prove a barrier in the 
clinical setting.  
Other   
Some of the earliest work in measuring aromas was used in diagnosing the presence 
of microbial pathogens, (209-212) such as detecting beta haemolytic streptococcal 
infection in leg ulcers (213).  
 
Sweat is the main source of VOCs found on the skin. Although commensal bacteria 
present on the skin surface, can alter the compounds secreted in sweat thus making 
analysis difficult. Saliva has also gained interest and may be able to reflect VOCs 
formed in blood (214). Vaginal secretions have been studied, especially in the 
diagnosis of pelvic infections as normal vaginal secretions are virtually odourless 
therefore contamination is minimal. Finally bile VOCs have shown some promise, 
but only by a single research group, in both the detection of malignant biliary 
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strictures in pancreatic cancer and cholangiocarcinoma associated with Primary 
Sclerosing Cholangitis (215). 
 
2.6.4 VOCs in gastrointestinal disease 
The diagnosis of a variety of GI pathology has been investigated using breath, urine, 
faeces and blood. One of the earliest breath studies was in 1992 when Sivertsen et 
al performed a small study looking at whether breath methane excretion differed 
between those with CRC and controls: they did not find any association (216). 
Studies reporting breath analysis in IBD and other GI disorders are lacking. A small 
body of evidence has linked breath alkanes with colonic inflammation (217), with 
ethane, propane and pentane significantly elevated compared with healthy controls 
(218). 
 
IBD has been the most studied disease in faecal headspace analysis with studies 
looking at IBD versus control with 76% sensitivity and 88% specificity (219). 
Using GC-MS, Walton and colleagues found a striking increases in ester and 
alcohol derivatives of short chain fatty acids in Crohn’s disease compared with the 
other groups. They also found that following treatment for Crohn’s disease VOC 
profiles were more similar to healthy controls (220). Active versus inactive IBD has 
also been evaluated using GC-MS (221). A detailed analysis was published in 2007, 
in which Garner et al explored the difference in faecal VOC emissions in health and 
in the presence of gastrointestinal disease. Using GC-MS, they analysed stool 
samples from those with UC, Campylobacter jejuni and Clostridium difficile. This 
was the first detailed analysis of faecal VOC emissions. A total of 297 VOCs were 
identified, the main classes of volatiles included (222):  
1. Acids, alcohols and esters – Short-chain fatty acids were seen commonly 
and arise form the metabolism of undigested carbohydrate 
2. Benzenoid and heterocyclin compounds  
3. Aldehydes and ketones – Ethanal which was present in all samples is 
thought to be associated with bowel cancer  
4. Alkanes, alkenes, alicyclic compounds –  
5. Ether compounds and chloro compounds 
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6. Nitrogen and sulphur compounds  
This paper confirmed the hugely varied VOC profile of faeces. Some compounds 
can be explained as breakdown products of certain foods, others will be explained 
by the alterations in microflora in the presence of disease, as there may be less 
microbial flora with consequent reduction in secondary metabolites. Other changes 
were difficult to explain.  
 
Through bacterially mediated gastrointestinal disease, several other potential faecal 
biomarkers have been detected. Escherichia coli has been linked to inflammatory 
gastrointestinal diseases, biomarkers such as terpenes, trimethylamine and ketones 
have been isolated from infected stool samples (184, 223). Through faecal odour 
analysis Moore et al and Suarez discovered that sulphur-containing compounds 
such as hydrogen sulphide, dimethyl disulphide, methyl disulphide and dimethyl 
trisulphide contribute most to faecal odour(224-226), these findings contribute to 
our understanding of the possible background VOCs that may be present in most 
normal faecal samples. Rossi et al recently assessed the effect of diet on the faecal 
VOC profile of patients with functional bowel disorders. Here patients were 
allocated to a low FODMAP (fermentable oligosaccharides, disaccharides, 
monosaccharides and polyols) diet or a sham diet with or without the addition of a 
probiotic, using a GC sensor device they found key VOCs associated with response 
to adopting the low FODMAP diet and response to probiotic (227). This study is 
the first to raise the possibility of using VOC profiling to predict response to dietary 
interventions in the functional bowel population.  Coeliac disease and radiation 
toxicity have also been studied using faecal biomarkers (228).    
 
Urinary markers in GI disease have been explored by Arasaradnam et al with IBD 
vs control study using the FAIMS instrument and the electronic nose. They found 
that both technologies were able to distinguish IBD cases from controls with >75% 
accuracy (p=0.001), replication of these findings in a larger study has not occurred 
but would be interesting (171). The same group also compared coeliac disease 
urinary samples with IBS-D controls, here 1,3,5,7 cyclooctatetraene was considered 
significant in the coeliac group but not the control (154).  
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Blood analysis has gained some interest, although sampling is less attractive to 
patients. In theory blood may be more able to represent the internal environment 
affected by GI disease and be less influenced by the external environment that can 
be potentially problematic in breath analysis. Only a handful of studies have 
explored blood VOC biomarkers. In 2016 Bhatt et al explored oesophageal cancer 
in a pilot study by looking at the plasma VOC profile of 20 cancer patients 
compared with 19 with gastro-oesophageal reflux disease (GORD), test accuracy 
was good with AUC 0.83 using ion flow tube mass spectrometry for analysis. They 
also identified a potential nine VOCs of interest in the cancer group (229). Hepatic 
encephalopathy in cirrhosis has been studied with 3-methylbutanal implicated as a 
potential biomarker, although results have been mixed (230). Using GC-MS, 
detection of blood biomarkers for liver cancer were explored and found hexanal and 
1-octen-3-ol to be of potential interest (231). 
2.6.5 VOCs in the detection of colorectal cancer 
Most clinically relevant VOCs in CRC are thought largely to consist of benzene, 
alkanes and aldehydes and their derivatives (232).  In cancer, several mechanisms 
have been postulated to cause alteration in the VOC profile: 
 Tumour growth creates gene and protein changes that can cause 
peroxidation of the cell membrane and subsequent release of VOCs (48).  
 There is increased prevalence of reactive oxygen species within a cancer 
cell causing alteration of the VOCs and induction of cytochrome p-450 
enzymes (232-234). 
 The microbiome, or human gut bacterial population is known to affect the 
VOC profile and there is growing evidence supporting the role of 
infections in cancer (235).  
 
Canine detection of CRC has also been explored by Sonoda et al where the 
sensitivity of canine scent detection of breath samples compared with colonoscopy 
was 0.91 and the specificity was 0.99 (158).  
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A recent useful review by Di Lena et al identified ten papers (164-166, 190, 232, 
235-239) examining VOC biomarkers in the detection of CRC (240). Table 2.1 
summarises each study.
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Table 2.1: Summary table of publications reporting VOC biomarker use in detection of CRC (up to 2016). Adapted from reference 
(240)  
First author Year VOC 
source 
Analysis  Patient numbers  Sensitivity/specificity 
Peng G 2010 Breath E-nose 
GC-MS 
26 Cancer 
22 Control 
Sensitivity: <30% 
Specificity: no data 
Silva CL 2011 Urine SPME/GC-MS 12 Cancer 
21 Control 
Not stated 
Altomare DF 2013 Breath GC-MS 37 Cancer 
41 Control 
Sensitivity: 86% 
Specificity: 83% 
Wang C 2014 Breath GC-MS 20 Cancer 
20 Control 
Not stated 
Arasaradnam RP 2014 Urine FAIMS/GC-MS 83 Cancer 
50 Control 
Sensitivity: 88% 
Specificity: 60% 
Wang C 2014 Blood GC-MS 16 Cancer 
20 Control 
Not stated 
De Meij TG 2014 Faeces E-nose 40 Cancer 
60 Advanced adenomas 
57 Control 
Sensitivity: 85% (CRC), 62% (adenomas). 
Specificity: 87% (CRC), 86% (adenomas) 
Batty CA 2015 Faeces SIFT-MS 31 High risk 
31 Low risk 
(based on colonoscopy) 
Sensitivity: 72% 
Specificity: 78% 
Westenbrink E 2015 Urine E-nose 39 Cancer 
35 Irritable bowel 
syndrome 
16 Control 
Sensitivity: 78% 
Specificity: 79% 
Amal H 2015 Breath GC-MS 
E-nose 
65 Cancer 
12 Advanced adenoma 
10 Non-advanced 
adenoma 
122 Control 
Sensitivity: 85% (CRC vs controls) 
Specificity: 94% (CRC vs controls) 
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Key 
E-nose: Electronic nose 
GC-MS: Gas Chromatography Mass Spectrometry 
SIFT-MS: Selected Ion Flow Tube Mass Spectrometry 
Dhs-SPME: Dynamic Solid-Phase Microextraction in headspace mode
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Of the papers reported in the Di Lena review, eight studies isolated VOCs that were 
found to be associated with CRC. Using SIFT-MS, Batty et al tentatively identified 
hydrogen sulphide as a key VOC (235) with high levels of sulphide purported to 
cause toxicity and potentially DNA damage at the genomic level. However the 
drawbacks of faecal analysis have already been discussed.  Ammonia and 
acetaldehyde were also found in higher quantities in the cancer cohort. Only one 
paper has specifically targeted the screening population by examining the use of 
faecal VOCs as a screening test for CRC (235). The heterogeneity between study 
methodology was high and a there was a wide variation in compounds found 
between the studies with an array of alcohols, alkanes, sulphurs and others meaning 
little overall conclusion can be made about the key biomarkers. However this could 
provide the basis for further work into compound detection and also postulations 
about the origin of these compounds in relation to cancer development.  Work into 
faecal analysis continues, recently a publication showed alterations in faecal 
microbiota and metabolome in samples from CRC cases versus controls. The 
abundance of Fusobacterium and Porphyromonas had a significant effect on the 
metabolic profile (241). 
 
Three papers focussed on urine: Silva et al performed a study involving three cancer 
groups (leukaemia, colorectal and lymphoma). For colorectal cases there were 12 
cancers and 21 control and analysis with two-stage using SPME followed by GC-
MS. A total of 82 volatiles were identified with three felt to be most characteristic 
of the CRC samples (1,4,5-trimethyl-naphthalene, 2,7-dimethyl-quinoline and 2-
methyl-3-phenyl-2-propenal) (164). In 2014 Arasaradnam et al performed a 
prospective case control study comparing 83 unselected CRC urine samples with 
50 controls using the FAIMS (field asymmetric ion mobility spectrometer) 
instrument. Using Fisher Discriminant Analysis the sensitivity and specificity to 
detect CRC were 88% and 60% respectively (236). The study reported the first 
evidence of urinary diagnostics in CRC, postulating that healthy controls can be 
distinguished from those with CRC using their VOC profile with accuracy. The 
same research group headed by Westenbrink investigated 39 CRC patients and 
compared these with IBS and control groups, sensitivity and specificity were 
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modest at 78% and 79% respectively. Using GC-MS this group identified the 
following 9 urinary chemicals in sporadic CRC. Chemicals include Acetone, 2-
Pentanone, 4-Heptanone, 1,3,,5,7-Cyclooctatetraene, Allyl Isothiocyanate, Oxime-
,Methoxy-phenyl, 1,3-Propanediamine, Carvone, Ethanone 1,1’ (1,4- 
phenylene)bis, Phenol, 2,4-bis (1,1-dimethylethlyl)- (238). 
2.6.5.1 VOC profile and cancer stage  
It is plausible that changes in cancer stage will alter the VOC profile progressively. 
The multifactorial effect of cancer on the colonocytes, microbiome and vasculature 
will all contribute to metabolomic changes. It has been postulated that the abnormal 
proliferation of cancer cells is key to the metabolic profile changes that differentiate 
cancer from controls (242). But it is unclear whether these gradual changes can be 
detected by the current technological abilities in VOC analysis.  
Given that cancer stage is key in survival (243), a central component of the work in 
this thesis is to investigate whether specific VOCs can predict CRC stage. Two 
publications explore VOC profile and CRC the stage (Table 2.1): Altomare et al 
used breath analysis to try and identify differences in VOC profile in cancer and 
control using GC-MS. When categorised by stage they found no difference in 
patterns when comparing stage I/II with III/IV cancer (232). Numbers were small 
in this study, with a total of 37 cancer subjects. Wang et al found no separation 
trend between early and late stage CRC in blood VOC analysis, but just 16 cancer 
patients were included. In order to answer this question more robustly conducted 
studies, with larger numbers are needed (237). 
To summarise, there is an increasing body of interest in VOC diagnostics but 
consensus is lacking on methodology and target VOCs. Diagnosis of CRC in 
particular, has raised interest with some encouraging results demonstrating altered 
VOC profiles. These have the potential to form the basis of a diagnostic test, 
although currently there is no VOC based marker in use in clinical practice.  
In conjunction with the above review of urinary biomarker diagnostics, the next 
section will provide the background to the experimental work completed in Chapter 
Six on urinary peptide analysis. This area of research continues to increase interest 
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amongst researchers, although little has been carried out to investigate CRC 
specifically.  
2.7 The proteome  
The proteome describes the entire protein make-up of an organism, such as a 
human. Proteins are the building blocks for cells, and provide a messaging role 
which is active in every cell and tissue in the human body. Analysis of these proteins 
has established key information on the composition and regulation of cellular 
pathways (56). Although the genome has been mapped, without understanding the 
consequent protein changes, knowledge about the pathogenesis of a disease process 
at the cellular level is limited. As yet mapping of the full human proteome has 
evaded researchers, but The Human Proteome Project aims to achieve this in the 
coming years (244). Difficulties in achieving proteome mapping are due to the huge 
numbers of proteins present in the body. Not only do they outnumber genes 
considerably, due to alternative splicing and post-translational modifications, there 
are also multiple copies of each protein that can alter their states, based on the 
cellular environment (245). Additionally, the dynamic nature of protein expression 
relates to various human factors including temperature, presence of disease, 
medications, diet and many others. This makes stabilisation and reproducibility of 
sampling extremely challenging. Finally, there is no expansion technique akin to 
the polymerase chain reaction (PCR) in DNA that can currently be applied to 
proteins. Previous studies have refuted the theory that mRNA levels would correlate 
with proteomic information, in addition translation does not occur at a constant rate 
and post-translational processing and degradation occur at varying speeds (245, 
246). Despite these difficulties, understanding the huge complexities of the 
proteome could result in an un-paralleled understanding of disease, and in particular 
cancer, heralding new targets for therapy and early detection (245).  
Proteomics is the study of proteins in a tissue or biological fluid and gained interest 
around twenty years ago, as a new focus for the identification of therapeutic targets 
for disease (247). It was postulated that polypeptides excreted in bodily fluids were 
likely to reflect bodily functions (248). Proteomics aims to complement genomic 
processes to better understand biological functioning.  There are estimated to be 
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around one million proteins in the human body, and as mentioned above, these 
proteins are in a constant state of change.  
Thousands of research groups have reported on protein-based disease biomarkers. 
Due to high biological variability it has been concluded by many of these 
researchers, that evaluation for the presence of a clinical condition on the basis of a 
panel of biomarkers, rather than a single peptide is far more likely to yield clinically 
useful results (249-251).  This allows for some degree of flux in individual analytes. 
Also, as carcinogenesis is a highly complex process influenced by vast numbers of 
elements such as genetics and environment, a single peptide marker is unlikely to 
be consistently present or always clinically relevant. Various bodily fluids offer a 
target for protein analysis and it is not clear whether one is superior to the other, 
one might postulate that sampling close to the site of disease would be logical e.g. 
breast ductal fluid in breast cancer or pleural fluid for lung disease but results to 
date have not consistently proved this theory (250).  
Renal diseases were the first major area of interest for proteomics in the detection 
of disease, with urine analysis being favoured partly due to ease of collection and 
availability and partly due to the hypothesis that it would closely match the system 
of its origin i.e. the kidney and urinary tract. In 2000 Mckee et al were one of the 
first groups to recognise the potential of complex protein analysis in urine by 
observing the presence of integral membrane transporters in the urine of mice (252). 
2.7.1 Proteomics and cancer detection 
The application of proteomic technology in the discovery of cancer biomarkers 
have been numerous and would be impossible to summarise.  There are several 
well-known and established single protein biomarkers, mainly detected in the serum 
(see table 2.3) and used to aid diagnosis, risk stratify and others to provide 
prognostic information and to aid in deciding therapy. 
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Table 2.3. Approved purely protein-based biomarkers in cancer 
Biomarker Source Cancer Use 
CEA Serum Colorectal Monitoring  
EGFR Colonic Colorectal Selection of therapy 
PSA Serum Prostate Monitoring 
HER2 Serum/breast 
tumour 
Breast Prognosis/selection of 
therapy and 
monitoring 
CEA: carcinoembryonic antigen, EGFR: epidermal growth factor receptor, PSA: prostate-specific 
antigen, HER2: human epidermal growth factor receptor 2.  
 
As mentioned above, theoretically, protein derived ‘fingerprints’ based on an array 
of peptide markers may have the potential to outperform current protein-based 
biomarkers. Some of the earliest work involving polypeptide expression or the 
‘peptidome’ was in breast cancer tissue versus benign fibroadenoma tissue. The 
investigators found heterogeneity of peptide expression between and within groups 
but there were some patterns tentatively reported (253). Around the same time 
Hirano et al studied lung cancer and Paweletz et al correlated the protein annexin 1 
with early onset oesophageal and prostate cancer (254, 255). Prostate cancer 
proteomics have been studied in tissue, serum and urine, in general study numbers 
have been small but tissue profiling seemed to be the most accurate (247, 256, 257). 
There has been some controversy over results involving the serum diagnosis of 
ovarian cancer using peptide analysis: Petricoin and colleagues were heavily 
scrutinised and re-analysis of data by a separate group revealed potential bias that 
may have resulted from change in methodology between analysis and perhaps the 
authors were holding significance with small peptides usually discounted as 
environmental or experimental artefacts (258). This incident highlights the 
drawbacks of this technology and the difficulties in establishing a reliable test 
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because the peptidome is in constant transition in response to factors such as 
environment, medications and recreational activities. 
In the last two decades there have been multiple studies investigating the role of 
specific protein effects on the chances of diagnosis, stage at diagnosis, response to 
treatment, chances of recurrence and many other parameters important in the 
diagnosis and treatment of malignant disease. Despite this work, investigation into 
the potential diagnosis of a variety of cancers using protein analysis has been met 
with mixed success and in most cases their role as a cancer biomarker is as yet not 
validated for a defined clinical application. Studies reporting predictions of 
response to treatment have been more encouraging: Okano et al detailed using the 
proteomic signature to assess likely response to Gefitinib, nine proteins were 
distinguishable in responders from non-responders (259).  In addition, Taguchi and 
colleagues used pre-treatment serum to predict benefit from an inhibitor of EGFR 
tyrosine-kinase in those with non-small cell lung cancer. Following use on a 
training set, they applied this model to validation cohorts, although there seemed to 
be merit in the predictions the actual proteins were unable to be identified therefore 
no assay could be developed (260).  
CRC has gained a large amount of interest in the field of proteomics, this is, in part, 
due to its high prevalence in the Western world, overall poor prognosis and lack of 
sensitive non-invasive tests for the disease. Many studies assessing protein-based 
biomarker utilisation have focussed on disease diagnostics (261, 262). Possibly the 
most promising markers to date, although not proteins, are DNA methylation 
markers based on the number of subjects and published reports (263, 264) . Samples 
used have been mainly tissue or in some cases serum. Blood based biomarkers have 
received the most attention in identifying panels of proteins with potential as 
diagnostic tests. Recently Fung et al used a three protein panel test to differentiate 
CRC from control with 73% sensitivity and 95% specificity in early stage disease 
(265). Urinary proteomics has gained some interest with studies focussed on 
urological cancer but thus far there is a paucity of proteonomic studies involving 
urinary CRC detection. Understanding the complex biology behind CRC 
development using proteomics has the potential to add knowledge not just to the 
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diagnosis of CRC but in the cancer development and to the risk stratification and 
profiling of patients for targeted therapy. 
2.7.2 Instruments used in protein analysis 
Proteomic techniques have changed and adapted as understanding of the technology 
has improved. Also as the complexities of protein and peptide mapping are 
discovered, the way data is captured has had to evolve alongside this. In the early 
stages of protein analysis a technique called Western blotting was employed (266), 
subsequently other immunologic methods of analysis gained popularity, such as 
immunohistochemistry and immunocytochemistry using enzyme-linked 
immunosorbent assay (ELISA). But these techniques are limited as they can only 
identify a small number of proteins at each step. This is helpful when the target 
proteins are already identified thus narrowing the targets of interest exponentially. 
Two-stage analysis was in development from the late 1990s, following refinement 
of well-established protein electrophoresis methods coined by Klose et al (267). 
Popular techniques included polyacrylamide gel electrophoresis (PAGE) and two-
dimensional electrophoresis (262) for protein separation combined with MS. MS 
was identified as a developmental breakthrough in the analysis of proteins and has 
become the central element in most projects today (268). Complementing protein 
capture with MS was subsequently recognised to be the way forward in isolating 
protein data in the extremely complex and fluctuant environment of the cell. 
Although these techniques of proteomic separation can detect thousands of protein 
spots, MS must be applied to each individual spot in turn, meaning use outside of 
the research field would be impractical and unsuited to the clinical environment 
(248). Hence the trade-off for more detailed analysis is time consumption (250). 
Technological advances have constantly been in development however, with the 
inefficiencies in the currently used techniques subject to ongoing refinement.  
Several other micro-array methods for capturing proteins have since been 
complemented with MS and are summarised in table 2.4. For example, surface-
enhanced laser desorption and ionisation (SELDI) MS is another important tool as 
it allows binding of specific fractions of polypeptides in a complex sample which 
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reduces the number of peptides requiring analysis using MS (269, 270). The 
SELDI-MS technique also has the advantage of speed of sample analysis, with the 
ability to sample multiple cases in one step without requiring specialist skills for 
operation (271). The disadvantage is that this only represents a small section of the 
samples limiting the peptide profile and therefore the diagnostic potential. It is 
however, still a popular mode of analysis. For example, Petricoin et al analysed 
serum in the diagnosis of ovarian cancer (272) and Hampel et al evaluated the 
urinary proteomics before and after radiocontrast administration using SELDI-MS 
(273). Ward et al also used SELDI-MS in two studies that focussed on serum and 
urine proteomics in CRC versus control demonstrating high sensitivity, earlier work 
by Chen and Yu also saw success using this technique in CRC proteomic detection 
(274, 275).  
Capillary electrophoresis developed shortly after SELDI-MS, and is widely 
accepted as an effective analytical technique with several advantages (276). These 
include a constant stable flow, thus avoiding a gradient which may change the 
ionisation parameters. Running costs are low and it also allows rapid separation, 
uses a small sample size and combined with MS is a powerful tool in proteomics 
(271). Furthermore it is also compatible with nearly all buffers and has a high 
resolution separation, resulting in a high number of potential  biomarkers displayed 
(249). Multiple modifications and resultant improvements in technique over the 
years are outlined in a review article by Dolnik et al (277).  
Several groups have demonstrated the diagnostic potential using this technique in 
the field of cancers including renal, bladder, pancreatic and prostate (249, 278-280). 
Most recently belczacka et al performed a large study investigating urinary peptide 
profiles captured using  CE-MS in five different cancers, to assess whether a general 
tumour marker was possible (281). 
CE-MS has been used for all proteomic experimental work in this thesis due to the 
advantages outlined above together with several years of previous experience using 
this technique by the collaborator group. A schematic demonstrating the steps of 
CE-MS analysis is shown in Chapter Six. 
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Table 2.4 Analytical techniques currently available for proteomics with 
advantages and limitations listed (reproduced with kind permission from 
Mosaiques diagnostics) 
 
Key: DE-MS – differential electrochemical mass spectrometry , SELDI-MS – surface enhanced 
laser desorption/ionisation, LC-MS- liquid chromatography mass spectrometry, CE-MS – capillary 
electrophoresis mass spectrometry 
As analytical techniques for protein detection have improved and continue to be 
modified, so too have the bio-informatics techniques. This is the process by which 
raw proteomic data is processed and through machine learning algorithms, (where 
known outcome data is inputted) a training set of samples can be used to predict the 
probability of a diagnosis of an unknown sample (269). So-called disease and 
control clusters are created as a training set model. As new patient data is analysed 
they are classified as disease or control based on the clusters they fall into. They are 
also scored based on their proximity to a certain cluster-the higher the score the 
higher the probability a sample belongs to that cluster group.  
Proteomics holds enormous potential, but until control for the sample variables can 
be improved or at least accounted for in a standardised format, it won’t be clear 
whether this technology has a firm place in future diagnosis of disease.  Ongoing 
developments in proteomic technologies allow increasingly sophisticated ways of 
identifying the differentially expressed proteins in various bodily fluids, creating a 
continual wave of excitement and possibility in this area.  
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2.8 Conclusion 
CRC carries a significant disease burden in the Western world and a large amount 
of work into improving diagnostic methods has been carried out in the UK and 
across the world, yet survival figures have not significantly changed in recent years. 
Finding ways to diagnose the disease earlier is key. Not only does a new test have 
to be suitably accurate but it also has to be acceptable to the patients, hence urine 
holds enormous promise. Identifying new biomarkers of CRC is an exciting and 
rapidly evolving area of interest. Extensive review of the existing literature 
confirms the work in this thesis is the first to systematically investigate the TWW 
pathway for the detection of CRC. In addition, the experimental work, both on gas-
phase and peptide biomarkers provides original results looking at the bowel cancer 
screening population and those with symptomatic disease.  
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CHAPTER 3: 
The effect of the two-week wait 
referral system on the detection of 
colorectal cancer: a systematic 
review and meta-analysis  
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3.1 Introduction 
Colorectal Cancer (CRC) is a significant cause of death in the UK so establishing 
ways to improve cancer detection and at an earlier stage to improve survival are 
vital. As discussed in Chapter One, national survival outcomes rank poorly when 
compared to many countries in Europe.  The two-week-wait (TWW) cancer referral 
pathway was devised in 2000 to standardise referral and investigations for 
suspected cancer and ultimately to speed up the diagnostic process. The lower 
gastrointestinal (GI) referral pathway has been subject to several updated versions 
since inception, the latest can be viewed on the National Institute for Clinical 
Excellence (NICE) website (147). Each updated version of the guidelines has 
resulted in a widening of referral criteria and consequent increase in referral 
numbers. The TWW pathway is a predominantly symptom-based referral system 
for a disease that is known to have very non-specific symptoms that are present in 
a wide range of benign conditions.  Inevitably a large proportion of patients without 
cancer are investigated using this pathway. A number of issues have been raised by 
specialists in secondary care and GPs regarding the utility of this system, as the 
majority of cancer is still diagnosed via other routes. This includes non-TWW GP 
referrals and emergency presentations. The latest figures from 2016 show only 31% 
of CRC is diagnosed via the lower GI TWW pathway (282). Additionally, the 
system is extremely resource heavy, diverting time for primary care clinicians, 
specialists, endoscopists and administration staff away from other duties in order to 
meet operational standards, or face a financial penalty for the trust. 
Despite the dominance of TWW work in both primary and secondary care, evidence 
for several key outcomes for this pathway are not available: for example cancer 
conversion rate and CRC stage at diagnosis are not collected nationally (148). NHS 
(National Health Service) England collects huge amounts of TWW data but this is 
not stratified into each cancer group; so the effect estimates calculated using this 
data may be unreliable. This information is vital to understanding the functionality 
of this pathway and whether it is meeting expectation. 
In 2006, Thorne et al reviewed and evaluated the effect of the TWW on CRC and 
found low CRC detection rates, with no improvement in stage at diagnosis 
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compared to other referral routes (excluding emergency admissions) (283). The 
poor reporting quality and limitations in methodology of this review made it hard 
to replicate the study. For example, the report lacked a detailed search strategy, 
study inclusion criteria, study selection and extraction processes, quality 
assessment, and the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) study flow diagram(284) .  
Given the gaps in evidence discussed above, there is a need for an updated 
systematic review to comprehensively evaluate and collate all available published 
data and research evidence assessing the effect of a TWW system on the detection 
rate, stage at diagnosis, and mortality from CRC in England and Wales. 
3.2 Objectives 
The aim of this systematic review is to evaluate comprehensively the latest evidence 
on several key outcomes related to the two-week wait referral system in relation to 
suspected lower GI malignancy. The outcomes of interest for this review are as 
follows: 
3.2.1 Primary outcomes 
 The proportion of patients investigated for suspected CRC via the TWW 
system who are later diagnosed with CRC (cancer conversion rate). 
 CRC stage at diagnosis. 
 Effect of the TWW system on mortality from CRC. 
3.2.2 Secondary outcomes 
 Diagnoses made via TWW referral system other than CRC. 
 Proportion of patients meeting the cancer waiting times standards for time 
to diagnosis and treatment i.e. a) proportion of patients seen within 14 days 
of referral, b) 31-day diagnosis to first treatment, c) 62-day wait for first 
treatment following GP urgent referral) 
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3.3 Method 
This systematic review is reported according to recommendations from the 
Preferred Reporting Items for Systematic Review and Meta-analysis [PRISMA] 
2009 statement[17]. Systematic review registration: PROSPERO 
CRD42016037368. The published protocol to this review can be located via 
PubMed ID::27784334 
3.3.1 Study eligibility 
 
All studies reporting the effects of the TWW system for suspected CRC on the 
detection rate, stage at diagnosis, and mortality from CRC were eligible for 
inclusion and those reporting on other diagnoses made and adherence to national 
TWW targets.   
3.3.2 Study inclusion criteria 
All UK-based reports addressing one or more of the primary or secondary outcomes 
of patients with suspected CRC referred through the TWW pathway, were included.  
Study design: Prospective or retrospective cohort studies, case-control studies, 
cross sectional studies. 
Study setting: Primary or secondary care based studies.  
Population: Aged >18 years referred according to the NICE guidance for cancer 
referral from primary care for suspected CRC (note these guidelines have been 
amended since the TWW introduction therefore several versions were used between 
the studies depending on year of data collection). 
Intervention: TWW referral system for suspected CRC. Studies reporting data on 
multiple speciality referrals via TWW were included if it was possible to separate 
outcome data by speciality to enable extraction of the CRC data only. 
Comparator: Any comparator used that provides data on one or more of the primary 
or secondary outcomes. Studies with TWW data, but without a comparator arm 
were included.  
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Outcome: Rate of diagnosis, stage at diagnosis, and/or mortality from CRC. Studies 
that included data on secondary outcomes without primary outcome data were 
included.  
Timing: Any length of follow up. 
Language of publication: English only. 
Date of publication: Eligible studies published in the year 2000 or onwards to 
correspond with implementation of the TWW referral system. 
 
Type of publication: Full-text reports and abstracts.  
3.3.3 Study exclusion criteria 
Population: a) Patients with suspected cancer other than colorectal, b) anal cancer 
cases, c) participants aged <18 years, and d) pregnant women.  
 
Intervention: The referral systems not related to the TWW pathway for CRC were 
excluded, for example urgent or routine GP referrals. Where it was not clear, 
attempts to contact the author were made. In cases where no response was gained 
the report was excluded as we could not be sure the results included only those from 
the TWW cohort. Non-UK based studies.   
 
Outcomes: Studies not including data on any of the three primary outcomes (CRC 
diagnosis, stage, and/or mortality) or secondary outcomes (other diagnoses made, 
adherence to cancer pathway targets). 
 
Study design: Reviews, editorials, letters, books, consensus statements or opinions. 
Review articles and letters were examined for identification of original studies but 
were not included if they contained no original data.  
Date of publication: Reports published prior to the year 2000 were automatically 
excluded as the TWW pathway was not introduced until then. 
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3.3.4 Search strategy 
Medline via Pubmed, Embase, TRIP and the British Library catalogue was searched 
from 1st January 2000 to 20th October 2017, using a combination of subject headings 
and keywords related to the TWW pathway and CRC. The search strategy is 
detailed in Appendix 1. 
A series of search strategies was employed using increasingly refined search terms 
to increase the chances of identifying all relevant publications, as some focussed on 
TWW clinic outcomes for a range of specialities. Where multi-speciality studies 
occurred, the full publication was reviewed and if data could be extrapolated for 
CRC in isolation, it was included in the review. The search criteria were devised in 
collaboration with an information specialist at UHCW library and also peer 
reviewed by Professor R Arasaradnam and Professor N Waugh, both with 
systematic review experience. 
Each reference list of eligible articles was hand searched to identify additional 
eligible reports/abstracts.  Individualised searches on authors of included studies 
were employed. PROSPERO was also searched to ensure no other similar 
systematic review was being undertaken. Unpublished studies (grey literature) were 
sought by examining relevant conference proceedings. The database search was 
updated directly prior to the writing of this review to ensure that the latest evidence 
was included.  
3.3.5 Study selection 
All records were de-duplicated and compiled from a specialised database using 
Clinical Evidence Based Information Service (CEBIS) into an Excel file. Four 
independent reviewers were involved to ensure no delays at any stage of study 
selection due to other commitments or absences. Initially, all the identified 
titles/abstracts were screened by at least two independent reviewers (EM, MM, MT, 
MW) using a pre-designed and piloted form. Afterwards, the eligibility of all 
potentially relevant publications passing the abstract/title screening level was 
examined at full text level independently. Conflicts regarding study eligibility 
arising at both title/abstract and full-text screening levels were discussed and 
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resolved between the two reviewers or with the help of a third adjudicator. Further 
information was gathered from authors via email where questions regarding 
eligibility arose, if contact could not be made, the paper was excluded.  
The study flow in terms of inclusion and exclusion is depicted in the PRISMA study 
flow diagram in figure 3.1.  
3.3.6 Data extraction 
Data extraction was performed using a pre-piloted data extraction sheet, and a 
minimum of three of a possible four reviewers completed data extraction on each 
eligible study independently (EM,MM,MW,MT). Disagreements between the 
reviewers were resolved via consensus. Where consensus could not be reached, 
additional opinion was sought from a senior reviewer (RA).  
The data extracted included: 
a) Study details (for example, author’s name and year of publication, location, 
setting, number of centres, length of follow up and funding source). 
b) Study participants (for example, recruitment dates, sample size, eligibility 
criteria, mean age, male/female ratio and ethnicity),  
c) Study intervention. 
d) Study outcomes (primary and secondary, and number of included patients 
and losses to follow-up). Where possible, missing statistical parameters of 
importance were calculated (for example, proportion, standard deviation 
standard error).   
 
 
3.3.7 Quality assessment 
Three independent reviewers used the National Institutes for Health study quality 
assessment tool for observational cohort and cross-sectional studies to appraise the 
methodological quality of studies (285). Assessment was based on 14 key questions 
with a yes/no answer, this allowed the reviewer to focus on the key concepts for 
evaluating the validity of the study, rather than a composite score or numerical value 
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that corresponded to an overall quality rating. The domains of bias covered by this 
tool include selection bias, information bias, measurement bias and also 
confounding.  The original quality ratings of this tool (i.e. good, fair or poor), were 
re-categorised for this review as good, adequate or low quality and consensus 
between reviewers had to be reached. Any disagreements in the assessments 
between the reviewers were resolved by a consensus final decision from a senior 
reviewer (RA).  
3.3.8 Data analysis and synthesis 
The study and population characteristics were organised into summary tables and 
text. The synthesised data were organised and presented by primary and/or 
secondary outcome. For studies without a comparator intervention, the summary 
proportions for the post-referral cancer conversion, staging and diagnosis rates were 
calculated with corresponding 95% confidence intervals (95% CIs).  
The summary measures were pooled across studies only if there was sufficient 
similarity in study design, settings, participants (age, sex, comorbidity), 
comparators (e.g. similar referral systems), length of follow-up and primary 
outcome measures (e.g. CRC diagnostic criteria, staging system and non-CRC 
diagnoses). 
The pooled estimates of the proportions were generated using the random-effects 
meta-analysis. The heterogeneity and its extent for the pooled estimates was 
assessed via visual inspection of forest plots and statistical test results (I2 
statistic>50%). 
For cancer stage, the Dukes staging system was used to allow comparison between 
groups, and where possible, TNM-reported stage was converted to Dukes. Forest 
plots were produced with collated staging data together with the national overall 
stage at presentation data to allow a comparator. Other diagnostic data was 
categorised and presented in a series of forest plots (e.g. polyp detection rate, non-
CRC cancer diagnosis and other GI disorders).  
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Factors measured and/or reported heterogeneously were not pooled, but instead 
were synthesised narratively (e.g. adherence).  
The meta-analyses were performed using an R package metafor (286). The raw 
proportions were transformed using Freeman-Tukey transformation during the 
estimation (287). Mortality data was incomplete in most cases therefore Kaplain-
meier plots could not be produced and available results were narratively synthesised 
in a summary table.  
The extent of publication bias was assessed by generating and inspecting funnel 
plot asymmetry as well as using the regression test for funnel plot asymmetry (288).  
3.3.9 Deviations from the protocol 
The review was conducted according to the previously published protocol (289). 
However, there have been minor deviations from the original methodology outlined 
in the protocol. Since devising the protocol the quality assessment strategy had to 
be altered as it became apparent that most included reports did not include a 
comparator group, therefore the quality assessment tool specified in the protocol 
was not appropriate as it was intended for use in studies with a comparator. An 
alternative validated quality assessment tool for observational cohort and cross-
sectional studies was used. Low quality studies were included due to the 
observation early on in the review process, that most papers were deemed of low 
quality and exclusion would significantly reduce the number of included studies. 
This was felt to be detrimental to the quality of the review and the intended aim to 
summarise the available evidence.  
Many included studies were of low quality with a lack of demographic data and 
clear methodology. Conference abstracts had initially been excluded from this 
review, but it was judged that abstract data may also be of similar quality to that in 
full text papers and therefore complete exclusion was unjustified.  As a result of 
this observation conference abstracts were included, but handled separately in the 
results section to avoid bias. Finally the intended data analysis was based on the 
assumption that most papers would provide a comparator group, as this was not the 
case, the data analysis was altered to account for this.   
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3.4 Results 
3.4.1 Search results 
The data collection period was 1st January 2000 to 31st October 2017. Between 
January 2016 and October 2017 a total of three separate searches (electronic 
databases, hand search and contacting authors) were undertaken and the results 
were collated.  In total, 1897 bibliographic records were identified with duplicates 
and ineligible removed. Of these, 1655 were excluded as they were not conducted 
in the United Kingdom. 95 full paper records and 28 conference abstracts were 
reviewed in full. Of the 95 full text reports examined, 49 full-text papers met the 
inclusion criteria (references are listed in table 3.1) 15 of the 28 abstracts met 
inclusion criteria. Of the 49 included papers there are 50 sets of results as one 
publication reported two datasets from different centres. The total study population 
was 93655. The study selection process and reasons for exclusion during the full-
text screening level are presented in fig 3.1 (the PRISMA Flow Diagram). A meta-
analysis was performed on the studies reporting cancer conversion rate, cancer 
stage at diagnosis and other diagnosis made. Due to low volume and lack of 
consistency in presentation, meta-analysis was not conducted on patient survival 
outcome data or adherence to guidelines data. This has been summarised in 
narrative text.  
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Figure 3.1. PRISMA flow Diagram of study selection process 
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3.4.2 Studies and their characteristics 
Of the 49 included studies, 34 were retrospective cohorts, 12 prospective cohort, 
one retrospective comparative, one audit and one review article which contained 
original data. Forty-seven studies were based in secondary care hospitals, two 
collected data both at primary and secondary care level (290, 291).   
Two pairs of cohort studies (Bevis and Schneider plus Hall and Peacock) reported 
results in two different papers at differing time intervals (292-295). Original data 
on cancer conversion rate was followed up by mortality data several years later. 
Duplication was avoided by summarising the common data once, additional data 
was looked at separately as it represented new information on outcomes.  
3.4.3 Population characteristics 
Study population characteristics for the included studies are provided in Table 3.1. 
The studies have been split into those with and without a comparator group.  Study 
details for each included conference abstract are found in Appendix 3.    
In the majority of studies the setting was secondary care outpatients. The 
geographical catchment area related to that of the hospital where the study was 
performed and study population size varied accordingly from 42 (296) to 16431 
(297) with total study population of 93,655. Only ten studies offered length of 
follow up data (293, 294, 298-305), which ranged from 6 months to 5 years. 
In general, studies adopted one of two alternatives to data collection: 1) identify a 
set number or time-frame and look at all the CRCs diagnosed within these margins 
and track back to assess the referral mode to identify the TWW group. As this group 
looked at all cancers, they also tended to provide data on comparator groups too i.e. 
patients with CRC referred via non-TWW means. 2) identify a set number or time 
frame and look at all lower GI TWW referrals within these margins. Data sources 
utilised included administrative databases kept locally for TWW patients and local 
hospital cancer registries. Hospital notes were interrogated where required. The two 
studies that included primary and secondary care patients (ref) analysed cancer 
registries. Where it was not clear if the TWW group were all purely TWW, for 
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example when the term ‘fast-track’ was used, the reviewers sought clarification 
from the author. If there was no reply the study was excluded.   
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Table 3.1: Study and population characteristics: With and without comparator group 
Study ID, 
year 
Study 
characteristics  Population characteristics 
Intervention 
groups Outcomes 
Methodologica
l quality  
Studies without comparator 
low 
Aljarabah,  2009 
(306) Design: Prospective, cohort % Women: n/s 
Intervention group 
(n=217): All lower GI tww 
referrals within 
recruitment period 
1. Cancer conversion rate 
 Study setting: Secondary care Median age (range): 75 (24-94) 
2. Other diagnoses 
made  
 No. of centres: 1 Recruitment dates: April 2006-Sept 2006 
3. Adherence to 
targets  
 Length of follow-up: n/s Total sample size (baseline): 217 
  
 
    Total drop-out/excluded: n/s   
Allgar, 2006 (307) Design: Retrospective, cohort % Women: 62 
Intervention group 
(n=444): All lower GI tww 
referrals within 
recruitment period, plus 
looked at all CRC's 
diagnosed within 
recruitment period. 1. Cancer conversion rate 
low 
 Study setting: Secondary care Median age (range): 66.7       
 No. of centres: 1 Recruitment dates: 1st Jan 2001-31st Dec 2002      
 Length of follow up: n/s Total sample size (baseline): 764        
    Total drop-out/excluded: 79             
Banerjea, 2017 
(308) Design: Retrospective % Women: n/s 
Intervention group 
(n=548): All lower GI tww 
referrals within 
recruitment period 1. Cancer conversion rate 
low 
 Study setting: Secondary care Median age (range): median 68.8 iqr 59-78.72   
2. Other diagnosis 
made  
 No. of centres: 1 Recruitment dates: 1st aug 2014 - 30th Nov 2014   
3. Adherence to 
targets  
 Length of follow up: n/s Total sample size (baseline): 553       
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    Total drop-out/excluded: 5             
Barwick, 2004 (309) Design: Retrospective, cohort % Women: 57 
Intervention group 
(n=149): All lower GI TWW 
referrals within 
recruitment period 
1. Cancer conversion 
rate  
Acceptable 
 Study setting: Secondary care Median age (range): 68 (27-100) 
2. Other diagnoses 
made  
 No. of centres: 1 Recruitment dates: Jan 2001-Aug 2001 
3. Adherence to 
targets  
 Length of follow up: n/s Total sample size (baseline): 149    
    Total drop-out/excluded: 5             
Beggs, 2011 (310) Design: Retrospective,  % Women: 36 
Intervention group 
(n=317): All lower GI TWW 
referrals within 
recruitment period 
1. Cancer conversion 
rate  
Acceptable 
 Study setting: Secondary care Median age (range): 66 (30-100) 
2. Other diagnoses 
made  
 No. of centres: 1 Recruitment dates: Oct 2004- Sept 2005 
3. Adherence to 
targets  
 Length of follow up: n/s Total sample size (baseline): 317       
    Total drop-out/excluded: 0             
Bhangu, 2010 (298) Design: Retrospective % Women: 27 
Intervention group 
(n=1725, 108 with CRC 
analysed): All consecutive 
new CRC's diagnosed in 
TWW clinic within 
recruitment period 
1. Cancer conversion 
rate  
Acceptable 
 Study setting: Secondary care Median age (range): 71.6 (57-87.8)    
 No. of centres: 1 Recruitment dates: Jan 2006- July 2009    
 
Length of follow up: 514 days 
median (iqr 160-788) Total sample size (baseline): 1725     
    Total drop-out/excluded: 0       
Borowski, 2016 
(291) Design: Retrospective % Women: 41.3 Intervention group 
(n=8273): All CRC 
adenocarcinoma cases 
within cancer registry from 
GP practices that referred 
>10 CRC cases in total. 
1. Cancer conversion 
rate  
Low 
 
Study setting: Somerset 
cancer registry (primary and 
secondary care) Median age (range): 72 (22-94)    
 No. of centres: 44 Recruitment dates: Jan 2009-Sept 2014    
 Length of follow up: n/s Total sample size (baseline): 8273        
    Total drop-out/excluded: 0             
Couch, 2014 (311) Design: Retrospective % Women: n/s 
Intervention group 
(n=968): All consecutive 
1. Cancer conversion 
rate  Low 
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Study setting: Somerset 
cancer registry (primary and 
secondary care) Median age (range): n/s 
CRC diagnosed via tww 
pathway in 2013 who had a 
colonoscopy as first line 
investigation      
 No. of centres: 1 Recruitment dates: All of 2013    
 Length of follow up: n/s Total sample size (baseline): 2950       
    Total drop-out/excluded: 0             
Debnath, 2002 
(312) Design: Retrospective % Women: n/s 
Intervention group (n= 
239): All lower GI TWW 
referrals within 
recruitment period. 
1. Cancer conversion rate 
Low 
 Study setting: Secondary care Median age (range): n/s 2. Cancer stage at diagnosis 
 No. of centres: 2 Recruitment dates: Aug 2000-July 2001 
3. Adherence to 
targets  
 Length of follow up: n/s Total sample size (baseline): 239       
    Total drop-out/excluded: 2             
Eccersley, 2003 
(313) Design: Prospective % Women: n/s 
Intervention group 
(n=173): All lower GI TWW 
referrals within 
recruitment period. 
1. Cancer conversion 
rate  
Low 
 Study setting: Secondary care Median age (range): n/s 
2. Other diagnoses 
made  
 No. of centres: 1 
Recruitment dates: A one year period 
(dates not included)    
3. Adherence to 
targets  
 Length of follow up: n/s Total sample size (baseline): 180       
    Total drop-out/excluded: 7             
Gaunt, 2011 (314) Design: Retrospective cohort % Women: 62.2 
Intervention group (n= 
137): All lower GI TWW 
referrals within 
recruitment period >80 
years old 
1. Cancer conversion 
rate  
Low 
 Study setting: Secondary care Median age (range): 84 (80-96)    
 No. of centres: 1 Recruitment dates: Feb- July 2009    
 Length of follow up: n/s 
Total sample size: 777 (of which 159 >80 
yrs)       
    Total drop-out/excluded: 22             
Glancy, 2004 (299) Design: Prospective % Women: n/s 
Intervention group (n= 
326): All lower GI TWW 
referrals within 
recruitment period except 
those with palpable rectal 
mass 
1. Cancer conversion rate 
Low 
 Study setting: Secondary care Median age (range): 70.8 2. Other diagnoses made 
 No. of centres: 1 Recruitment dates: Aug 2000-Nov 2001 3. Adherence to targets 
 
Length of follow up: 6 months 
after referral Total sample size: 326    
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    Total drop-out/excluded: n/s             
Hall, 2015 (294) Design: Retrospective  % Women: 53 Intervention group (n= 
1350): All lower GI TWW 
referrals within the three 
recruitment periods (pre, 
post and long-term post 
'be clear on cancer' 
campaign( *Shared data 
with Peacock, 2013 
   
Acceptable 
 Study setting: Secondary care Median age (range): 69 (61-79) 1.Cancer conversion rate* 
 No. of centres: 1 
Recruitment dates: Nov 2011- Jan 2012, 
Feb-Apr 2012, May-July 2013 2. Other diagnoses made* 
 Length of follow up: 8 months Total sample size: 1403    
    Total drop-out/excluded: 53       
Hammond, 2007 
(296) Design: Prospective % Women: n/s 
Intervention group (n=42): 
All lower GI TWW referrals 
within the recruitment 
period if <80 years, no 
requirement for advocate 
and able to take bowel 
preparation 
1. Cancer conversion rate 
Low 
 Study setting: Secondary care Median age (range): n/s 2. Other diagnoses made 
 No. of centres: 1 
Recruitment dates: 8th Jan 2007-16th Feb 
2007    
 Length of follow up: n/s Total sample size: 42    
    Total drop-out/excluded: 0             
Khan, 2007 (315) Design: Retrospective % Women: 59 
Intervention group 
(n=225): All consecutive 
lower GI TWW referrals 
within the recruitment 
period who underwent CT 
Colonography. 
1. Cancer conversion rate 
Acceptable 
 Study setting: Secondary care Median age (range): 74 (62-81) 
2. Other diagnoses 
made  
 No. of centres: 1 Recruitment dates: Aug 2000-Dec 2003    
 Length of follow up: n/s Total sample size: 225       
    Total drop-out/excluded: 0             
Khong, 2015 (300) Design: Retrospective cohort % Women: 54 
Intervention group 
(n=2349): All consecutive 
lower GI TWW referrals 
within the recruitment 
periods. 
1. Cancer conversion rate 
Acceptable 
 Study setting: Secondary care Median age (range): 67.5 (20-98)    
 No. of centres: 1 
Recruitment dates: 1st Feb 2012- 30th 
April 2012 and 1st Sept 2012-31st Oct 2012 
plus 'similar dates' in 2011 (Feb/Sept)    
 Length of follow up: 2 years Total sample size: 2349       
    Total drop-out/excluded: n/s             
Leung, 2010 (316) Design: Retrospective % Women: n/s 
Intervention group 
(n=1100): All consecutive 
lower GI TWW referrals 
1. Cancer conversion rate 
Low  Study setting: Secondary care Median age (range): n/s 2. Cancer stage at diagnosis 
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 No. of centres: 1 
Recruitment dates: 12 month period 
(dates not stated) 
within the recruitment 
period. 
3. Adherence to 
targets  
 Length of follow up: n/s Total sample size: 1100       
    Total drop-out/excluded: n/s             
Maruthachalam, 
2005 (317) Design: Prospective % Women: n/s Intervention group (n= 
630): All consecutive lower 
GI TWW referrals within 
the recruitment period. 
1. Cancer conversion rate 
Low 
 Study setting: Secondary care Median age (range): n/s 2. Other diagnoses made 
 No. of centres: 3 Recruitment dates: Jan 2003- Dec 2003 3. Adherence to targets 
 Length of follow up: n/s Total sample size: 639       
    Total drop-out/excluded: 9             
Mukherjee, 2010 
(318) Design: Retrospective % Women: n/s Intervention group (n= 
662): All consecutive lower 
GI TWW referrals within 
the recruitment period. 
1. Cancer conversion rate 
Low 
 Study setting: Secondary care Median age (range): n/s    
 No. of centres: 1 Recruitment dates: Feb 2007- Feb 2009    
 Length of follow up: n/s Total sample size: 662       
    Total drop-out/excluded: 0             
Padwick, 2013 (319) Design: Retrospective % Women: 59 
Intervention group (n= 
940, smaller subset of 573 
used for some data): All 
lower GI tww referrals 
within the recruitment 
period.  
1. Cancer conversion rate 
Low 
 Study setting: Secondary care Median age (range): 68.4 (21-98) 2. Other diagnoses made 
 No. of centres: 1 Recruitment dates: 2010    
 Length of follow up: n/s Total sample size: 940       
    Total drop-out/excluded: 68             
Panagiotopoulou, 
2013 (320) Design: Retrospective % Women: 53.8 Intervention group (n= 
918): All consecutive lower 
GI tww referrals referred 
for anaemia only, within 
the recruitment period.  
1. Cancer conversion rate 
Acceptable 
 Study setting: Secondary care Median age (range): 72 (61.9-80.9)    
 No. of centres: 2 
Recruitment dates: Nov 2008- Jun 2009 
and Apr 2010-Mar 2011    
 Length of follow up: n/s Total sample size: 1251       
    Total drop-out/excluded: 333             
Patel, 2014 (321) Design: Retrospective % Women: 53.1 
Intervention group (n= 
720): All consecutive lower 
1. Cancer conversion 
rate  Acceptable 
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 Study setting: Secondary care Median age (range): 68.5 (21-101) 
GI tww referrals within the 
recruitment period.  
2. Cancer stage at diagnosis 
 No. of centres: 1 
Recruitment dates: 1st Jan 2008- 31st 
December 2008 
3. Other diagnoses 
made  
 Length of follow up: n/s Total sample size: 720       
    Total drop-out/excluded: n/s             
Patel, 2016 (301) Design: Retrospective % Women: 54.3 
Intervention group 
(n=197): All consecutive 
lower GI tww referrals  
aged <50 referred within 
the recruitment period.  
1. Cancer conversion rate 
Acceptable 
 Study setting: Secondary care Median age (range): 45 (igr 41-48) 2. Cancer stage at diagnosis 
 No. of centres: 1 Recruitment dates: Dec 2008- May 2014 3. Survival data 
 
Length of follow up: Up until 
Sept 2014 (variable time 
depending on when recruited) Total sample size: 197    4. Adherence to targets 
    Total drop-out/excluded: 0             
Peacock, 2013 (295) Design: Retrospective % Women: 53 
Intervention group 
(n=887): All lower GI tww 
referrals referred within 
the two recruitment 
periods. (*shared data with 
Hall, 2015) 
1. Cancer conversion rate* 
Acceptable 
 Study setting: Secondary care Median age (range): 69 (61-79) 2. Cancer stage at diagnosis 
 No. of centres: 1 
Recruitment dates: Nov 2011 -Jan 2012 
and Feb 2012-Apr 2012 3. Other diagnoses made* 
 Length of follow up: n/s Total sample size: 933    
    Total drop-out/excluded: 46       
Rai, 2007 (322) Design: Review article  % Women: n/s 
Intervention group (n= 
1222): Not clearly stated 
1. Cancer conversion 
rate  
Low 
 Study setting: not stated Median age (range): n/s 
2. Adherence to 
targets  
 No. of centres: 2 Recruitment dates: Not stated       
 Length of follow up: n/s Total sample size: 1222       
    Total drop-out/excluded: n/s             
Rai, 2008 (323) Design: Prospective % Women: 52.8 Intervention group 
(n=509): All lower GI tww 
referrals within 
recruitment period 
1. Cancer conversion rate 
Acceptable 
 Study setting: Secondary care Median age (range): 68 (21-95)    
 No. of centres: 9 Recruitment dates: Sep 2003-Aug 2004    
 Length of follow up: n/s Total sample size: 1422       
    Total drop-out/excluded: 0             
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Raje, 2005 (324) Design: Rectrospective % Women: n/s 
Intervention group (n=not 
clearly stated): CRC's 
diagnosed within an 
undefined timeframe in 
2003 
1. Adherence to 
targets  
Low 
 Study setting: Secondary care Median age (range): n/s    
 No. of centres: 1 Recruitment dates: Not clearly stated    
 Length of follow up: n/s Total sample size: 77       
    Total drop-out/excluded: n/s             
Royle, 2014 (305) Design: Retrospective % Women: 54 
Intervention group 
(n=1606):  lower GI tww 
referrals with left-sided 
symptoms only within 
recruitment period. 
1. Cancer conversion 
rate  
Acceptable 
 Study setting: Secondary care Median age (range): 68 (18-96) 
2. Other diagnoses 
made  
 No. of centres: 1 Recruitment dates: Nov 2005-Nov 2009    
 
Length of follow up: 58 
months (12-58) median 35 Total sample size: 1690       
    Total drop-out/excluded: 84             
Saratzis, 2015 (302) Design: Retrospective, cohort % Women: 42 Intervention group (n= 
955):  lower GI tww 
referrals who had declined 
or had a negative FOB as 
part of BCSP (aged 60-75)  
1. Cancer conversion 
rate  
Acceptable 
 Study setting: Secondary care Median age (range): 62 (sd 5) 2. Cancer stage at diagnosis 
 No. of centres: 1 
Recruitment dates: 1st Jan 2012-31st Dec 
2012 3. Survival data  
 
Length of follow up: 20 
months (14-26) Total sample size: 955    
4. Other diagnoses 
made  
    Total drop-out/excluded: 0             
Shaw, 2009 (325) Design: Retrospective  % Women: 54.5 Intervention group 
(n=2159):  All lower GI tww 
referrals within 
recruitment period 
1. Cancer conversion rate 
Low 
 Study setting: Secondary care Median age (range): 58 (18-98)    
 No. of centres: 1 Recruitment dates: Aug 2005-Aug 2007    
 Length of follow up: n/s Total sample size: 2159       
    Total drop-out/excluded: 0             
Shaw, 2008(326) Design: Retrospective  % Women: 58.3 Intervention group 
(n=204):  Lower GI tww 
referrals with anaemia only 
within recruitment period 
1. Cancer conversion 
rate  
Low 
 Study setting: Secondary care Median age (range): 76 (40-97)    
 No. of centres: 1 Recruitment dates: Sep 2005-Sep 2006    
 Length of follow up: n/s Total sample size: 204       
    Total drop-out/excluded: 0             
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Smith, 2007 (327) Design: Prospective  % Women: 57 Intervention group (n= 
2748):  All lower GI tww 
referrals  within 
recruitment period 
1. Cancer conversion rate 
Acceptable 
 Study setting: Secondary care Median age (range): 66 (17-96) 2. Cancer stage at diagnosis 
 No. of centres: 1 Recruitment dates: Jan 2002-Dec 2004 3. Adherence to targets 
 Length of follow up: n/s Total sample size: 2748       
    Total drop-out/excluded: 0             
Sorelli, 2014 (328) Design: Retrospective audit % Women: 68 
Intervention group (n=50):  
All lower GI tww referrals  
within recruitment period 
1. Cancer conversion 
rate  
Low 
 Study setting: Secondary care Median age (range): 70 (35-86) 
2. Other diagnoses 
made  
 No. of centres: 1 Recruitment dates: Mar 2009-May 2009 
3. Adherence to 
targets  
 Length of follow up: n/s Total sample size: 59       
    Total drop-out/excluded: 9             
Spencer, 2004 (329) 
Design: Prospective 
(presented as a  letter) % Women: n/s Intervention group (n= 
243):  All lower GI tww 
referrals  within 
recruitment period 
1. Cancer conversion 
rate  
Low 
 Study setting: Secondary care Median age (range): n/s    
 No. of centres: 1 Recruitment dates: Jul 2000-Dec 2000    
 Length of follow up: n/s Total sample size: 243       
    Total drop-out/excluded: n/s             
Vaughan-Shaw, 
2013 (330) Design: Retrospective cohort % Women: 57 Intervention group 
(n=2731):  All lower GI tww 
referrals within 
recruitment period 
1. Cancer conversion rate 
Acceptable 
 Study setting: Secondary care Median age (range): 72 (19-102) 2. Other diagnoses made 
 No. of centres: 1 Recruitment dates: Jul 2007-Jul 2011    
 Length of follow up: n/s Total sample size: 2735       
    Total drop-out/excluded: 4             
Vulliamy, 2016 
(331) Design: Retrospective cohort % Women: n/s 
Intervention group 
(n=n/s):  All lower GI tww 
referrals within 
recruitment period 
1. Adherence to targets 
Low 
 Study setting: Secondary care Median age (range): n/s  
 No. of centres: 2 Recruitment dates: April 2009 - April 2015    
 Length of follow up: n/s Total sample size: n/s       
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    Total drop-out/excluded: n/s             
Studies with comparator       
Aslam, 2017 (297) Design: Retrospective, cohort % Women: n/s 
Intervention group 
(n=1139): All CRC's 
diagnosed via tww within 
the time frame. Also data 
on total tww population 
but not focus of the study.  
1. Cancer conversion rate 
Low 
 Study setting: Secondary care Median age (range): n/s 2. Cancer stage at diagnosis 
 No. of centres: 1 Recruitment dates: Jan 2005 - Dec 2012 3. Adherence to targets 
 Length of follow up: n/s Total sample size (baseline):16431 4. Survival data 
  Total drop-out/excluded: n/s Comparator group 
(n=2479): All CRC's 
diagnosed via non-tww 
within the timeframe 
   
            
Bevis, 2006 (292) Design: Retrospective % Women: 50.7 
Intervention group 
(n=97):All consecutive 
CRC's diagnosed within 
recruitment period via tww 
route 
1. Cancer stage at diagnosis 
Acceptable 
 Study setting: Secondary care Median age (range): 72 (25-96) 
2. Adherence to 
targets  
 No. of centres: 1 Recruitment dates: Oct 2002-Sept 2004    
 Length of follow up: n/s Total sample size: 216 Comparator group (n=96): 
multiple a) non fast track 
referrals b)emergency 
presentations 
   
      
    Total drop-out/excluded: 23       
Chohan, 2004 (332) Design: Retrospective % Women: n/s Intervention group (n= 
462): All lower GI TWW 
referrals within 
recruitment period 
1. Cancer conversion rate 
Low 
      
 Study setting: Secondary care Median age (range): n/s 2. Cancer stage at diagnosis 
 No. of centres: 1 
Recruitment dates: July 2000-December 
2001 
Comparator group (n= not 
clear): multiple a)non tww 
referral b) surgical/medical 
outpatient referrals c) 
medical inpatient referrals 
3. Other diagnoses 
made  
 Length of follow up: n/s 
Total sample size: 462 (comparator total 
size not stated) 
4. Adherence to 
targets  
      
    Total drop-out/excluded: n/s       
Courtney, 2013 
(333) 
Design: Retrospective, 
comparative analysis % Women: n/s 
Intervention group (n= 
9393): All lower GI TWW 
1. Cancer conversion 
rate  Low 
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referrals within 
recruitment period aged 
60-79 only 
   
 Study setting: Secondary care Median age (range): n/s 2. Cancer stage at diagnosis 
 No. of centres: 3 Recruitment dates: July 2006- Dec 2010 Comparator group (n= 
3322): Bowel cancer 
screening referrals within 
same recruitment period 
   
 Length of follow up: n/s Total sample size: 12715  (all ages)    
    Total drop-out/excluded: 0       
Currie, 2012 (303) Design: Prospective % Women: 49 
Intervention group (n=52): 
All cases of rectal cancer 
referred via any route 
within recruitment period 
1. Survival data  
Low 
 Study setting: Secondary care Median age (range): 68 (39-78) 
2. Adherence to 
targets  
 No. of centres: 1 Recruitment dates: Jan 2000-Dec 2005    
 
Length of follow up: Median 
5.03 years (0.91-5.89) Total sample size: 125  Comparator group (n= 73): 
Routine lower GI referrals 
   
    Total drop-out/excluded: 0       
Dua, 2009 (334) Design: Retrospective % Women: 70 
Intervention group (n= 
75): Cases of CRC 
diagnosed via lower GI 
TWW clinic 
1. Cancer stage at diagnosis 
Acceptable 
      
 Study setting: Secondary care Median age (range): 69 (24-88) 
2. Adherence to 
targets  
 No. of centres: 1 Recruitment dates: not stated Comparator group (n=75): 
Non-tww GI referrals that 
subsequently are diagosed 
with CRC 
   
 Length of follow up: n/s Total sample size: 150    
    Total drop-out/excluded: 0       
Flashman, 2004 
(335) Design: Prospective audit % Women: 60 Intervention group (n= 
695): All lower GI TWW 
referrals within 
recruitment period. 
1. Cancer conversion rate 
Low 
      
 Study setting: Secondary care Median age (range): 70 (25-93) 2. Cancer stage at diagnosis 
 No. of centres: 1 
Recruitment dates: 1st July 2000- 30th 
June 2001 Comparator group 
(n=1815): Routine lower GI 
surgical outpatient 
referrals 
3. Adherence to targets 
 Length of follow up: n/s Total sample size: 2573    
    Total drop-out/excluded: 63       
John, 2008 (290) Design: Retrospective % Women: n/s 
Intervention group (n= 
100): All consecutive lower 
GI TWW referrals within 
the recruitment period. 
1. Cancer conversion rate 
Low 
      
 
Study setting: Primary and 
Secondary care Median age (range): n/s 2. Other diagnoses made 
 No. of centres: 1 Recruitment dates: Not stated    
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 Length of follow up: n/s Total sample size: 200 
Comparator group (n= 
100) : Routine consecutive  
lower GI clinic referrals 
   
    Total drop-out/excluded: 0       
Neal, 2007 (304) Design: Retrospective % Women: n/s 
Intervention group (n= 
51): All CRC's diagnosed 
within the recruitment 
period for all referral 
routes.  
1. Cancer stage at diagnosis 
Low 
      
 Study setting: Secondary care Median age (range): n/s 2. Survival data 
 No. of centres: 1 
Recruitment dates: 2000-2001 (total 2 
years) 
Comparator group (n= not 
clear) : All non-tww CRC  
cases within recruitment 
period. 
3. Adherence to targets 
 
Length of follow up: Up until 
June 2003 Total sample size: 239    
    Total drop-out/excluded: 22       
Rao, 2005 (336) Design: Prospective % Women: n/s 
Intervention group (n= 
319): All lower GI tww 
referrals within 
recruitment period 
1. Cancer conversion rate 
Low 
 Study setting: Secondary care Median age (range): n/s 2. Adherence to targets 
 No. of centres: 1 
Recruitment dates: June 2003-December 
2003    
 Length of follow up: n/s Total sample size: Not clear 
Comparator group (n= not 
clear): Non-tww referral 
pathways 
   
    Total drop-out/excluded: n/s       
Schneider, 2012 
(293) Design: Retrospective  % Women: 50.7 Intervention group (n= 
96):  All CRC patients 
referred via any route with 
recruitment period  
1. Survival data 
Acceptable 
      
 Study setting: Secondary care Median age (range): 73    
 No. of centres: 1 Recruitment dates: Oct 2002- Sep 2004 Comparator group (n= 93): 
a) Non-tww referral 
pathways b)emergency 
presentation 
*Linked with Bevis, 2006 
 Length of follow up: 5 years Total sample size: 193    
    Total drop-out/excluded: 4       
Thornton, 2016 
(337) Design: Retrospective cohort % Women: 44.4 
Intervention group (n= 
197):  All CRC's diagnosed 
within recruitment period 
under care of two 
designated consultants 
1. Survival data  
Acceptable 
      
 Study setting: Secondary care Median age (range): 73    
 No. of centres: 1 Recruitment dates: Apr 2006-Dec 2012 
Comparator group (n= 
361): a)non-tww routes of 
referral b)acute admissions 
   
 Length of follow up: n/s Total sample size: 558    
    Total drop-out/excluded: 0       
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Walsh, 2002 (338) Design: Prospective audit % Women: n/s 
Intervention group (n= 
105):  All lower GI referrals 
within recruitment period 
1. Other diagnoses 
made  
Low 
      
 Study setting: Secondary care Median age (range): n/s 
2. Adherence to 
targets  
 No. of centres: 1 
Recruitment dates: 1st Aug 2000-31st Oct 
2000 Comparator group 
(n=124): a) non-tww 
referral pathway with 
lower GI symptoms 
   
 Length of follow up: n/s Total sample size: 229    
    Total drop-out/excluded: not clear       
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3.4.4 Studies including a subset population 
Eleven of the 49 papers reported outcome data on only a subset of the two-week 
wait cohort. Table 3.2 shows the subset papers by author, together with the 
subgroup category.  
Table 3.2: Summary of all papers reporting only TWW subset data and 
description of the subgroup. 
Author, year Subgroup 
category 
Number of full text 
papers 
Courtney 2013 Aged 60-79 1 
Currie, 2012 Rectal cancer 
cases only 
1 
Gaunt, 2011 Aged >80 1 
Glancy, 2004 Only investigated 
using barium 
enema 
1 
Hammond, 2008 Aged <80 1 
Khan, 2007 Only investigated 
using CT 
colonography 
1 
Panagiotopoulou,2013 
Shaw, 2008 
Referred for 
anaemia only 
2 
Patel, 2016 Aged <50 1 
Royle, 2014 Left sided 
symptoms only 
1 
Saratzis, 2015 Aged 60-75 1 
 
3.4.4.1 Age- restricted cohort 
Six papers included patients within a defined age range. These were categorised as 
follows; a) aged <50 years b) Aged 60-75 years c) Aged 60-79 years d) aged <80 
years  e) aged >80 years. The studies by Saratzis, 2015 and Courtney, 2013, 
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collected TWW data on a pre-defined age group in order to age-match this group 
with the Bowel Cancer Screening Programme (BCSP) population.  
3.4.4.2 Symptom-restricted and image-restricted cohorts 
Two studies included only the patients referred using the anaemia criteria. Royle, 
2014, excluded those with anaemia and palpable right sided mass. Two studies 
focussed on using one imaging modality only: Glancy, 2004, used a barium enema 
and Khan, 2007, investigated the use of CT colonography, with particular focus on 
extra-colonic pathology.  
Through consensus discussion between reviewers, it was agreed to include these 
TWW subset papers in the review as they included important results. However as 
these studies were not representative of the TWW cohort as a whole, and are 
therefore liable to distort results, they were analysed separately. Therefore unless 
otherwise stated in this results section, the eleven papers presenting subset populate 
data are not included in the main analysis.   
3.4.5 Quality of included studies 
The methodological quality of studies are provided in Table 3.1. No study was 
deemed to be of high quality. Nineteen of the 49 studies were of acceptable and 
remaining 30 were of low quality. Poor reporting of study population characteristics 
(item 2) and poorly defined outcomes (item 11) were the main contributory factors 
leading to the judgement of low quality. In the studies with a comparator, it was not 
clear what differences there were between patient groups regarding sex and age, 
making it difficult to assess a potential bias due to confounding. Conference 
abstracts were all judged to be of low quality due to the lack of comprehensive 
methodology possible due to a restricted word count policy.  
3.4.6 Synthesis of outcome data 
Results are reported according to outcome, as set out in the method. 
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3.4.7 Cancer conversion rate 
A total of 38 (77.5%) full-text study reports provided cancer conversion rates with 
a total study population of 70569. Nine (18%) of these provided data on a subset of 
patients (see table 3.2). 13 (86%) conference abstracts reported cancer conversion 
rate. Rai et al reported two separate cancer conversion rates, resulting in 52 values 
from 51 texts.  
The cancer conversion rate was reported as a total number, together with a 
percentage. Weighted mean cancer conversion rates were 8.4% (95% CI: 7.5-9.3) 
for the total group, 7.7% (95% CI: 6.9-8.5) for full papers, 8.2% (95% CI: 5.5-11.3) 
for the subsets and 10.4% (95% CI: 7.8-13.2) for abstracts. Figure 3.2 shows the 
results as a forest plot for the full paper reports with overall pooled cancer 
conversion rate using a random effects model.  The forest plots for cancer 
conversion rate for the subset and abstract groups are shown in appendix 4. 
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Figure 3.2. A forest plot of cancer conversion rate for full paper reports with corresponding 95% CI. Overall pooled 
conversion rate using random effects model is shown at the bottom of the plot. 
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3.4.8 Cancer stage data from studies with no comparator group 
The CRC stage was reported in 14 (28.5%) papers, 3 (21.4%) of which provided 
data only on a subset and therefore were analysed separately. Total study population 
was 39678. Of the reports that analysed an unselected TWW cohort, there were 9 
reporting Dukes staging. In 1 case, it was possible to convert TNM staging to Dukes 
(339) equating to a total of 10 staging results. Dukes D data was not reported in two 
of the studies.   Pooled data shows the proportion presenting at Dukes A = 11.2% 
(95% CI: 7.4-15.6), B=36.7% (95% CI: 30.8-42.8), C= 35.7% (95% CI: 30.8-40.8) 
and D=11.1% (95% CI: 7.3-15.5) (figures 3.3a and 3.3b). Data from the National 
Cancer Registration and Analysis Service (282) on Dukes staging at presentation 
for all CRC in England, are plotted using a vertical coloured line on each of the 
Dukes stage forest plots. This forms a comparison with national data on Dukes stage 
at presentation, corresponding values are: A=13.2%, B= 36.9%, C=35.9%, D= 
14.0%. The vertical lines transecting the CI bars in each Dukes stage plot indicate 
that there is no statistically significant difference between the distribution of stage 
at diagnosis in the TWW cohort, compared with using any route combined.  
Where the subset data was analysed, Courtney et al was the only study to report 
Dukes staging data and in the 60-79 age group only. Patel et al, who looked at the 
< 50 year age group only, reported that 22.2% had metastatic disease at 
presentation. In comparison Saratzis et al considered only patients aged 60-75 who 
had declined, or had a negative FOB, and found 19.2% of patients had metastatic 
disease at diagnosis.  
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Figure 3.3a and 3.3b Forest plot of papers reporting proportions presenting at Dukes stage A and B (figure 3.3a) and stages C 
and D (figure 3.4b). The coloured vertical lines represent the proportions presenting at each stage via any non-emergency route. 
Where reported, comparator group data is stated numerically. 
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3.4.9 Cancer stage from studies with a comparator (non-TWW) group 
Five groups also reported staging data on non-TWW cohorts for comparison. The 
proportion of patients presenting at each stage by comparator group is listed within figures 
3.3a+b but are also shown in table 3.3. On the forest plot, numbers in brackets represent 
sample size. The comparator groups were not consistent between studies. Aslam, 
Flashman and Neal analysed Dukes stage on an unselected TWW cohort, Courtney et al 
only looked at a subgroup aged 60-79 and provided comparative staging data on the 
Bowel Cancer Screening Programme patients.  
Table 3.3. Staging data from comparator (non-TWW) groups. Any statistical analysis 
provided by the author is also stated.   
 
Study ID, year Dukes staging Statistical analysis 
Aslam, 2017 TWW 
Comparator 
(urgent 
referrals) 
Calculated OR's for likelihood of 
having metastatic disease  
 A: 128 (17%) A: 63 (18%) tww vs Routine OR:1.33 CI: 0.98-
1.54 p=0.072  B: 287 (38%) B: 127 (37%) 
 C: 213 (28%) C: 108 (31%)  
 D: 90 (12%) D: n/s BCSP vs tww OR: 0.34 CI: 0.27-
0.47 p=<0.001   u/k: 38 (5%) u/k 14 (4%) 
Flashman, 2004 TWW 
Comparator 
(non-tww 
outpatient 
clinic) None performed 
 A: 9% A: 15%  
 B: 46% B: 38%  
 C: 44% C: 46%  
  D: n/s D: n/s   
Dua, 2009 
TWW 
(converted) Comparator 
Comparison between proportion 
with stage i/ii vs stage iii/iv in 
TWW and non-TWW was not 
significantly different p=0.87 
 A: 14 (18.6%) A: 13 (17.4%) 
 B: 26 (34.7%) B: 30 (40%) 
 C: 22 (29.4%) C: 18 (24%) 
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 D: 9 (12%) D: 14 (18.6%)  
  u/k: 4 (5.3%) u/k: 0   
Neal, 2007 TWW 
Comparator 
(Non-tww 
lower GI 
referrals) 
No significant difference in TWW 
vs non-TWW Dukes staging  
p=0.683 
 A: 4 (12%) A: 15 (19.5%)  
 B: 14 (42%) B: 29 (37.7%)  
 C: 15 (46%) C: 33 (42.9%)  
  D: 0 D: 0   
Courtney, 2013 TWW 
Comparator- 
BCSP 
Proportion of tumours at each 
Dukes stage were significantly 
different between TWW and BCSP 
groups i.e. significantly more 
Dukes A in BCSP group and more 
Dukes D in TWW group p=< 0.001 
(Aged 60-79 years 
only) A: 45 (15.4%) 
A: 180 
(50.6%) 
 B: 92 (31.5%) B: 79 (22.2%) 
 C: 86 (29.5%) C: 77 (21.2%) 
  D: 62 (21.2%) D: 16 (4.5%) 
 
The comparator data demonstrated there was more early stage disease in the BCSP 
compared with the TWW group with a significantly reduced OR. There were also fewer 
patients presenting with Dukes A in the emergency presentation group (8% vs national 
average of 13.3%).  
3.4.10 Other information on cancer stage 
Bevis et al, reported TNM staging data on those who underwent surgery with curative 
intent only, but it was not in a format that could be converted to Dukes staging.  They 
compared TWW data with those presenting to outpatients via non-TWW modes and 
emergency presentations. They did not find a statistically significant different in the 
proportion presenting with metastatic disease between the three groups (p=0.86).  
3.4.11 Other diagnosis 
This includes polyp detection rate, IBD, diverticular disease, non-colorectal cancer and 
other diagnoses (normal, IBS or haemorrhoids) 
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3.4.12 Polyp detection rate 
15 (30.6%) papers reported on polyp detection rate with a combined study population size 
of 7936. Only 6 stated that polyps detected were adenoma type, the remaining 9 did not 
state polyp type and therefore have been labelled as ‘undefined’. Pooled weighted polyp 
detection rates were calculated both for adenomas and polyps undefined separately and 
then as one group. Proportions were compared with the adenoma detection rate (ADR) 
found in the BCSP population (the figure was taken from the Coventry and Warwickshire 
regional bowel screening data for 2017); they were also compared with the UK global 
ADR (27, 340) (figure 3.4).  
The report by Khan et al was excluded from combined analysis as they only performed 
CTC on patients therefore the results are not representative of the standard TWW 
investigation pathway and have the potential to introduce unnecessary bias. 
ADR was 8.5% (95% CI: 6.6-10.6), polyp undefined detection rate was 12.6% (95% CI: 
9.3-16.3) and the detection rate for all polyps combined was 10.8% (95% CI: 8.5-16.3). 
All are lower than the ADR from colonoscopies via all routes combined and via the BCSP 
of 15.9% and 50.8% respectively.  
3.4.13 Non-CRC malignancy and other GI diagnoses 
17 papers reported on other diagnoses with a total sample size of 8150 (figure 3.5). 
Diagnoses were separated into non-CRC cancer, IBD, diverticular disease and other 
(normal, IBS or haemorrhoids). Diagnosis of non-CRC cancer and IBD were very low 
at 3.2% (95% CI :0.9-6.6) and 3.9% (95% CI: 2.9-4.9) respectively. Overall, 
diverticular disease was seen in 23.4% (95% CI: 18.9-28.1) of cases and 54. 6% (95% 
CI: 46.2-62.8) fell into the other category. 
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Figure 3.4. Forest plot of adenoma and undefined polyp detection rate with 95% CI. Red vertical line represents national ADR for all 
procedures, green vertical line represents ADR for the BCSP cohort.  
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Figure 3.5. Forest plot of non-CRC diagnosis rates with 95% CI. This includes a) other cancer (non-CRC), b)IBD, 
C) diverticular disease and d) Other (normal, IBS or haemorrhoids)
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3.4.14 Adherence 
Of those papers reporting on adherence to the TWW targets, the total study 
population was 9227. Data was categorised based on the operational standards set 
out by NHS England. Data reporting on compliance to standards is summarised in 
table 3.4. No statistical analysis was possible due to the small volume of data and 
heterogeneity between result reporting.  
Table 3.4. Summary of all data reported on adherence to operational standards 
for TWW referrals. Alphabetised by first author, time range in brackets where 
stated.  
 
TWW Routine 
Author, year Median 
days to 
specialist 
clinic 
Median 
days to 
diagnosis 
Median 
days to 
treatment 
Median 
days to 
specialist 
clinic 
Median 
days to 
diagnosis 
Median 
days to 
treatment 
Aslam, 
2017 
12 13 63 35 55 112 
Banerjea, 
2017 
 
24.5 
    
Barwick, 
2004 
10 (0-54) 
     
Bevis, 2006 31 (5-
127) 
 
42.5 (5-
173) 
69 (9-
1021) 
 
57.5 (7-
273) 
Chohan, 
2004 
12 (2-28) 
 
36 (9-
134) 
24 (1-
118) 
 
36.5 (1-
226) 
Currie, 
2012 
 
57 (31-
101) 
  
74 (31-
122) 
 
Dua, 2009 10 
 
74 57 
 
161 
Eccersley, 
2003 
10 (1-47) 
     
Flashman, 
2004 
12 
  
27 
  
Patel, 2016 11 (iqr 7-
13) 
     
Rao, 2005 13 (0-
276) 
  
25 
  
Vulliamy, 
2016 
11 (8-14) 
 
58 (49-
62) 
   
Walsh, 
2002 
8.64 47 
    
Abstract 
Gandy, 
2002 
9.7 (sd 5.1) 
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In general, the median days to specialist clinic target met the 93% operational 
standard in a high proportion of cases. Conversely, days from referral to treatment 
initiation were associated with median days outside of the desired timeframe (exact 
proportions cannot be calculated from the available data). 
3.4.15 Survival 
Only 7 papers reported any survival data with few consistent methods of data 
reporting, therefore meta-analysis was not possible. The total study population was 
18698. Table 3.5 provides a summary of the available information. 
 Table 3.5. Studies that reported survival rates in the TWW vs non-TWW cohorts.  
Author, year TWW non-TWW   
  2-year 
survival 
5-year 
survival 
2 year 
survival 
5 year survival 
Schneider, 
2012 
  60.3% +/- 
5.2 
  58.8 +/-5.3 
Currie, 2012   49% (1521 
days) 
  52% 
(1591 
days ) 
  
Thornton, 
2016 
74.10% 52.30%  73.9% (tww 
vs non-tww 
p=0.837) 
 53.8% 
p=0.889 
(tww vs 
non-
tww) 
  
 
2-year survival was only reported by Thornton, with 74.1% in the TWW cohort and 
73.9% in the non-TWW group alive at two years, p=0.837. They also found no 
statistically significant difference in 5-year survival between the TWW and non-
TWW groups, with survival at 52.3% and 53.8% respectively, p=0.889. Mean 
survival in this group was 52.7 months in the TWW cohort and 64.1 months in the 
non-TWW group p=0.912. Unsurprisingly the patients presenting acutely in this 
study had poorer survival trends with 2-year survival of 38.2% and 5-year survival 
of 23.7%.  
5-year survival was reported by Schneider as 60.3% in the TWW group and 58.8% 
in the non-TWW group. Mean survival was also similar; 43.5 months for TWW 
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and 43.7 months for non-TWW. In this study patients who presented acutely had 
43.5% chance of 5-year survival with mean survival 33.7 months. 5-year survival 
in the study by Currie was 49% in the TWW group and 53% in the non-TWW group  
Aslam found a median survival of 3.5 years in the TWW group, 5.4 years in those 
diagnosed via the routine pathway, 3 years in those referred urgently and 1.1 years 
in those presenting as emergencies. 
Few conclusions can be drawn based on this small amount of survival data.   
3.4.16 Assessment of heterogeneity and publication bias 
Heterogeneity was generally high for all reported outcomes, as calculated by I2. The 
main reason for heterogeneity was considered to be related to sample size, as stated 
previously, sample size was highly variable. However, this theory was tested by 
splitting the cancer conversion outcome data according to study sample size. 
Medium sample size was 630 patients, there were 16 papers below this sample size 
and 14 above. I2 values were 72% and 90% respectively. The two corresponding 
forest plots are contained in appendix 5. Therefore only a modest reduction in 
heterogeneity was demonstrated. In this case, other causes for heterogeneity are 
unknown.  Although demographic data reporting was inconsistent, where stated, 
the results for study population age and sex ratios were similar. In addition, the 
methodology behind the study design was similar. A funnel plot was not possible 
as there were too few studies comparing the two-week wait pathway with a 
comparator group 
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3.5 Discussion 
In this systematic review and meta-analysis the available data on key outcome 
measures for the lower GI TWW referral pathway has been summarised and 
analysed in 49 studies and 15 abstracts with a total study population of 93,655. 
3.5.1 Cancer conversion rate and stage at diagnosis 
3.5.1.1 Major findings 
The pooled cancer conversion rate was 7.7%. This is comparable to the cancer 
detection rate in the asymptomatic BCSP population of 8% (2017 data) and applies 
to a similarly aged cohort: median age of the patients in this study was 72 years, 
compared with the 60-75 age group for cancer screening. This result is also 
consistent with the overall cancer conversion rate for all cancers diagnosed through 
any TWW pathway which is 7.6%(148). Although a large amount of data is 
collected on a quarterly basis on TWW pathways by NHS England, as mentioned 
previously, the national TWW performance data for cancer conversion rate is not 
kept for each individual cancer. Data can be extrapolated to give an estimate of the 
conversion rate for each site, but there is the likelihood of introducing error as 
cancer diagnosis is calculated from the total number meeting the target to start 
treatment within 62 days. This is likely to be inaccurate as there is no definite way 
of ensuring cases that don’t meet the target, but have cancer, or those not treated 
are not missed. In addition, it is not entirely clear patients included in the figures 
have a diagnosis of colon adenocarcinoma as it is not possible to cross check 
individual cases with histology.  Due to the above gaps in accurate data collection, 
results of this review provide the largest and most comprehensive dataset on cancer 
conversion rate in the lower GI TWW population.  
This is the first report to document staging data for the TWW cohort. Overall stage 
at diagnosis for Dukes A-D was 11.2%, 36.7%, 35.7% and 11.1% respectively. 
When compared with the national staging data (341) no statistically significant 
difference in stage distribution was seen in the TWW cohort compared with CRC 
diagnosed via any route combined. Nearly half of patients present with stage three 
or four disease with corresponding survival of 47.7% and 6.6% respectively (342). 
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According to the National Cancer Intelligence Network (NCIN) report on colorectal 
staging data quality (343), nationally collected data is poorly reported and 
incomplete. Stage at diagnosis is directly linked to survival, results from this review 
indicate that the TWW process is not having a significant impact on improving CRC 
survival.   
3.5.1.2 Strengths and limitations of the evidence 
This review encompasses a large unselected population size with a high number of 
reports evaluated from a wide range of centres nationally, this should theoretically, 
provide data on a far reaching socio-economic and ethnically diverse population, 
although this cannot be confirmed as this data was not presented by any study. As 
discussed previously, the general quality of papers was predominantly poor. Cancer 
conversion rate is a hard endpoint: it is therefore reasonable to assume values were 
accurate and comparable unless, where stated, a subset was used. The value of 
abstract data was limited as it appeared to be subject to significant bias resulting in 
a higher cancer conversion rate than seen from the full paper reports. Several 
reasons could explain this. Firstly, most of this abstract data was produced in the 
one to two years following TWW implementation, therefore it is possible that the 
referral criteria were more rigorously adhered to hence the higher cancer detection. 
Also there is likely to be a degree of lead time bias due to the implementation of a 
new system for cancer detection, so a transiently higher incidence would be 
expected. It has been acknowledged in this review that heterogeneity is high 
between the studies, and cannot be fully explained by sample size. This must be 
taken into consideration when assessing the results.  
3.5.1.3 Consistency of the findings  
There has been only one other review looking at TWW outcomes in lower GI cases. 
As highlighted in the introduction Thorne et al left some gaps in methodology and 
evidence collection. They found a cancer detection rate of 10.3%. The higher 
detection rate may relate to the year of publication of included studies. It was 
performed close to the initiation of the TWW pathway, with the same bias that 
applied to the conference abstract results playing a role. Additionally, the referral 
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criteria have since been widened. This has resulted in an increase in the number of 
patients eligible for referral and a subsequent increase in the number of non-CRC 
cases being investigated.  
3.5.2 Other non-CRC diagnoses made and adherence to referral targets  
3.5.2.1 Major findings 
There were a high proportion of non-CRC diagnoses made through the TWW 
pathway, which reiterates the fact that lower GI symptoms are largely non-specific 
and present in a variety of GI complaints. ADR was 8.5%, much lower than the 
BCSP rate at 50.8% or the overall ADR via all routes to colonoscopy at 15.9%. The 
lower ADR may be related to year of data collection, as many are over ten years 
old. There has been a concerted drive in recent years through targets and guidelines 
to use ADR as a marker of endoscopist performance (340). Endoscopists receive 
their individual ADR and this is monitored by the Joint Advisory Group (JAG) 
against expected targets.  Advances in scope technology and bowel preparation 
have added further to improvements in polyp detection.    
The presence of adenomas probably represent incidental findings rather than being 
related to symptomatology in the majority of cases, most small polyps are unlikely 
to cause symptoms. 
Other diagnoses were split into other non-CRC cancers, IBD, diverticular disease 
and other (comprised of IBS, normal and haemorrhoids). Cases of IBD and other 
cancers were low and over half the patients either had a diagnosis of normal, IBS 
or haemorrhoids. This reiterates the poor predictive value of the symptomatic 
patient in the diagnosis of significant lower GI pathology. NHS England makes no 
comment on the probability or expectation that non-CRC diagnoses will be made 
through the TWW pathway, but these results indicate that a patient is more likely 
to have no pathology than any other diagnosis combined.  
Adherence data was heterogenous and comparisons were difficult as the median 
days to target does not make it clear if operational standards were met. There were 
widely varying ranges within each result with very little adherence data on target to 
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starting treatment. It is possible that this data is harder to capture from computer 
databases. In summary, no firm conclusions on adherence data can be made from 
this review due to the paucity of data and variations in reporting technique.  
3.5.2.2 Strengths and limitations of the evidence  
The reporting of non-CRC diagnoses was sporadic in the reviewed papers and 
incomplete in many cases, with just specific diagnoses reported (often just GI) 
therefore cases outside the GI tract may not have been declared. Nonetheless, the 
diagnosis is based on a highly sensitive test (colonoscopy) so, where stated, the 
result is likely to be accurate. Adherence to referral target data was poorly reported 
and is liable to bias depending on the year it was reported from. It was difficult to 
extract meaningful data from reports hence comparative analysis was not possible.  
3.5.2.3 Consistency of findings 
This is the first systematic review to report on non-CRC diagnoses or adherence to 
operational targets in the lower GI TWW cohort. Adherence data is collected 
nationally and demonstrates poorer compliance with targets related to treatment 
initiation within 62 days compared with the 14-day initial target referral out outset. 
The limited data in this review is consistent with these findings.   
3.5.3 Survival  
Most studies did not include patient follow up and hence did not provide survival 
data. However, the limited data indicates there was no difference observed between 
the survival in the TWW and non-TWW cohort, although those presenting as 
emergencies tended to have a poorer outcome, which correlates with evidence 
demonstrating they present at a later stage of disease. Data from the National Cancer 
Intelligence Network demonstrates that there are only marginal differences in one-
year survival between patients presenting through any outpatient referral pathway 
and the TWW. In the TWW cohort around 82% survive one year compared with 
around 80% one year survival in non-TWW GP referrals (341). This suggests a 
longer time from referral to diagnosis and subsequent treatment as seen in the non-
TWW cohort does not affect survival. However, the impact of morbidity must not 
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be underestimated: delays to treatment in patients with known malignancy has a 
significant psychological impact despite no effect on cancer survival.  
3.5.3.1 Strengths and limitations of the evidence 
The evidence of survival was sparse therefore no firm conclusions can be made on 
survival in the TWW lower GI cohort from this systematic review. 
3.5.4 Impact of the results 
The results provoke a reconsideration of the benefits of the TWW pathway for CRC  
Although there is no defined cancer detection target, there has been a series of DOH 
proposals: the now archived NHS Cancer plan, published in 2000 declared an 
aspiration that ‘90% of cancer be diagnosed via the TWW pathway’(144). This 
indicates that the pathway is falling short of expectation with a low cancer 
conversion rate and majority of patients diagnosed with CRC via a non-TWW route, 
but this is mirrored when looking at nationally collected data on cancer conversion 
rate via TWW. Conversely the vast majority of TWW patients do not have cancer 
at all.  Latest results from the National Cancer Registration and Analysis Service 
from 2016 report conclude that around 31% of all CRCs are diagnosed via the 
TWW route, compared with 10% via screening, 23% via non-TWW GP referral 
and 23% as emergency presentations (282). This raises questions about the 
justification for resource prioritisation to TWW patients. A precedent for re-
evaluation and change to the current system should be considered.  
Key to the difficulties in diagnosing CRC is the poor predictive value of lower GI 
symptoms for CRC: they are often vague with a large cross over with symptoms of 
benign disease, therefore a referral system heavily based on symptoms is highly 
likely to result in investigation of patients with benign disease or no disease at all. 
So-called ‘soft’ symptoms such as abdominal pain, constipation and diarrhoea with 
PPVs of around 1% (146). Anaemia is a more useful referral criterion with a higher 
PPV. A case –control study found the PPV of a Haemoglobin <11 in men and < 10 
in women for CRC was 13.3% and 7.7% respectively in the over 60s age group 
(344). This is supported by anaemia sub-group in this review where a higher 
incidence of cancer was found.  
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In 2015 the NICE referral guidelines were revised with inclusion of symptoms with 
PPV of 3% or more for cancer, a reduction in PPV from 5%. As a future study it 
would be useful to compare outcome data before and after this change was 
implemented to observe its effect on cancer conversion rate. Khong and Peacock 
both analysed data shortly after a Government awareness campaign. It is interesting 
to note that this did not significantly affect cancer conversion rate but did increase 
the total number of TWW referrals(295, 300),  suggesting that heightened 
awareness has a bigger effect on the ‘worried well’, without targeting those with 
disease.   
Although not a defined outcome measure in this review, it is well documented that 
adherence to the referral criteria by GPs is poor. The reasons for this are 
multifactorial. Firstly, the vast majority of what GPs deal with daily is benign 
disease. A full time UK GP will see a new cancer approximately once a month (any 
cancer), they therefore become expert in diagnosing what is not cancer, as opposed 
to what is cancer (146). In addition up to 10% of general practice consultations are 
due to abdominal pain and most will have a benign cause (103). The National Audit 
Office reported in 2010 a more than fourfold variation in referral rates across 
England and Wales. Although some of this can be explained by variations in 
proportions of elderly in the population, and the impact of social differences such 
as smoking and alcohol intake, this does not fully explain the referral behaviour 
(345).  
GPs face an enormous challenge in balancing their referral behaviour with the 
knowledge that they are judged predominantly on their pick-up of cancer, with little 
credit or recognition for management of benign disease. There is, perhaps, a culture 
of criticising the GP at secondary care level for inappropriate referral behaviour, 
but well-recognised are the non-specific symptomatology that many cancers cause 
that can often be attributed to benign disease. It is not surprising that primary care 
fast-track referrals are more readily initiated for cancers with more specific 
presentations e.g. breast or testicular (346). Some GPs have welcomed the idea of 
feedback on their referral patterns and ‘hit rates’ in terms of cases referred that have 
malignancy. Some feel this will have a positive influence on their decision making, 
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but conversely, others may feel even more pressure to ‘get it right’ leading to high-
pressured decision making which neither benefits the patient nor the GP. Certainly 
more cohesion between primary and secondary care is likely to beneficial.  
Lack of an alternative option for patients with symptoms to be seen rapidly, 
encourages TWW referrals from primary care. Perhaps if the time-frame for urgent 
and routine appointments were more reliable, allowing the GP reassurance that their 
patient would be seen within a set time-frame, they might be less inclined to use the 
TWW pathway when a patient does not entirely meet the criteria. Before the TWW 
process was introduced, it was clear that patients were waiting vastly different 
amounts of time for investigations depending on the pressure facing each NHS trust 
and regression to this system would be wrong.  However the current targets are 
without good quality supportive data to justify them and this review does not 
support an improved stage at diagnosis.  
Undoubtedly there is psychological morbidity associated with waiting for 
investigations for suspected cancer, however a pragmatic approach must be taken 
in the financially strained NHS. An all-encompassing referral pathway that all 
patients with lower GI symptoms can be referred through, e.g. six week-pathway, 
with subsequent targets for diagnosis and treatment has been suggested by some at 
both primary and secondary care level. It is unclear whether this would be feasible 
or, conversely, put more strain on the system by holding every patient to a tight 
time-frame. A recent study by Redaniel et al gauged clinicians’ opinion on the CRC 
TWW pathway: many acknowledged they used the pathway knowing some patients 
did not quite meet the referral criteria, but they had clinical concerns about them 
and felt reassured they would be seen within two weeks (149). This is likely to be 
a common scenario that would be addressed by a one-target referral pathway 
regardless of symptom. 
The move by the DOH to encourage increased direct access tests for GPs may be a 
positive step in the diagnosis of cancer at an earlier stage or conversely corroborate 
a suspected benign diagnosis, but this will need monitoring to evaluate whether this 
is just simply increasing a trend towards more investigations in the well or whether 
it constitutes a less convoluted diagnostic journey for those with malignancy (347). 
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At secondary care level, once a referral is made, investigation pathways are variable 
and devised to balance cancer pick-up rates with logistical feasibility given the 
demands the system places on a hospital trust. Several NHS trusts who collected 
data included in this review used, or suggested tailoring, the referral pathway to a 
straight-to-test model or alternatively phone-based consultations. Innovative ways 
of meeting the heavy demands due to rising referrals numbers are important. Their 
results demonstrated success with a potential cost advantage by avoiding additional 
steps in the pathway to diagnosis. There is no suggestion from this review that these 
pathways improved cancer conversion rates, but they did not seem to miss cancer 
either. A large-scale case control study may provide more evidence for the 
feasibility of this model.  
The introduction of an objective laboratory test in risk stratifying a patient with 
symptoms has the potential to increase both sensitivity and specificity of referrals 
in the future and would mark a shift away from a predominantly symptom-based 
referral system. Although FOBT was introduced to the 2015 NICE lower GI 
suspected cancer referral criteria, there is currently no robust evidence for its use in 
the symptomatic population, particularly using the guaiac faecal test which is still 
in use. An update to the guidelines in 2017 introduced FIT testing to the referral 
criteria for patients with ‘unexplained symptoms’. Although there is little data on 
its use in the symptomatic population, it is a rapidly expanding field of research. As 
a screening tool, there is already a large body of evidence that FIT is superior to the 
standard guaiac faecal occult blood test (134, 348, 349), although implementation 
across the UK is still in planning stages. Currently FIT seems to perform poorly for 
detecting adenomas, but it is likely in the next few years that there will be an 
increased understanding of the role of FIT in CRC detection outside the screening 
setting with probable key role in risk stratifying TWW referrals for suspected CRC, 
with a negative FIT as a rule out test. Widlak et al looked at 430 patients from the 
TWW cohort using FIT and FCP in combination to assess positive and negative 
predictive values for CRC. NPV were high at 99%, but this did not alter whether 
FIT was used in combination with FCP, or alone (350).  
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Also of increasing interest, and implemented in the United States is multitarget stool 
DNA testing. Currently one commercial test, called Cologuard is available and 
works to detect ten DNA-based markers and one human haemoglobin biomarker in 
stool. Results are combined to produce a diagnostic algorithm which equates to a 
positive or negative test (101).  Results from one blinded screening study were 
impressive, with sensitivity of 92.3%  (351) and results were similar from a second 
study with sensitivity and specificity data seen at 100% and 93% respectively, 
although numbers were small (352). Currently this test is not available within the 
NHS but may hold promise in the future.  
3.5.5 Strengths and limitations of the review 
This is the first systematic review of all available evidence on key outcomes of the 
lower GI TWW pathway. There are several limitations to be acknowledged. Firstly, 
the restrictions created by lack of data reporting in some studies limits the 
comprehensiveness of evidence and precision of the review findings. However, 
exclusion of these studies would have led to data gaps. In addition, where reported, 
demographic data was largely consistent meaning it is reasonable to assume in a 
similar unrestricted TWW cohort in another area the population should be generally 
comparable. Due to slight deviations in TWW protocol papers from Scotland and 
Northern Ireland were excluded at the full paper stage and therefore the results of 
this review may not be generalisable to the whole UK population. As already 
acknowledged the heterogeneity of the studies was moderate to high when results 
were pooled in the meta-analysis. 
3.5.6 Future research recommendations 
Future research recommendations according to the PICOTS (Population, 
Intervention, Comparator, Outcome, Timing, and Setting) framework along with 
limitations in evidence are provided below: 
Population and setting 
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Limitations: There is a paucity of well conducted studies on the TWW cohort with 
complete demographic data including race, BMI, smoking status and other 
important variables. 
Recommendations: Evidence from well conducted prospective cohort studies with 
comprehensive demographic data that can be matched against key outcomes such 
as cancer conversion rate and stage, would be welcomed and provide crucial 
evidence allowing better risk stratification of the TWW cohort. 
Intervention and comparator 
Limitations: Although the TWW cohort was clearly defined, most studies lacked a 
comparator group and those that did provided inconsistent comparator outcome 
data. 
Recommendations: Clearly defined comparators such as urgent or routine referrals 
are extremely useful when calculating effect of key outcomes in conjunction with 
the TWW group  and facilitate risk of bias assessment better. 
Outcome 
Limitations: Apart from cancer diagnosis, there was significant variability in 
outcome reporting e.g. cancer stage was reported as Dukes, TNM, or just as a 
percentage with metastases making comparisons more difficult. Also polyp 
detection rate was ambiguous in some cases as it was not clear if polyps or 
adenomas were counted   
Recommendations: The use of accurate and standard methodology for reporting 
cancer staging and adenoma conversion rate would ensure more valid estimations 
and comparability. 
Timing 
Limitation: There was a lack of follow up in the majority of studies meaning 
survival data was scanty and, where present, was inconsistently reported. 
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Recommendations: Five-year follow up data would provide robust information on 
mortality to fill a knowledge deficit in TWW survival. 
Policy implications 
The findings of this review will help to inform those implementing the TWW 
pathway of its effect on key performance measures. It also serves to provide 
feedback to both primary and secondary care of the possible outcomes for their 
patients who meet TWW criteria. 
3.6 Conclusion 
This systematic review is the first to summarise comprehensively, key outcome data 
for the TWW lower GI referral pathway in a large subset of patients. Results 
indicate that cancer conversion rate is low with no difference in stage at diagnosis 
using this pathway compared with other routes to diagnosis. Clearly the 
Government’s ‘cancer-plan’ holds focus on not missing cancer, and picking up 
more cases. This is not supported by the results of this review. A referral system 
heavily weighted on symptoms has a low PPV detecting malignancy. Solutions to 
the problem of balancing improving cancer detection without over-saturating an 
extremely stretched system are not easy to devise. Target-driven health services are 
important, but must be regularly evaluated to ensure they serve their purpose and 
that costs are justified.  Several areas for change have been suggested in this review 
in order to improve the cancer conversion rate: in particular the wider use of FIT 
testing in conjunction with symptoms is likely to provide an adjunct to better predict 
cancer in the symptomatic population in the future.    
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CHAPTER 4: 
 Methodological development of 
volatile organic compound 
analysis in the detection of 
colorectal cancer 
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4.1 Introduction 
There are many analytical instruments that are able to detect VOCs. The choice is 
dependent on a variety of factors including experience, expertise, cost and 
accessibility. In order to transcend the clinical environment for point of care testing, 
ideally, they need to be portable and easy and cheap to use. They must also be highly 
sensitive and selective, as VOCs are likely to contain a variable mix of compounds 
with a variety of molecular weights (156). GC-MS is often seen to be the gold 
standard analytical technique, as it provides chemical separation and isolation 
allowing the observer to potentially pinpoint the required chemical (156). However, 
GC-MS has many practical drawbacks when being used in a clinical environment. 
For example, it is large and immobile, and requires specialist training for use and 
interpretation of results (170, 232). FAIMS collects data by detecting ions based on 
their mobility. This technique has been selected for the majority of VOC 
experimental analysis in this thesis. FAIMS was chosen due substantial experience 
gained by previous FAMISHED research groups, which demonstrated the 
diagnostic ability of FAIMS in a variety of diseases (154, 236).  Furthermore, 
FAIMS demonstrates high levels of sensitivity in ion detection and because of its 
portability, has potential for use within the clinical setting as a point of care 
diagnostic tool. However, GC-IMS was used for a subset of patients as an emerging 
diagnostic tool with exciting potential, in order to make comparisons with the 
FAIMS results and also to capture chemical information in an attempt to establish 
the identity of the chemicals within the urine samples. 
 
In this chapter the analytical techniques used in this thesis will be described in 
detail. In addition, a series of experiments that were carried out for methodological 
development purposes in order to optimise sampling technique and reduce factors 
that may confound results are reported. 
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4.2 Analytical techniques 
4.2.1 FAIMS 
FAIMS is also known as differential mobility spectrometry (DMS). It is a gas 
detection technology that identifies chemical ions based on their mobility under 
high electrical fields. Sample analysis involves a number of stages (figure 4.1) 
(353). 
FAIMS can detect volatiles from aqueous, solid and gaseous sources, which means 
it can be used to analyse a wide variety of bodily products. Sample preparation will 
depend on the type of sample you are analysing and the user’s preference. 
Throughout this thesis the Lonestar (Owlstone, UK) instrument was used. There 
have been several Lonestar software upgrades during the time period of the 
experimental work. Each upgrade is specified by version number (earliest version 
is 1 and the latest used was 4.1), the outer body of the instrument has not changed 
between experiments nor the computer element. The version used for each 
experiment is denoted within the corresponding method.  
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Figure 4.1 Schematic of the FAIMS analysis process from sample introduction to 
ion count detection. (Schematic adapted from Owlstone, UK manual with 
permission(353)) 
 1. Vapour phase – the sample is introduced via a carrier gas to the ionisation region. 
Here components are ionised via a charge transfer process or by direct ionisation. 
Both positive and negative ions are formed.  
2. The ion cloud enters the electrode channel, here a radiofrequency (RF) waveform 
is applied, creating a varying electric field under which the ions follow different 
trajectories depending on their mobility.  
3. A direct current (DC) voltage, called a compensation voltage (CV) is swept 
across the electrode channel shifting the trajectories to the path of the detector 
allowing more ions to reach it. The detector then recognises both positive and 
negative ions.  
4. The number of ions detected represents the concentration of chemical in the 
sample.  
 
 
Chemical detection using FAIMS  
The Lonestar requires a carrier gas to drive ions through the electrode channel to 
the detector plate, this initiates ionisation. The proportion of ions that make it to the 
detector increases with increasing flow, improving sensitivity, but it is essential that 
the carrier gas is free from impurities. Ion detection is based on detecting varying 
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mobility of ions based on their mass to charge ratio via the following process (170, 
353):  
Ionisation 
An ionisation source is required. In this case radioactive nickel-63 was used. Ni-63 
undergoes beta decay which generates energetic electrons that interact with the 
carrier gas to form stable +ve and –ve intermediate ions. These give rise to reactive 
ion peaks (RIP) in the positive and negative FAIMS spectra (figures 4.4 and 4.5). 
The RIP ions transfer their charge to neutral molecules through collisions. The 
likelihood of ionisation is determined by the analytes affinity towards protons and 
electrons. 
Mobility 
Ions in air under an electric field will move at a constant velocity proportional to 
the electric field, this denotes their mobility. In FAIMS, when the ions enter the 
electrode channel, applied radio frequency (RF) voltages create oscillating areas of 
high and low velocity electric fields as the ions are moving through the channel. 
Depending on the ion’s mobility, the trajectory of the ion moving through the 
channel will change as the high and low electric fields are applied. The composition 
of a chemical ion will directly affect its mobility through the oscillating electric 
field, and other factors such as humidity, temperature and pressure all have an 
effect.  
Compensation Voltage 
Ions of different mobilities travel along the electrode channel, some will not arrive 
at the detector as they are destroyed by colliding with an electrode. To increase the 
proportion of ions reaching the detector, a compensation voltage (CV) is applied 
between the top and bottom electrode. This serves to re-centre some ions allowing 
them to hit the detector, it also produces a CV spectrum. Ion mobility can be 
demonstrated as a compensation voltage at a set electric field.  
Factors affecting sampling  
Several sampling factors will affect the concentration of vapour analysed: 
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 a) The pre-concentration time is key as build-up of vapour concentration in the 
headspace increases with time until the headspace is saturated. 
 b) Sample temperature has a direct effect on altering evaporation rates and the time 
taken for the headspace to reach saturation. The more volatile chemicals will 
evaporate more readily. The volatility of analytes can be reviewed by looking at 
their vapour pressure, where the pressure at which the gas phase of the analyte is in 
equilibrium with the liquid phase. Increasing the temperature may help to increase 
the rate of evaporation of a sample. If the chemical tested for is known, then the 
sampling temperature can be set to optimise detection, however previous 
experimental work performed found temperatures over 400C forced water into the 
system which disrupted results.  
c) It is also important to recognise the effect of analyte solubility on chemical 
detection. In the case of biological sampling the chemical profile is yet unknown, 
the more soluble the analyte, the less likely it is to leave the urine.  
d) pH also effects analyte solubility, increased acidity can result in more of the 
analyte being in vapour form, but with other solutions the reverse is true. Again, if 
the chemical in question is known, the pH of the solution can be altered to maximise 
headspace vapour concentration (354). In all experiments in this thesis the pH was 
not altered. 
Manual headspace sampling 
The At-Line Sampling Module (ATLAS, Owlstone, UK) was designed to be 
combined with the Lonestar system to ensure that headspace sampling is simple and 
reproducible. The headspace refers to the compounds in the gas phase above the 
liquid sample within the vial and this is where the VOCs are extracted from. 
Sampling occurs as follows (354). 
 
1. A 10ml headspace glass vial (Thames Restek, UK) containing 5mls of 
thawed sample is placed in the ATLAS sampler. It is important the dip tube 
(which collects the headspace) does not come into contact with the liquid 
sample.  
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2. It is held at a constant temperature of 40 0C whilst in the sampling device 
3. Chemicals from the urine sample desorb and move into the headspace of the 
vial.  
4. A dip tube is lowered into the headspace.  
5. A constant flow of clean, dry air (purge flow) is passed through the 
headspace and into the Lonestar, sweeping the analytes into the detector 
using a dynamic sampling method. 
6. Standard Lonestar settings were: Flow rate 2000 mL/m, 0.978 pressure 
barg.  
 
Figure 4.2 Picture of the ATLAS sampling module (red arrow) which introduces 
sample headspace to the Lonestar device (gas flow shown by blue arrow) 
 
 
 
Auto sampling 
There is no commercially available auto sampling system produced by Owlstone 
for use with the Lonestar instrument, therefore the Biosensors team at Warwick 
University developed a method to connect a modified Gerstal MPS to the Lonestar 
to improve speed and consistency of sampling.  
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Sampling method:  
1. Once defrosted, 3ml samples were aliquoted out into 10mL glass vials 
suitable for use with an auto sampler. After the samples were aliquoted, each 
vial was sealed using the crimp cap and septa (Chromacol). 
2. Sample ‘blanks’ of air were sealed using the same method. 
3. Both the air blanks and the samples were then placed into the auto sampler 
trays. The auto sampler tray for the urine samples was set to 400C. Once the 
urine samples were placed in this tray their temperature was allowed to 
equilibrate for 30 minutes prior to sampling. 
4. Flow rates for the Lonestar were controlled by the MFC, settings were 
determined by earlier experimental work. The settings were as follows: 
300mL/min of air to the sample and 1700 mL/min make up flow. The set-
up of the auto sampler was bespoke, allowing the sample air flow to move 
through the auto sampler with a purge tool directly into the sample vial, then 
back out and into the Lonestar by use of heated transfer lines. 
5. Prior to the sample data being obtained, both the samples and the air blanks 
were heated to 40 0C and agitated. Air blanks were heated and agitated for 
90 seconds, whilst the chilled samples were heated and agitated for 8 
minutes. This was automated by auto-sampler software. 
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Figure 4.3 Picture of the Lonestar FAIMS instrument together with auto 
sampler. 1. Lonestar FAIMS  display screen 2. ATLAS Pneumatic control box and 
heater control box 3. Auto sampler 4. Cooling tray containing sample vials 5. 
Chiller control.  
 
 
4.2.2 FAIMS matrix 
The Lonestar FAIMS is set up to scan between 0 and 100% dispersion field in 51 
steps and a compensation voltage of between -6 V and +6 V in 512 steps. The 
chemical information gathered is termed a matrix and represents 52,224 data points 
for both positive and negative ions collectively. Multiple matrices can be gathered 
for each sample, by performing multiple sample runs where the process is repeated. 
A matrix is most frequently presented as a 2D colourplot: here colour contours 
represent data on chemical composition forming a unique spectra. This is dictated 
by the ion current at each electric field/compensation voltage point and are 
constructed using a bespoke software program (figure 4.4). A colourplot should 
have two peaks: the reactive ion peak (RIP) and product ion peak (PIP). The RIP 
demonstrates the background ion detection present in any environment, as even 
after cleaning there will still be some contamination in the system, but as this is 
constant it does not interfere with analysis. The PIP represents information 
collected from sample analysis. To further demonstrate what the colourplot 
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represents the same information is shown as a 3D waterfall plot in figure 4.5. Files 
can be saved within the Lonestar computer, or exported for analysis.  
Figure 4.4 Lonestar colourplot showing a dispersion field matrix. Orange circle 
represents the Reactive ion peak (RIP) due to ‘background noise’, green circle 
represents product ion peak (PIP)representing information collected from the 
specific sample 
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Figure 4.5 Lonestar dispersion field matrix demonstrated by a waterfall plot 
showing the same data points as figure 4.4. The z axis is the ion current. (image 
used with permission from Owlstone, UK) 
 
 
 
In order for this method of chemical detection to be successful in testing biological 
samples for disease it requires several factors: 
1. The disease in question produces a specific set of chemical changes in urine 
that are seen consistently when the disease is present. 
2. This unique chemical fingerprint must be stable within the urine sample 
under collection and storage conditions. 
3. The chemicals must be consistently present in high enough concentrations 
to allow detection by the Lonestar. 
4.2.3 Statistical analysis 
Analysis is performed using machine learning methods. This method utilises a 
computer-devised algorithm that can make predictions on unknown datasets 
comprised of thousands of data points that are created following the analysis of a 
single urine sample. Firstly, the algorithm builds a model based on a training set of 
data where the output, or diagnosis, is known. Once this model is constructed, 
datasets of unknown outcome can be fed into the algorithm and a diagnostic 
prediction can be made.   
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Machine learning methods of data analysis for disease detection is a new, but 
rapidly expanding area. Multiple data analysis pipelines have been developed, and 
continue to be advanced in order to improve data classification and disease 
detection. The three methods used in this analytical work are now described: 
Method one 
Statistical analysis of data obtained through Lonestar was processed in a custom 
LabVIEW program (Ver 2012, National Instruments, USA) using Fisher 
Discriminant Analysis (FDA). FDA assesses the separation in the data between 
classes of samples. The ion count data for each sample was wavelet transformed to 
identify specific signals and reduce noise. FDA then identifies a projection of this 
data onto a one dimensional subspace which maximises the separation between 
classes. Varying a threshold across this subspace allows Receiver Operating 
Characteristic (ROC) curve analysis of the resulting FDA classifier to assess the 
ability of the Lonestar data to discriminate between classes. 
Method two 
The raw Lonestar data are analysed through a four-step process. This is used as part 
of a cross-validation analysis, which makes efficient use of the number of samples 
in the study.  
1. Wavelet transformation. Raw Lonestar data are known to have a lot of 
correlation between the different variables, so a wavelet transformation is 
used to exploit this. This data compression step reduces the dimensionality 
of the data, helping extract the highly correlated patterns within the data set.  
2. Feature selection. Mann-Whitney-Wilcoxon rank-sum test is applied to 
each of the features in turn. This assigns a p-value to each feature which can 
be used to rank variables by how much information they provide on the 
desired outcome. The top ‘n’ features are selected and passed to the 
classifier.  Within the cross-validation, only the training data are used in 
each fold to select these features. 
3. Classifier training. The data for the selected features are passed into the 
classifier algorithm (Stochastic Gradient Boosting) the classifier is then 
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used to predict the data points not used in training the classifier (i.e. the 
current fold) 
4. ROC Curve. The classifier gives each sample a probability indicating how 
likely it is to be a case rather than a control. All the scores from the cross 
validation are put together to produce a ROC curve.  
 
Method 3   
The latest data analysis technique follows on from method one, with data analysed 
using R studio (R Foundation for Statistical Computing, Vienna, Austria). The 
analysis pipeline involves the following steps, once again being used inside a cross-
validation.: 
1. Data input – The raw data is collected from the 2D matrix  
2. Aligning and cropping – Large amounts of irrelevant data is extracted prior 
to analysis  
3. 2D Discrete Wavelet Transformation – Allows extraction of subtle 
chemical signals hidden within a much larger signal. This is conducted 
using the Wavethresh package in R studio.  
4. Feature Selection/ Exclusion – Applies a simple threshold on the standard 
deviation of the feature e.g. remove wavelet features where the variance is 
~0 (as these are expected to be uninformative). Then using Wilcoxon rank-
sum test each remaining feature in turn, keeping only those with the most 
significant p-values.  
5. Principle component analysis (PCA) – a further data compression step, to 
de-correlate the remaining features. 
6. Classification model training – Five classification models are used:  
a) Sparse logistic regression. 
b) Random Forest.  
c) Gaussian process classifier. 
d) Support vector machine. 
e) Neural network.  
Each model is compared to find the most accurate for the specific data 
analysed, this may change depending on each dataset.  Data are fed into the 
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pipeline using samples where the outcome is known. This serves to ‘train 
the algorithm’ in order that it may recognise the same data patterns if they 
present again in another sample e.g. CRC. Once trained, the algorithm can 
be applied to unknown samples.  
7. Balance the data – If the two comparator groups have uneven numbers the 
data needs to be balanced. This is achieved using Synthetic Minority Over 
Sampling Technique (SMOTE) to achieve unbiased balancing.  
8. ROC analysis – classification data is presented as a ROC curve   
9. Performance metrics – Information gathered from this analysis pipeline 
are Area Under the Curve (AUC), Sensitivity, Specificity, PPV and NPV.  
 
4.3 GC-IMS analysis 
Gas-capillary column ion mobility spectrometer (GC-IMS) is a gas column coupled 
to an Ion Mobility Spectrometer and this has been used in a sub set of patients in 
this thesis (Chapter Five). It involves a two-stage analytical process; firstly 
separation occurs by GC and secondly detection via IMS (355). Samples are 
separated before they reach the sensor, thus theoretically improving chemical 
detection and, in theory, allowing identification of specific composite chemicals. A 
schematic of the instrument is shown in figure 4.6. The instrument used in this thesis 
is the GC-IMS Silox (IMSPEX diagnostics Ltd, South Wales, UK). It has been used 
in industry for several years, in particular in the food industry for freshness quality 
control and has theoretical advantages when applied to the medical field for 
detection of disease. Firstly it has a very fast run time and secondly it is low 
maintenance with low running costs and is portable, unlike the GC-MS (176, 178, 
356, 357).  
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Figure 4.6 Schematic of the separation process and ion detection using GC-IMS. 
1. Sample passes through the gas column where initial separation occurs. 2. The 
discrete compounds are consecutively fed into the ionisation chamber where 
ionisation occurs 3. Ions pass through the drift tube at varying speeds dependent 
on their mobility 4. Ions hit the sensor plate and are detected 5. Ion peaks are 
calculated based on drift time.   
 
 
Data output is twofold: GC gives peaks representing retention time as they pass 
through the column. This is coupled with IMS data, based on the mobility of the 
ions as they pass through the drift tube and hit the sensor as represented in figure 
4.7. The culmination of this two-phase analysis is illustrated in an IMS 
chromatogram which is represented by millions of data points in a heatmap (figure 
4.8). These data points are subject to very similar statistical analysis as is applied 
to the Lonestar data in method three above.   
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Figure 4.7 The two-stage separation of a biological sample using GC-IMS. Initial 
separation using a gas column and subsequent separation according to ion mobility 
(image adapted with permission from Imspex, UK) 
 
 
Figure 4.8. 3-dimensional representation of GC data output with corresponding 
IMS chromatogram. 1. Single IMS spectra data is combined with GC run time 
peaks. 2 Heatmap corresponding to GC-IMS peaks (yellow and blue lines) (Image 
adapted with permission from Imspex, UK) 
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4.3.1 Manual sampling method  
1. The urine sample is stored and then thawed as per the method for the 
Lonestar. 
2.  A five ml urine sample is aliquoted into a glass vial and sealed with a 
crimp lid. 
3. A 21g needle is attached to the GC-IMS input port. 
4. The needle with attached port is inserted into the sample headspace one 
cm above the urine. 
5. The needle is held in place for twenty seconds to allow for vapour 
aspiration. 
6. The total run time is five minutes per sample. 
7. The carrier gas flow rate is 150ml/min and sample flow rate through the 
instrument is 20ml/min. 
8. The sample heating was carried out in accordance with manufacturer 
instructions to a maximal level of 80 0 C. 
 
GC-IMS has only been studied in the detection of disease in a handful of cases 
(174, 175) including a recent pilot study of patients with respiratory tract 
infections (176). Results were encouraging but work using this modality is only in 
the pilot stage.    
 
4.4 Experimental work 
The application of FAIMS in the diagnosis of disease is novel and the analysis of 
biological samples is still in the research phase. In order to understand the optimal 
sample storage and analysis conditions a series of experiments were conducted on 
both healthy volunteers and a selection of disease groups. In addition, a number of 
setbacks were encountered due to technical and practical issues whilst running case 
and control samples.  This led to re-evaluation of the methodology and run settings 
of the instrument, with consequent method improvement. 
These key experiments are described below in chronological order:  
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4.4.1 Experiment one: urine validation 
Data analysis: April 2015 
Background: During repeated use for analysis and due to background VOCs present 
within the lab, it is common for the Lonestar to still show evidence of signal 
intensity reflected in the plume even after repeated air or ‘blank’ runs (seen as the 
RIP). This low level signal intensity, is referred to as ‘background noise’. 
Background noise is expected in any environment that the Lonestar is being used 
in as there is a constant supply of VOCs present. However, it is crucial that this 
noise is consistent throughout testing because during analysis a signal that persists 
and is common to each sample analysed can be removed from data analysis, but if 
there is fluctuation in the background noise or high intensity signal pick-up then 
this may well confound results. 
A ‘run’ refers to the flow of headspace from a sample through the Lonestar analysis 
process. Multiple runs per sample are required in order to ensure that signal pickup 
is maximised.  It is important when deciding on the number of runs to perform per 
sample, that ion current intensity is not increasing with each sample. The ion current 
represents the amount of ionic activity passing through the sensor and although this 
cannot specify which ions are being detected, it potentially correlates with the key 
targets within the urine sample. When selecting the number of runs, ionic activity 
needs to be lower on the last run that it was on previous runs, i.e. show a decreasing 
pattern.  This suggests activity has peaked and the strongest ion concentration has 
been captured. 
Method: During February 2015, 2x20ml urine samples were collected from 25 
randomly selected medical students at UHCW for use as ‘validation samples’, to 
optimise sample run parameters. This group were chosen for validation reasons 
with the assumption that due to the lack of complex medical history or current 
pathology their urine would not produce significant signal change in the Lonestar 
output. 
Participants were consented and completed a standardised FAMISHED CRF with 
basic demographic and medical detail (table 4.1).  
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Table 4.1. Study characteristics of the urine validation cohort 
Female (%) Median age 
(mean) 
Non-smokers 
(%) 
Mean alcohol 
intake (u/wk) 
15 (60%) 24 (24.8) 25 (100) 6 
 
One was vegetarian, the rest had a normal diet. There were no significant co-
morbidities.   
Ionic activity per run is shown below in Table 4.2 for each healthy control. Each 
matrix represents a sample run. The fourth matrix demonstrates a decreasing ionic 
concentration in the majority of samples meaning that the peak ionic concentration 
has been captured containing the most intense VOC data.  
154 
 
Table 4.2 Ion concentration data per FAIMS matrix for each urine validation sample (peak concentrations in red) 
 
 
 
 
 
 
 
 
 
 
 
Matrices 1 2 3 4 Matrices 1 2 3 4 
Sample No   
  
Sample No 
   
1 1.261 3.971 4.155 4.116 14 0.892 4.009 4.183 4.132 
2 1.122 3.654 3.671 3.616 15 1.259 4.14 4.306 4.228 
3 1.215 3.629 3.923 3.858 16 1.364 4.076 4.287 4.268 
4 1.236 3.865 4.01 3.928 17 1.367 4.285 4.636 4.711 
5 1.112 3.646 3.932 4.173 18 1.294 4.559 4.619 4.603 
6 1.3 3.834 3.99 3.978 19 1.323 4.096 4.273 4.093 
7 1.337 4.073 4.187 4.101 20 0.999 3.902 4.064 4.073 
8 1.027 3.22 3.355 3.297 21 1.003 3.907 3.93 3.87 
9 1.352 3.865 3.95 3.936 22 1.2 4.184 4.244 4.172 
10 1.348 3.855 3.982 3.988 23 1.13 4.393 4.427 4.337 
11 1.15 3.956 4.066 4 24 1.15 3.903 4.047 4.018 
12 1.322 3.977 4.113 4.087 25   
   
13 1.041 3.861 4.17 4.334 
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Following a sample run, the Lonestar needs to be ‘washed-out’ before a second 
sample can be analysed. This is to ensure no residual information from the previous 
sample is still present within the Lonsestar instrument. As with sample run number, 
the number of ‘air’ or ‘blank’ runs that need to be performed will vary depending 
on the sample under analysis. Through previous experimental work ten air runs was 
found to be optimal, allowing sample washout with a marked decrease in ion 
concentration. This was confirmed during the urine validation analysis: the 
Lonestar was adequately ‘clean’ after ten runs. Each run took 2.5 minutes to 
complete. Therefore each sample/air cycle was 35 minutes. Sample analysis was 
performed manually, therefore it was predicted that approximately 12 samples 
could be run per day (allowing for sample thawing).  
4.4.2 Experiment two: CRC and controls 
Data analysis: July 2015 
88 CRC and 40 IBS sample urines were analysed by manual processing on the 
Lonestar v1 instrument. Although collection of sample headspace was achieved as 
expected, following sample processing, it was found that a major ‘drift’ had 
occurred on the plume. A drift refers to the shifting of the plume, demonstrating an 
atypical dispersion field. This signifies an error in sample processing. Therefore 
any difference in signal change between CRC and IBS sample will not be detected 
accurately. This may be due to contamination of the system or a fault with the 
ionisation process. In this case there was a build-up of charge on the Lonestar chip. 
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Figure 4.9 An abnormal Lonestar plume in both positive (blue) and negative (red) 
mode. Here there is poor signal intensity with little variability in ionic capture. See 
figure 4.4 for comparison.  
 
Following this technical issue, a replacement chip was inserted resulting in 
resolution of the error. This unforeseen problem was only detectable once the 
samples had been analysed. The instrument also had a hardware/software upgrade 
to Lonestar v3, resulting in improved processing and faster run time, allowing a run 
to complete in 45 seconds. This, so called, fast scan allows the same amount of data 
capture as the prior slower version with 15 runs being completed per sample with 
30 air runs to ensure adequate cleaning.  
4.4.3 Experiment three:  sample storage 
Data Analysis: August 2015 
Background: There is little in the literature about the storage of urine specimens for 
VOC analysis and whether the storage and thawing process has a significant effect 
on the number and type of VOCs seen during analysis. This work was led by 
Esfahani and Sagar with myself as a co-author and is published in PLoS one (358). 
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The aim was to understand the rate of urinary degradation during long-term storage 
at -80 degrees.  
Method: Patients with type 2 diabetes mellitus were recruited from UHCW between 
December 2009 and May 2014 as part of the FAMISHED study. Once collected, 
samples were initially stored at -800C. 87 samples were analysed using the Lonestar 
v2 manually. All had T2DM as defined by WHO criteria, exclusions were IBD, 
IBS, coeliac disease and malignancy.  
Results: The analysis showed that total chemical concentration decreases with 
sample age (figure 4.10), with a particular decline after nine months of storage. The 
chemical diversity of the samples is defined as the amount of different chemicals in 
the sample. This was higher in samples of increasing age, but most prominent in 
samples older than nine months. (figure 4.11).  
Figure 4.10 – Scatter plot showing change in total number of urinary VOCs over 
time (from December 2009 to May 2014). The graph shows the total amount of 
chemicals released  (number of dots) decreases with age and the concentration also 
decreases (drop in ion count with time). 
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Figure 4.11 Scatter plot showing chemical diversity of urinary VOCs over time 
(from December 2009 to May 2014), the red dots represent different chemicals 
within samples of differing ages, a larger number of dots equates to more 
chemical diversity. A threshold for chemical detection was set to avoid picking up 
‘background noise’ which represents chemicals within the sample due to the 
environment.  Linear fit emphasises output change.  
 
In conclusion, with increasing age, even stored at -800C samples are losing ion 
count and diversity is changing. This must be taken into account during sample 
analysis. The changes seem more predominant after nine months of storage. Further 
experimental work, looking into storage and determining whether the sensitivity of 
disease detection is affected over time would be extremely helpful. This study 
tentatively recommends storage of samples for a maximum of 12 months but ideally 
they should be analysed within nine months. However, the practicalities of sample 
analysis within nine months need to be considered within the research setting as it 
often takes a longer period to recruit a satisfactory number of patients.  
4.4.4 Experiment four: urine degradation 
Data analysis: February 2017 
Background: There is no published data on the effect of variation in time at room 
temperature, prior to urine sample freezing for storage. This is an important 
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consideration in the clinical setting. Depending on the location of sample collection, 
the time of day and access to freezer storage, it would be common for samples to 
be kept at room temperature for varying amounts of times after recruitment.  
Through joint experimental work between myself and Dr Michael McFarlane, the 
effect of room temperature on total ion count and ion variability using the Lonestar 
instrument was explored. This work is included in Dr McFarlane’s MD thesis 
submitted to the University of Warwick. 
Method: 26 UHCW outpatient and endoscopy staff were recruited at random during 
October 2016. Basic patient information was collected via the standard 
FAMISHED CRF. 2x 20ml universal container of urine was collected from each 
patient. Once collected, urine was immediately aliquoted into six universal 
containers, labelled with the study code and the additional number 000, 012, 
024,036,048 or 072 to denote the number of hours the sample would remain at room 
temperature. Sample 000 was placed immediately into the freezer within the 
research department at -200 C and transferred to -800C in tissue bank at UHCW for 
long term storage within 48 hours of collection. Sample 012 was left at room 
temperature for 12 hours before freezing.  Samples 024,036,048 and 072 were left 
for 24, 36,48 and 72 hours respectively at room temperature prior to freezing. 
Lonestar v3.1 with attached auto sampler was used for analysis. All samples were 
analysed within the same week. Analysis time was 10 minutes which equates to 
approximately 15 runs per sample. Air runs were completed between samples to 
ensure no residual sample was present in the instrument. Analysis was completed 
using Fisher Discriminant Analysis after feature extraction from the raw data 
(statistical method one). Spearman’s Rank correlation coefficient was used to assess 
the relationship between the two variables.  
 
Results: 20 complete samples were analysed. 15 (75%) were female with an average 
age of 49 years. 
Three important observations were seen from this analysis: 
1. Variation from baseline. When comparing Lonestar matrices as an average 
over all samples, signal variation increased with time. There was a slight 
160 
 
plateau at 12-48 hours with a further rise at 72 hours. This pattern was seen 
with both positive and negative matrices (figure 4.12). Spearman’s rank 
correlation coefficient was used to test for a monotonic relationship between 
time and variation from baseline (where an increase in the independent 
variable is associated with an increase in the dependent variable). Spearman 
ῤ = 0.94, p=0.017 for positive matrices and ῤ=0.83, p=0.058 for negative 
matrices.  
 
Figure 4.12 – Chart of variation of FAIMS matrices, as an average of all 
samples with increasing time. Bars show standard error.  Relative 
variation increases with time at room temperature, although it plateaus at 
12-48 hours with a particular rise in signal production at 72 hours.  
 
 
  
 
The greater variation in matrices with increasing time can also be visualised 
in the plume structure with increasing time (figure 4.13). The same spectra 
changes with time are observed in the negative matrices too.  
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Figure 4.13 Variation in FAIMS matrices as seen by plume structure. Top 
left: FAIMS plume at time zero. Middle left: FAIMS spectrum at 72 hours. 
Bottom left: Difference between spectrum at 72 hours and baseline. Right 
hand panels show the difference at 12,24 and 36 hours, showing a consistent 
pattern developing with time 
.   
2. Changes in total ion count: There is an increase in total ion count, observed 
with increasing time at room temperature before freezing (figure 4.14). The 
average total ion number detected for each patient at each point in time was 
compared with the average number of ions detected at time zero for that 
patient. For positive matrices the mean ion count with time gives Spearman 
ῤ=0.94 p=0.017 and ῤ=0.94 p=0.017 for negative matrices.  
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Figure 4.14 - Chart of trend in total ion count from mean of FAIMS 
matrices. Bars indicate standard error. The top panel shows the positive 
matrices and the bottom shows the negative ones. There appears to be a 
positive correlation between relative ion count and time.  
 
Variation and total ion count with matrix number: When looking at the 
pattern of degradation during sample analysis with each consecutive matrix 
or run, the positive matrices showed a consistent monotonic decrease in ion 
count and increase in variation as each matrix was formed (see figures 4.15a 
and 4.15b and 4.16a and 4.16b respectively). Conversely, when looking at 
the negative matrices a transient increase in ion count is observed, with 
subsequent decaying and an increase in variability. This pattern did not 
seem to be affected by how long the sample was stored at room temperature, 
so each pattern was replicated in all samples irrespective of time. This loss 
of ion count can also be visualised when observing the plume, or Lonestar 
spectrum structure over subsequent matrices (figure 4.17). 
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Figure 4.15a – Positive FAIMS matrices: variation in ion count from 
baseline as a function of matrix number for each time point, showing 
decreasing ion count per matrix. Bars show standard deviation. 
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Figure 4.15b - Negative FAIMS matrices: variation in ion count from baseline  
as a function of matrix number for each time point, showing decreasing ion count 
per matrix. Bars show standard deviation. 
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Figure 4.16a - Positive FAIMS matrices: variation from baseline as a function 
of matrix number for each time point, showing increasing variation with each 
matrix. Bars show standard deviation. 
 
 
.  
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Figure 4.16b - Negative FAIMS matrices: variation from baseline as a function 
of matrix number for each time point, showing increasing variation with each 
matrix. Bars show standard deviation 
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Figure 4.17: Positive FAIMS matrices: difference from baseline with matrix 
number: Top left: First FAIMS spectrum at time zero. Middle left: Fourteenth 
FAIMS spectrum at time zero. Bottom left: Difference between fourteenth and first 
spectrum. Right hand panels show the difference for matrices 5, 8, and 11 from 
baseline, showing a consistent pattern, developing with time. All matrices averaged 
over all patients. 
4.5 Discussion 
This developmental work has provided unique insight into the complexities of 
maintaining analytical consistency when detecting VOCs and also the effect of 
different sample storage procedures on sample analysis. Clear alterations in sample 
results with time left at room temperature were demonstrated. But it is not clear if 
this relates to a loss of VOCs and, most importantly, whether if there is a loss, the 
lost VOCs are crucial to disease detection.  
It would seem perhaps logical, that urine samples would degrade at an accelerated 
rate at room temperature as opposed to when frozen as biological activity is higher 
with increasing temperature. The variation in the Lonestar spectra seem to increase 
monotonically with the age of the urine, with the exception of a plateau phase 
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between hours 12-48. The total ion count also appears to grow monotonically with 
age. Both these changes suggest an effect on the VOC capture, but more work is 
needed to establish which VOCs are affected and whether it affects the sensitivity 
of the Lonestar to detect specific disease. The increase in ion count is interesting: 
one might expect a decrease in total ions if it is assumed that VOCs are lost, but it 
depends where these ions are generated. It may be the result of sample degradation 
at room temperature. It is also possible that the presence of bacteria in the urine is 
causing biological breakdown of substances resulting in an increase in VOC’s. 
However, in the absence of infection, urine should be sterile. There is often 
contamination on exit from the body, but it seems unlikely it would explain the 
pattern of consistent increased ion count and variability present in all samples. 
Increased variability with time supports the notion that a urine breakdown process 
is occurring, resulting in more small ions. It maybe that the plastic universal 
container may produce more VOCs whilst in contact with urine at room 
temperature, than would be observed while in frozen conditions. 
When observing the effect of multiple samples runs though the Lonestar, in all 
samples there was consistently an increase in variation and reduced ion count with 
each matrix, except for a transient rise in ion count in the negative matrices. This 
may suggest that most information is gained from the first matrix, and subsequent 
runs may not add additional useful information in gleaning the VOC profile of urine 
in any particular disease. More work would need to be carried out to explore this 
finding before any changes to run numbers were made. In particular, a case-control 
study as an initial investigation, would establish whether key signals were lost after 
the first couple of runs. In the urine validation work documented in experiment one, 
an increase in ion count was found initially with a decrease at run four. However, it 
is important to note that the urine degradation samples in experiment four were run 
on a later version of Lonestar, this also had the addition of an auto sampler. Due to 
the differences in run speed and sampling technique between manual and auto 
sampling, it is likely results using differing sampling techniques cannot be directly 
compared.    
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Based on these preliminary results, ideally urine should be stored at -800C as soon 
as possible until further investigation into the nature of the lost VOCs is established 
and whether they are key to disease detection or not. 
4.6 Conclusion and further work 
VOC analysis using FAIMS is still in the experimental stage, but represents an 
exciting technology that has the potential to herald a new wave of non-invasive 
testing for a multitude of diseases. For FAIMS to be a real competitor as a 
diagnostic tool in the clinical setting it is important that minor changes in sample 
collection, storage and analysis technique or environment do not affect disease 
detection. The conflicting results seen between experiments one and four with 
regard to the effect of matrix/run number on ion count, also highlights the 
importance of consistency when testing samples as it may be that the auto sampling 
method cannot be compared to the manual method. These results provide new 
insight into the effect of sampling and storage on urinary analysis. However, these 
findings need to be corroborated in a case-control study to understand the impact 
on disease detection as changes to total ions and variability do not necessarily 
equate to an influence on the ability to detect a specific disease.     
As a result of the experimental work described in this chapter, the following 
recommendations for samples analysis using the Lonestar FAIMS are: 
1. Where possible, no changes should be made to any step of analysis during 
an experiment as even minor methodological changes have the potential to 
confound results. 
2. Following sample collection, transfer to -800C should occur as soon as 
possible, but as a minimum within 12 hours of collection.  
3. Samples should be stored at -800C for a maximum of 12 months prior to 
analysis. 
 
 
 
170 
 
 
 
 
 
CHAPTER 5: 
 The application of urinary volatile 
organic compound analysis in the 
detection of colorectal cancer  
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5.1 Introduction 
The search for a non-invasive test that is both sensitive and specific in detecting and 
diagnosing CRC at an earlier stage, is ongoing. Applying the use of gas phase 
markers to diagnosis CRC is a rapidly expanding area. Over the past decade, many 
research groups have been focussed on the detection of VOCs in health and disease. 
Some disease-specific patterns have already been identified (200, 359). Yet there 
are currently no VOC-based tests used in the clinical setting (164, 229, 360).  
Using urine for VOC detection has the advantage of being simple to collect, with 
high patient satisfaction. It is also easy to store and shows stability in the medium 
term (203). These factors make it an ideal focus for the development of a diagnostic 
test. The benefits of urine over other biological samples are discussed in Chapter 
Two.  
Detection of VOCs in CRC using a variety of different mediums, has been 
investigated in small-scale studies (238, 240), but few have used urine analysis and 
none have focussed on the asymptomatic bowel cancer screening programme 
(BCSP) cohort. The BCSP uses a FOBT for CRC detection and has reduced 
mortality from CRC by increasing the proportion of patients being diagnosed at an 
earlier stage. However the full potential of bowel screening is limited by modest 
patient uptake (around 60%) and low specificity, which results in many unnecessary 
colonoscopies (117). The introduction of FIT as the first-line bowel screening test 
is anticipated within the next year and is associated with higher uptake and higher 
sensitivity, but there is still substantial room for improvement in both patient uptake 
and overall test accuracy. As VOC detection in the diagnosis of CRC in the 
asymptomatic population is currently unchartered territory, it is not clear whether a 
VOC based screening test would be feasible or effective.  
In order to address these gaps in knowledge and carry out a comprehensive 
investigation of urinary VOC analysis in the detection of CRC, a series of three 
experiments were conducted. Firstly, in experiment one a large symptomatic patient 
group were included in order to investigate the detection of disease versus control, 
but also to establish whether different CRC groups could be classified based on 
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tumour stage. The second and third experiments concentrated on the asymptomatic 
BCSP population. Two different experiments were performed in the BCSP cohort 
because methodological improvements in sampling and analysis were utilised and, 
in addition, the first VOC analysis using GC-IMS was performed.  
5.2 Hypothesis 
The urinary VOC profile in CRC can be distinguished from the urinary VOC profile 
of benign bowel diseases. 
5.3 Aims  
1. To evaluate the use of VOC biomarkers to stage CRC and differentiate 
between cancer and advanced adenomas. 
2. To establish whether urinary VOCs can form the basis of a new bowel 
cancer screening tool that is sensitive and specific, with high patient 
acceptability. 
 
5.4 Research questions 
1) a) Does CRC have a specific VOC biomarker ‘fingerprint’? 
b) Can this be applied as a diagnostic test for CRC in the bowel cancer 
screening population? 
c) What is the sensitivity and specificity of this test in the screening 
population? 
2 a) Can urinary VOC biomarkers differentiate between different stages of 
CRC? 
b) Can urinary VOC biomarkers differentiate between colorectal adenomas 
and CRC? 
 
5.5 Ethical approval 
 
Scientific and ethical approval was obtained from the Warwickshire Research & 
Development Department and Warwickshire Ethics Committee 09/H1211/38. 
Written informed consent was obtained from all patients who participated in the 
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study. Approval was granted by the Bowel Cancer Screening Programmed 
Research Committee. 
 
 
5.6 Machine Learning 
The analysis of data created through FAIMS and GC-IMS analysis employs 
machine learning methods. In brief, they involve the construction of 
computerised algorithms that can learn from and make predictions on the output 
data from the instrument. The algorithms build a prediction model from a 
training set of known cases and use this knowledge to predict output decisions 
(diagnoses) on unknown cases. The construction of these algorithms is 
described in more detail in Chapter Four section 4.2.3. 
 
5.7 Experimental work 
 
5.7.1 Experiment one: The application of urinary VOC analysis in the 
detection and differentiation of CRC by tumour stage in the 
symptomatic population: A retrospective case-control study.  
 
Data analysis: August 2016 
Study aim: To establish whether CRC can be correctly classified from control and 
whether the VOC profile is affected by cancer stage. Setting: UHCW. Inclusion 
criteria: Patients at UHCW diagnosed with colorectal adenocarcinoma of any stage 
between 2012-2014. Exclusion criteria: Any other histological cancer of the 
colorectum.  
Method 
Patient recruitment: The UHCW tissue bank database was used to identify all 
samples collected from patients with CRC in long-term storage at -80oC. 
Recruitment was conducted by the gastroenterology research nurses at UHCW 
between 2012-2014. Cancer cases were found by weekly review of the colorectal 
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multi-disciplinary team meeting at UHCW. Patients with a new diagnosis of CRC 
were contacted by phone to determine their interest in the study. Those who agreed, 
were approached at UHCW on the day of surgery prior to attending theatre. Patient 
characteristic data, co-morbidities and medication history were collected according 
to a pre-defined CRF and patients were consented. Control samples were collected 
between 2012-2014 from un-selected colorectal outpatient clinics in cases where 
no CRC, colonic adenomas or other gastrointestinal conditions were diagnosed and 
where a diagnosis of IBS was made. As per CRC samples, IBS samples were placed 
into long-term storage at -80 0C. 
Sample collection and storage: 2x 20ml samples of urine were collected. Samples 
were immediately transferred to -20oC storage and then to -80 oC within 24 hours 
for long-term storage.  
Sample analysis: All samples were analysed in august 2016 on the Lonestar 
instrument using an auto-sampler (Biomedical sensors laboratory, School of 
Engineering, University of Warwick). Please refer to Chapter Four for the detailed 
methodology. Outcome data including cancer stage was matched with VOC profile 
and compared to control sample VOC profile. Lonestar data was processed using 
method one, as described in Chapter Four.    
Results 
Study population: A total of 77 CRC samples and 109 IBS samples were analysed. 
Demographic details and major comorbidities are displayed in Table 5.1. The 
majority of cancers were found in the left colon (Table 5.2), Dukes C was the most 
common stage of presentation, seen in 36.4% of patients (Table 5.3). 
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Table 5.1. Study population characteristics for CRC and IBS groups 
 CRC IBS 
% Male 60.0 27.5 
Median age (mean) 69 (66.6) 44 (45.9) 
Current smoker (%) 4 (5.2) 18 (16.6) 
Median BMI 27.8 25.5 
Median alcohol 
consumption (units/week) 
6 0 
Co-morbidity  Number (%) affected 
Hypertension 36 (46.8) 13 (12) 
Diabetes 9 (11.7) 3 (2.7) 
Irritable bowel syndrome 0 103 (100) 
Inflammatory bowel 
disease 
1 (1.13) 0 
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5. 2. Cancer distribution by site. 
 
  
Table 5.3. Stage of cancer according to Dukes criteria. 
 
Dukes stage No. of patients (%) 
A 20 (26.0) 
B 21 (27.2) 
C 28 (36.4) 
D 8 (10.4) 
 
Cancer detection: When comparing the FAIMS matrices for cancer versus control, 
reclassification was found to be no better than random with AUC of 0.58, 95% CI 
0.5-0.65 (figure 5.1).  In view of the lack of separation demonstrated between the 
two groups no attempts were made to sub-analyse the data based on cancer stage.  
 
 
 
 
Cancer site No. of patient (%) 
Rectum 36 (46.8) 
Sigmoid colon 8 (10.4) 
Descending colon 2 (2.6) 
Splenic flexure 3 (3.9) 
Transverse colon 4 (5.2) 
Hepatic flexure 7 (9.0) 
Ascending colon 11 (14.3) 
Caecum 6  (7.8) 
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Figure 5.1. ROC curve for CRC vs control in the symptomatic population. The 
Middle line represents the sample point estimates, the outer lines represent 95% 
CI’s.  
 
 
Discussion 
This analysis of a large number of CRC samples versus control using the Lonestar 
instrument, demonstrated no ability to correctly classify CRC from the control. This 
means the VOC fingerprint of CRC could not be distinguished from control. 
Separation between disease and control has been demonstrated in past studies using 
FAIMS, and in particular in small-scale studies involving CRC, but these results 
did not replicate those findings. 
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There are a number of possibilities to consider when interpreting these results that 
may have influenced outcome. Firstly sample age: the samples had been in long 
term storage prior to sample analysis, this was due to unavoidable logistic and 
technical delays. The analysis was performed at the first available opportunity and 
both cancer and control samples were collected and stored over the same time 
period, so conditions prior to analysis were comparable. Although research by the 
FAMISHED group has suggested a decline in VOC number even at -80 0 C (358). 
There is no data to confirm whether key VOCs are lost in this process, or whether 
it is simply a decrease in total VOCs, many of which may represent ‘background 
noise’. These results support the argument that vital signalling information is lost 
as the samples ages. It is also important when considering a VOC based test in 
clinical practice, as it is likely samples would need an expiry date, after which 
results are invalid.   
Secondly, these samples were analysed using an auto-sampling method. 
Theoretically there is no element of this sampling model that should affect the VOC 
detection, but samples are out of the fridge for longer than they would be via manual 
sampling (although on a cooling tray). Test experiments performed within the 
laboratory did not pick up any issues with the auto-sampling method, but this was 
the first analysis set involving large numbers of samples. Auto-sampling is a 
necessary step in the application of FAIMS in biological samples analysis, as 
manual testing is time consuming and cannot be feasibly carried out on large 
numbers. However, more work may need to be done to optimise sample processing 
using this method and to establish whether aspects of the auto-sampling process 
need refinement.  
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5.7.2 Experiment two: A prospective cohort study in the BCSP 
population, comparing urinary VOC profiles with diagnostic 
outcomes: (phase one).  
Data analysis: February 2016 
 
Study aim: To establish whether patients with cancer, adenoma or normal colons in 
the BCSP population could be correctly classified based on their VOC profile using 
the Lonestar. Setting: UHCW. Inclusion criteria: Any patient attending the BCSP 
clinic at UHCW following a positive FOBT. Exclusion criteria: Patients who 
declined investigation as per BCSP protocol, as no outcome data would be 
available. Patients on renal dialysis as the effect of renal replacement therapy on 
VOC profile is unknown.  
 
Method  
Patient recruitment: All patients with a positive FOBT attending an appointment 
with a bowel cancer screening nurse at UCHW were eligible for inclusion. Eligible 
patients were highlighted using the trust clinic list database. Both the local UHCW 
bowel cancer screening team and the bowel cancer screening hub in Rugby, 
England, were approached in order to facilitate recruitment. Recruitment was 
conducted at the UHCW screening clinic between April 2015 and February 2016.  
All patients who agreed to further investigations were recruited.  
Sample collection and storage: As per experiment one.  
Sample analysis: Detailed methodology has not been repeated here. Manual 
sampling using the Lonestar instrument was performed as per the method outlined 
in Chapter Four. Statistical analysis was performed using method one from Chapter 
Four. Outcome data was collected either from the colonoscopy or CTC report.  Any 
cancer detected was cross-checked with the histology and staging was determined 
via detail from the MDT meeting and oncological correspondence. Any detected 
polyps were cross-checked with the histology report and included only if adenoma 
was confirmed. Hyperplastic polyps were excluded from analysis.  
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Results 
127 patients were recruited, 125 samples were available for analysis. 57% were 
male, and the median age was 68. Average BMI was 28.73. 120 (96%) stated that 
their diet was normal, 5 (4%) were vegetarian, 1 (0.80%) ate no red meat and 1 
(0.80%) ate no beef. Average weekly exercise duration was 3.08 hours but the 
median was 0 hours. Average weekly alcohol intake was 11.25 units; the median 
was 4. 13 (10.4%) were taking probiotics. Table 5.4 details major co-morbidities 
and those on anti-platelets/anti-coagulants or Non-Steroidal Anti Inflammatory 
Drugs (NSAIDS).  
 
Table 5.4. Study population characteristics and medications for BCSP patients 
Condition Number (%) affected 
Hypertension 60 (48%) 
Diabetes 16 (12.8%) all type 2 
Irritable bowel syndrome 7 (5.6%) 
Inflammatory bowel disease 2 (1.6%) both ulcerative colitis 
Drug No. of patients  
Aspirin 12 
NSAIDS 8 
Warfarin 7 
Other antiplatelets 6 
 
Table 5.5 lists the patient diagnosis. Where applicable, the cancer site and adenoma 
risk category are stated. The majority of cancers were in the left colon which is 
consistent with the national trend. 
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Table 5.5: Diagnostic outcomes in the BCSP cohort (A total of 12 cancers as one 
patient had synchronous tumours in the caecum and sigmoid) 
 
Sample groups were paired using five different combinations based on disease 
outcome: numbers in brackets denote sample size. Test accuracy in correctly 
classifying cases into the each group is displayed as AUC below. This data is also 
shown in Table 5.6, together with the sensitivity and specificity values and 
corresponding 95% CIs.  
a) Adenoma (55)  vs no Adenoma (70) – the adenoma group included all those with 
adenomas regardless of risk category. No adenoma group, included all other 
samples without the presence of adenoma. AUC was 0.554 with 95% CI 0.451-
0.657.  
 b) Adenoma (55) vs no disease (27) - no disease group included all those with an 
outcome of normal. AUC was 0.548 with 95% CI 0.44-0.655. 
Diagnosis No. patients (%) 
CRC Total                      11 (8.8) 
Rectum                  5 (41.6 
Sigmoid                 3 (25) 
Descending            0 
Transverse             1 (8.4) 
Ascending             1 (8.4) 
Caecum                 2 (16.6) 
Adenomas Total                      55 (44) 
High risk               10 (8) 
Intermediate risk   22 (17.6) 
Low risk                23 (18.4) 
Diverticular disease 12 (9.6) 
Haemorrhoids 5 (4) 
Normal 27 (21.6) 
Other 15 (12) 
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 c) Cancer (11) vs no disease (27) – here all samples from patients with a diagnosis 
of CRC were compared with samples with an outcome of normal. AUC was 0.660 
with 95% CI 0.46-0.87. 
 d) Cancer (11) vs no cancer (114)- patients with cancer were compared with all 
remaining samples that had any other diagnosis apart from cancer. AUC was 0.636 
with 95% CI 0.497-0.776. 
e) Disease (98) vs no disease (27) - patients with any diagnosis including cancer 
were compared with samples where no diagnosis was found and the reported 
outcome was normal. AUC was 0.571 with 95% CI 0.468-0.674.  
 
Table 5.6: Classification of BCSP cohort by outcome: AUC, sensitivity and 
specificity with 95% CI. 
Groups AUC (CI) Sensitivity (C.I) Specificity 
(C.I) 
a) Adenoma vs no 
Adenoma 
0.554 (0.451-0.657) 0.582 (0.421-
0.531) 
0.574 (0.494-
0.593) 
b) Adenoma vs no 
disease 
0.548 (0.44-0.655) 0.545 (0.421-0531) 0.552 (0.509-
0.616) 
c) Cancer vs no 
disease 
0.660 (0.46-0.87) 0.636 (0.459-0.73) 0.655 (0.601-
0.703) 
d) Cancer vs no 
cancer 
0.636 (0.497-0.776) 0.636 (0.571-
0.824) 
0.598 (0.359-
0.442) 
e) Disease vs no 
disease 
0.571 (0.468-0.674) 0.538 (0.493-
0.594) 
0.534 (0.518-
0.624) 
 
  
  
Using this classifier test, no significant separation between any of the five groups 
based on VOC profile was demonstrated. The groups c) Cancer vs no disease 
classifiers and d) Cancer vs no cancer, displayed 95% CI’s that just include 0.5. 
This was due to the small sample size and suggests statistical discriminative power 
is poor between groups (table 5.6). Figure 5.2 shows graphically the poor 
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classification of cancer versus no disease curve.  Larger numbers would be required 
to ascertain if there was any significant difference between the two groups. The 
sensitivity and specificity data was consistent between groups with the exception 
of c) cancer vs no disease where a slightly higher sensitivity of 0.636 with 95% CI 
0.459-0.73 was seen. None were statistically significant. Although this falls well 
below the values expected for a satisfactory test, it suggests that a larger sample 
size would be required to investigate this further. Adenoma compared with other 
groups was also poorly classified, therefore further sub-analysis based on adenoma 
risk category was not performed.  
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Figure 5.2. ROC curve for CRC vs no disease in the BCSP cohort using sparse 
logistic regression. The bold central line represents the sample point estimate and 
the outer lines represent the wide 95% CI’s, suggesting poor separation of 
groups. 
 
 
Discussion 
The results of this investigation into the analysis of VOCs in the FOBT positive  
BCSP population did not show any satisfactory degree of separation between cancer 
and any other group or adenoma vs any other group. Sensitivity and specificity 
results were comparable. Therefore it was not possible to correctly classify patients 
into the correct group based on their diagnosis. Although the total group size was 
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large in comparison to previous VOC-based studies, the cancer cohort was small 
and reflects the low incidence of cancer in the screening population (approximately 
8%) (117), In light of these results, recruitment was continued to improve sample 
size and subsequently perform re-analysis. These results are described in 
experiment three.   
 
5.7.3 Experiment three: A prospective cohort study in the bowel cancer 
screening population comparing urinary VOC profiles with 
diagnostic outcomes (phase two).  
Data analysis: October 2017 
As with phase one of this study, the experiment included patients recruited via the 
BCSP at UHCW. Therefore the aims and research questions remain the same.  This 
experiment was repeated for the following reasons: 
1. Recruitment was extended from April 2015 to November 2016, resulting in 
a larger sample size. 
2. Lonestar development: since experiment one the Lonestar instrument had a 
software update and system clean. 
3. Data analytical techniques also improved, allowing more accurate 
classification and extraction of key data features, resulting in higher 
performing prediction models.  
4. Access to GC-IMS analysis became available, allowing evaluation of a 
second instrument for VOC detection. 
 
Method 
Sample collection and storage: this remained unchanged and is outlined in the 
earlier section. Sample analysis: manual analysis took place in October 2017 using 
the Lonestar v3.1. In addition, GC-IMS analysis was conducted on a sub-set of 
patients in the same laboratory. Detailed methodology plus data analysis methods 
for GC-IMS are found in Chapter Four. Statistical analysis: method three was used. 
As cancer numbers were small, a balancing technique was applied to the data in 
order to fairly match the non-CRC samples with the same number of CRC samples. 
Rather than randomly selecting a set number of controls to compare to the CRC 
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group, balancing involved a Synthetic Minority Over-Sampling Technique 
(SMOTE), (361) where artificially generated points are plotted to represent the 
control group as a whole and is used to provide a more fair representation. Patients 
were grouped into six categories for analysis. In order to extrapolate the most 
clinically relevant comparisons, study numbers are denoted in brackets.  
a) Cancer (12) vs Normal (12): here the data has been balanced by matching the 
number of normal cases to that of the control, as described above. 
b) Cancer +all adenomas (93) vs normal (37)  
c) Cancer + high risk adenomas (30) vs normal (37)  
d) Cancer + high risk adenomas (30) vs other (70) 
e) Cancer + all adenomas (93) vs other (70) 
f) Non- cancer (113) vs normal (37): ‘non-cancer’ describes all polyps plus other 
diagnoses except normal and cancer. ‘Other’ includes all other diagnoses plus 
normal 
 
Results 
A total of 201 samples were collected, however, following the use of samples for 
experiment one in February 2016, 171 were available for phase two. A further 8 
patients were excluded because there was no outcome result, therefore a total of 
163 samples were analysed. 93 (57%) were male, average age was 66.57 median 
age was 67 years.12 (7.4%) were current smokers. 41 (25.4%) were ex-smokers and 
109 (67.2%) had never smoked (there was no data on one patient). Table 5.7 lists 
the diagnosis for the group analysed.  
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Table 5.7. Diagnostic outcomes for BCSP cohort (phase two) and distribution of 
cancer by site (total of 13 cancer sites as one patient had synchronous tumours.) 
 
Diagnosis Number (%) 
Cancer Total                         12 (7.6) 
Rectum           4 (2.4) 
Sigmoid            4 (2.4) 
Descending colon      0 
Transverse colon       1 (0.58) 
Ascending colon       2 (1.17) 
Caecum         2 (1.17) 
Adenoma Total                         80 (49.1) 
High                         17(10.5) 
Intermediate             36 (21.1) 
Low                          27 (17.5) 
Diverticular disease                                  14 (8.2) 
Normal                                  37 (19.3) 
Haemorrhoids                                   5 (2.9) 
Other                                  14^ (8.2) 
Excluded                                   8* (4.7) 
^7 IBD, 2 rectal telangiectasia, 1 rectal ulcer, 1 radiation proctitis, 1 inflammatory pseudopolyp, 1 
non-specific sigmoid inflammation, 1 ischaemic sigmoid stricture 
*1 not fit enough for investigations, 7 declined investigations 
 
For each group, the results for the classification model that demonstrated the best 
separation are displayed in Table 5.8. 
Group a) Cancer vs normal demonstrated the highest degree of separation with 
AUC 0.98 95% CI 0.93-1 (figure 5.3) with 12 patients in each group. Sensitivity 
and specificity were also high: 1 95% CI 0.74-1 and 0.92 95% 0.62-1 respectively 
p=0.000002. 
In groups b) - e) cancer was grouped with adenomas and showed only modest AUC 
and corresponding sensitivity and specificity without any statistical significance. 
The highest separation of the adenoma groups was seen in b) cancer + all adenomas 
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vs normal; sensitivity was low at 0.48 95% CI 0.38-0.59 but specificity was high at 
0.89 95% CI 0.75-0.97 p=0.9937. In f) when cancer was excluded, separation was 
low with sensitivity 56%, 95% CI 0.46-0.65.  
A further set of analyses were carried out to investigate the classification of the 
adenoma groups in more depth and to compare cancer with three categories of 
adenoma: a) High risk, b) Intermediate risk and c) Low risk, according to the BSG 
guidelines (table 5.9). Numbers were small, but high sensitivity was demonstrated 
when each adenoma group was compared with cancer. The most accurate overall 
classification was seen in cancer vs high risk adenoma with a sensitivity of 0.83 
95% CI 0.52-0.98 p=0.0006.
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Table 5.8. Classification of BCSP cohort (phase two) by outcome. Using the best feature classifier with corresponding 95 % CI. 
Numbers in brackets in group section denote sample number.  
Group Feature Classifier AUC Sensitivity Specificity PPV NPV  
a) Cancer (12) vs normal 
(12) 
Sparse Logistic 
Regression 
0.98 (0.93-
1) 
1 (0.74-1) 0.92 (0.62-1) 0.92 1  
b) Cancer + all 
adenomas (93) vs 
normal (37) 
Sparse Logistic 
Regression 
0.64 (0.54-
0.74) 
0.48 (0.38-
0.59) 
0.89 (0.75-
0.97) 
0.92 0.41  
c) Cancer + high risk 
adenomas (30) vs 
normal (37) 
Gaussian Process 0.62 (0.48-
0.76) 
0.57 (0.37-
0.75) 
0.68 (0.5-
0.82) 
0.59 0.66  
d) Cancer +high risk 
adenomas (30) vs 
other (70) 
Sparse Logistic 
Regression 
0.6 (0.47-
0.73) 
0.47 (0.28-
0.66) 
0.80 (0.68-
0.89) 
0.52 0.76  
e) Cancer + all 
adenomas (93)vs 
other (70) 
Sparse Logistic 
Regression 
0.56 (0.47-
0.65) 
0.91 (0.84-
0.96) 
0.25 (0.15-
0.38) 
0.64 0.67  
f) Non cancer (113) vs 
normal (37) 
Gaussian Process 0.61 (0.51-
0.71) 
0.56 (0.46-
0.65) 
0.68 (0.5-
0.82) 
0.83 0.35  
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Figure 5.3. ROC curve for classification of CRC vs normal in BCSP cohort 
(balanced) using SLR classifier. The bold line on the left of the graph represents the 
point estimate for the samples analysed (the shape of the line is due to the low number 
of samples) and indicates a high degree of accuracy for separation of the two groups. 
 
. 
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Table 5.9. Classification of BCSP cohort: CRC vs adenoma (hr-high risk ir- intermediate risk lr- low risk) using the best feature 
classifier with corresponding 95% CI  
Group Feature 
Classifier 
AUC Sensitivity Specificity PPV NPV  
a) Cancer (12) 
vs Adenoma (7) 
(hr) 
Random 
Forest 
0.92 
(0.77-
1) 
0.83 (0.52-0.98) 1 (0.59-1) 1 0.78  
b)Cancer (12) vs 
Adenoma (12) 
(ir) 
Random 
Forest 
0.84 
(0.67-
1) 
0.83 (0.52-0.98) 0.75 (0.43-0.95) 0.77 0.82  
c)Cancer (12) vs 
Adenoma (12) 
(lr) 
Gaussion 
Process 
0.83 
(0.66-
1) 
0.75 (0.43-0.95) 0.92 (0.62-1) 0.90 0.79  
 
GC-IMS analysis  
A subset of 109 patient samples were analysed through the Silox GC-IMS instrument. Five comparator groups were devised according 
to outcome: a) Cancer vs normal, b) Cancer+ high risk adenoma vs normal, c) Cancer vs other, d) Cancer+ all adenomas vs other e) 
All adenomas vs normal. All five feature classifiers were used, the result with the best fit is displayed in Table 5.10. 
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.  
Table 5.10. Classification of BCSP cohort using GC-IMS using best feature classifier with corresponding 95 % CI. Sample 
numbers are denoted in brackets
Group Feature 
Classifier 
AUC Sensitivity Specificity PPV NPV  
a) Cancer (10) vs 
normal (24) 
Gaussian 
Process 
0.82 (0.67-
0.97) 
0.80 (0.44-0.97) 0.83 (0.63-0.95) 0.67 0.91  
b) Cancer + high 
risk adenomas 
(23) vs 
normal(24)  
Gaussian 
Process 
0.53 (0.36-
0.70) 
0.48 (0.27-0.69) 0.67 (0.45-0.84) 0.58 0.57  
c) Cancer (10) vs 
other (20)  
Support Vector 
Machine 
0.77 (0.60-
0.94) 
1 (0.66-1) 0.57 (0.34-0.78) 0.5 1  
d) Cancer  + all 
adenomas (65) vs 
other (42) 
Support Vector 
Machine 
0.61 (0.49-
0.72) 
0.71 (0.58-0.81) 0.55 (0.39-0.70) 0.71 0.55  
e) All adenomas 
(55) vs normal 
(24) 
Gaussian 
Process 
0.61 (0.47-
0.75) 
0.58 (0.44-0.71) 0.62 (0.41-0.81) 0.78 0.39  
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As with the analysis using FAIMS, when comparing cancer versus normal (group 
a) there was a high degree of separation with a sensitivity of 80%, 95% CI 0.44-
0.97 and specificity of 83%, 95% CI 0.63-0.95 but with a p value of 0.9986, the 
corresponding ROC curve is seen in figure 5.4. Cancer vs other also had a high 
sensitivity of 100% 95% CI 0.66-1 but specificity dropped to 57%, 95% CI 0.34-
0.78. When cancer samples were grouped with adenomas and compared with 
‘other’ groups the sensitivity dropped to a modest level of 71%, 95% CI 0.58-0.81. 
Adenomas vs normal showed a low level of separation, with a sensitivity of only 
58% 95% CI 0.44-0.71. 
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Figure 5.4:  ROC curve for classification of CR-C vs normal using GC-IMS. 
(GP classifier). The bold line is the point estimate for the samples analysed. The 
sample line is to the left of the AUC=0.5 line which is inserted for comparison.  
This emphasises the high test accuracy found in separating these two groups.  
 
The GC-IMS produces thousands of data points following analysis of a sample, this 
data can be presented as a heatmap which can represent the raw data graphically. 
This is shown in figures 5a and 5b. The drift time on the X axis comes from GC 
and the retention time on the Y axis comes from IMS. Feature selection is a step in 
the data analysis algorithm outlined in Chapter Four. The purpose of feature 
selection is to remove data that is outside of a defined threshold for which important 
information is contained. It removes data that doesn’t contain useful information 
and may represent background data due to environmental changes.  The change in 
heatmap before and after feature selection demonstrates how the algorithm used to 
manage the raw data ‘cleans’ up the points, focussing in on those of interest.  
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Figure 5.5a: GC-IMS raw output 
data before feature  selection 
applied. X axis – drift time (M/s), Y 
axis – retention time (M/s.) White 
areas represent clusters of ionic 
activity. 
These figures demonstrate the actual 
output data from running a urine 
sample before conversion to 
numerical values and represents 
thousands of data points. 
 
Figure 5.5b: GC-IMS raw output 
data after feature selection. White 
clusters are more well defined, 
highlighting specific points of 
interest. Data representing 
‘background noise’ due to 
environmental factors is removed, 
leaving refined  and more well 
targeted data points.  
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5.8 Discussion  
Overall this experimental work, which examined the use of urinary VOC markers 
as a tool to detect CRC, produced varied results. This is, in part, a reflection of the 
evolving understanding of VOC analysis and the ongoing improvement of sample 
and data analysis.   
FAIMS analysis 
Results using the most up to date methodology for FAIMS analysis (experiment 
three) in the FOBT positive BCSP population showed: 
 Classification of CRC from normal was high with AUC 0.98, sensitivity of 1 
and specificity of 0.92 
 Classification of CRC from low, intermediate and high risk adenomas was high 
with test accuracy ranging from 0.83-0.92.  
 When CRC was grouped with adenomas and attempts made to classify this 
combined group with other or normal groups the separation was low with test 
accuracy ranging from 0.56-0.64. 
GC-IMS analysis 
Results of the first study using GC-IMS to detect CRC showed: 
 Classification of CRC from normal was high with AUC 0.82, sensitivity of 0.80 
and specificity of 0.83. 
 Classification of CRC from other disease groups demonstrated an AUC 0.77, 
sensitivity of 1 and a low specificity of 0.57. 
 When CRC was grouped with adenomas test accuracy dropped to 0.53-0.61. 
 Classification of adenoma from normal was low with AUC 0.61, sensitivity 
0.58 and specificity 0.62. 
The results from both FAIMS and GC-IMS show consistency. The separation of 
CRC from normal cases was high, yet when CRC cases were grouped with 
adenomas the accuracy dropped significantly. This suggests that CRC has a VOC 
profile that distinguishes it from other GI pathologies, and therefore when this 
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profile is combined with that of other disease groups the VOC signal is not distinct 
enough to be correctly classified from normal groups. The observation that CRC 
and adenomas have distinct profiles, was further supported by the analysis using 
FAIMS to separate cancer from adenomas. In this case the separation was high, 
which suggests that it is possible to separate malignant from pre-malignant disease 
based on urinary VOC profile. Specificity when comparing CRC and adenoma 
groups was particularly high. This set of results warrant further exploration to 
ascertain whether the separation seen is simply because the adenoma group 
represent another non-cancer group or whether there are changes specific to the 
VOC profile of colonic adenomas that make it more distinct from CRC than other 
groups.  
CRC-specific VOCs are thought to occur via genetic and protein changes that cause 
peroxidation of the cell membrane. In addition, there is an increase in reactive 
oxygen species within the cancer cell. Finally, alterations in the microbiome have 
a direct effect on the VOCs. As discussed in Chapter Two, there has already been 
work carried out by other research groups, to isolate the chemicals that may be 
specific to CRC cases. Currently, there is little consensus as to which hold most 
importance. Hydrogen Sulphide has also been implicated in CRC by mediating 
DNA damage (235), but this has also been associated with colonic adenoma 
formation  (362). It is well established that colonic adenomas are linked to microbial 
dysbiosis (363), with higher proportions of Proteobacteria and less Bacteroidetes 
in those with adenomas compared with controls. This suggests changes in the 
microbial environment may be a factor in adenoma development. In established 
CRC, changes in microbes found at the tumour site have been observed compared 
with normal tissue (364, 365) such as increased Fusobacterium, making it plausible 
that dysbiosis could be the cause of adenomas but a consequence of CRC. If 
dysbiosis is the key driver of altered VOC patterns, this would help to explain the 
difference in VOC signals between adenomas and CRC seen in this work. 
The experiments in this chapter focussed not only on cancer, but on the detection 
of colonic adenomas versus non-cancer groups. This is the first study to examine 
adenoma detection using the urinary VOC profile. The adenoma group showed poor 
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separation from normal cases. Few groups have published data on colonic 
adenomas. De Meij et al (166) carried out faecal analysis and found sensitivities of 
62% when advanced adenoma was compared with control. However, unlike the 
results seen here, when adenomas and cancer cases were grouped together against 
control the sensitivity improved to 85%. Amal et al used breath testing to 
differentiate advanced adenomas from controls with sensitivity of 100% which 
performed better than cancer vs control where sensitivity was 85% (239). This 
suggests current understanding is conflicting and there is more work needed to 
establish the mechanism of VOC profile change with colonic adenomas and other 
GI diseases.  
The analytical technology associated with VOC detection is improving constantly. 
Refinement in data software and ion capture, as seen in experiment three, is likely 
to explain, at least partially the inconsistent results seen in the three experiments 
presented here. This reinforces the importance of ongoing modifications of the 
analytical instruments used for VOC capture. Machine learning models that utilise 
data analysis algorithms of the VOC output must be able to transform raw data into 
points of interest, whilst excluding excess information that does not reflect the 
disease state. This complex statistical processing is constantly improving, and the 
transition to more sophisticated data analysis is outlined in Chapter Four and has 
been demonstrated in this chapter. There are many positive developments in 
sampling and data analysis, yet the variables affecting VOCs are complex, and to a 
certain extent, as yet unknown.  
The benefits of using FAIMS as the detection method of choice, have been 
described in detail in Chapter Four, but the inconsistent results between 
experiments reflect the many factors that alter VOC detection. These include 
temperature, background VOCs and storage factors and as yet have not been fully 
controlled for.  The level of repeatability required for equipping the clinical setting 
with this technology has not yet been demonstrated. A major drawback of this 
technology, is the lack of ability to identify chemical compounds using FAIMS. 
Chemical identification would help to focus VOC profiling more intently and 
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improve understanding of the pathology of CRC. Unlike FAIMS, GC-MS has the 
ability to identify the chemical profile of a biological sample.  
It is widely accepted that GC-MS is the gold standard in VOC detection (176, 182). 
In contrast to the other modes of analysis described in this thesis that rely on a 
pattern recognitions, GC-MS has the ability to detect aberrant VOCs that may serve 
as diagnostic biomarkers of individual disease.  However, the benefits are matched 
by disadvantages, these include size, running cost and operation requiring highly 
trained staff (356). Therefore, GC-MS cannot be referred to as the gold standard for 
clinical practice. In view of the difficulties with GC-MS, the multitude of 
technologies being used by different research groups for analysis will continue, 
until a consensus is reached on which are most suitable. GC-IMS is a relatively new 
instrument, but it has the ability to provide chemical information and it is portable 
and easy to use for urine analysis. This means it has great potential with 
encouraging results presented in this chapter. But progress is hampered somewhat 
due to a lack of operators with experience in biological sampling. Therefore its 
adaptation in the clinical field is still in its infancy, a chemical registry that allows 
identification of the chemical make-up of biological samples has not yet been 
established. The panacea for VOC analysis is still awaited.  
Future research 
Important considerations in the storage and sampling conditions of urine specimens 
have been raised in this chapter and these considerations apply to FAIMS, GC-IMS 
and any other VOC detection modality. As examined in Chapter Four, sample age 
is important when capturing VOCs. The varying age of the samples analysed is 
likely to have had an impact on the results. This applies to experiment one 
particularly as some samples were collected in 2012. The knowledge and 
understanding the optimal conditions for storage prior to analysis is still in the early 
phases and more work focussed solely on this would be welcomed. However, VOC 
mediated disease detection is going to be a real contender in the clinical 
environment, the VOCs of interest will need to be stable enough to ensure an 
element of variability in terms of storage procedure.  
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It is important to highlight that the bowel screening patient group recruited for 
experiments two and three were those that had a positive FOBT. The current guaiac 
FOBT has poor selectivity for CRC, therefore it would be interesting to repeat this 
experiment once the FIT is introduced as the current screening tool, because it has 
both superior sensitivity and specificity compared to the current FOBT. Also key 
when comparing a new screening tool with FOBT is to examine the FOBT negative 
patients too, however access to this group is difficult as it requires permission from 
the BCSP research committee and recruitment of patients in the community rather 
than a hospital setting.  
Combining VOC detection with other biochemical tests such as FIT as a two-stage 
test in the symptomatic population (392) is a newly proposed area of interest and 
holds potential in the field of CRC diagnosis. Work in this field is expected in the 
next twelve months and heralds new wave of possibility in the use of VOC detection 
in disease. 
Limitations 
A major limitation with these experiments is the small sample sizes for the CRC 
groups, therefore only tentative conclusions can be made. In isolation, VOC-based 
diagnostic testing in CRC has not yet demonstrated consistency or accuracy on a 
large scale.  
Recommendations 
VOC based diagnostics holds huge potential with multiple advantages for the 
patients, but there is still extensive work to be done before this can become 
functional in today’s NHS. It is a rapidly developing area and further large scale, 
studies are taking place in VOC breath analysis.  
The following recommendations are made based on this work  
An international collaborative approach would be welcomed to formulate 
consensus statements on sampling technique and instruments used in VOC 
detection.  Also of vital importance is the development of a GC-MS based registry 
of chemicals isolated from CRC samples. This would contribute to a pattern-
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recognition library for all diseases investigated for using VOC detection and would 
allow more focused analysis by narrowing the chemical window of interest. It 
would also contribute to the understanding of the pathophysiology of disease 
development, as investigation into the role of highly abundant chemicals could take 
place. Alongside these measures for improvement, it is also important to engage 
with manufacturers of the analytical instruments in order to motivate their focus on 
specific designs for human disease testing, rather than researchers relying on 
adapting industry-specific devices for biological samples  
Research questions with answers 
1 a) Does colorectal cancer have a specific VOC biomarker ‘fingerprint’? 
The results from experiment three show the ability to correctly classify CRC 
samples from normal or ‘other pathologies’ with high sensitivity and modest 
specificity using FAIMS and GC-IMS. This suggests a chemical fingerprint 
that is unique to CRC. However the low study numbers must be taken into 
consideration.   
b) Can this be applied as a diagnostic test for colorectal cancer in the bowel 
cancer screening population? 
Recruitment for urine sampling was >90% suggesting a clear advantage of 
urine screening over faecal screening, but significant developments in 
methodology and analysis using VOC detection, are required before a 
suitable test is available in the clinical setting.  
c) What is the sensitivity and specificity of this test in the screening 
population? 
These results show a sensitivity between 80-100% and specificity 57-92% 
in FOBT positive patients. In comparison the current guaiac FOBT has a 
sensitivity of around 50% and specificity of 75%, therefore the urinary VOC 
test holds promise in this small group, but requires validation on a larger 
scale.  
 
2 a) Can urinary VOC biomarkers differentiate between different stages of 
colorectal cancer? 
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This could not be established from the experiments performed in this 
chapter.  
b) Can urinary VOC biomarkers differentiate between colorectal adenomas 
and CRC? 
Analysis from this work indicates a high degree of separation using FAIMS 
VOC analysis for cancer vs adenomas with the largest separation seen 
between cancer and high risk adenomas (Sensitivity 0.83 95% CI 0.52-0.98, 
P=0.0006). This is an important finding that warrants further investigation 
and is also supported by the low sensitivities seen when cancer and 
adenomas are grouped together, suggesting they have substantially different 
VOC profiles.  
5.9 Conclusion 
The series of experiments described in this chapter investigates the feasibility of 
detecting CRC and adenomas using FAIMS for urinary VOC detection. This has 
not been replicated by any other research group in such high numbers, or in the 
BCSP population.  In addition it is one of the first studies to report on the detection 
of colorectal diseases using GC-IMS. These results indicate that CRC can be 
correctly classified from control and adenomas using FAIMS and GC-IMS, but the 
classification of adenomas from control was poor. This approach to disease 
detection faces multiple challenges, that reflect the complexity of human disease 
and does not currently have a role in clinical diagnostics. There is a need for better 
encoding of features, future identification of the VOC composite molecules would 
be a huge step forward in achieving this. Collaborative research in the field of VOC 
diagnostics would allow investigation in more depth and with larger numbers than 
have currently been studied. This would more substantially address the plethora or 
variables that have an effect on this method of disease detection.   
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CHAPTER 6: 
Investigating the urinary proteome 
in the detection of colorectal 
cancer 
 
 
 
 
 
204 
 
6.1 Introduction 
The experimental work in this chapter demonstrates the first application of urinary 
peptide markers, to form a novel diagnostic test for CRC detection. It also evaluates 
the role of the proteome in the development of CRC. 
Cancer can cause protein specific changes both local to the site of the malignancy 
and also systemically. Normally, daily urinary protein excretion is only 
<150mg/day (366) due to the process of reabsorption in the renal proximal tubules, 
but when cancer is present it has been hypothesised that the urinary proteome 
changes, and cancer-specific alterations may be detected as a marker of the presence 
of disease. Urinary proteomics is increasingly being used to identify new 
biomarkers of disease, but also to improve the understanding of the pathogenesis of 
disease. Urinary protein profiling has already been investigated for cancers of the 
urinary tract and pancreas (249, 367), but has not been explored in gastrointestinal 
cancers. 
The heterogeneity between different colonic cancers has been acknowledged at the 
genomic and proteomic level, but also between tumour subtypes (368). Proteomic 
research has the potential to further explain the mechanisms of progression and 
prognosis of CRC that, as yet, have evaded researchers.  Through focus on the 
proteome it may be possible to isolate key alterations in peptide sequencing that are 
specific to CRC. This could be achieved by identifying small numbers of disease-
specific biomarkers from thousands of polypeptides using urine for analysis. 
Previously in this thesis, an outline of the benefits of urine as a source for disease 
detection or screening compared with other mediums, has been discussed. In 
addition to the advantages already mentioned, it has been postulated that the urinary 
proteome is less complex than other bodily fluids, such as blood, with a lower 
dynamic range (369), potentially making analysis easier.   
The experiments performed in this chapter are multi-stage, with the aim of 
evaluating carcinoma-specific changes to the protein profile, in both the urine and 
colonic tissue of a patient with CRC. Firstly, a new technology in the medical 
diagnostic field, called capillary electrophoresis coupled with mass spectrometry 
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(CE-MS) was used. This is a highly sensitive method of identifying urinary peptides 
and their corresponding amino-acid chains. But it has rarely been applied to the 
field of urinary diagnostics before. Secondly, the marker peptides found in the urine 
were sequenced and linked to a target list of proteins.  In the third stage of analysis, 
immunohistochemistry (IHC) was used to establish whether key proteins can be 
linked to the site of cancer by using an immunoassay applied to the colonic cancer 
tissue. The possible role of these proteins in the pathology of CRC was discussed.  
6.2 Aims 
1. To test the development of a urinary peptide diagnostic assay using CE-MS 
for the detection of CRC.  
2. To identify proteins with a role in CRC, based on sequencing of the urinary 
peptides. 
3.  To establish if key proteins are present within the CRC tissue and discuss 
their role in the pathology of the disease.   
6.3 Research questions 
1. Do patients with CRC have a different urinary peptidome to controls? 
2. What are the key proteins coded for by the peptide sequences detected in 
the urine of patients with CRC?  
3. What is the potential role of these proteins at the cancer site? 
6.4 Ethical approval 
Scientific and ethical approval was obtained from the Warwickshire Research & 
Development Department and Warwickshire Ethics Committee 09/H1211/38. 
Written informed consent was obtained from all patients who participated in the 
study.  
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6.5 Experimental work 
6.5.1 Identification of urinary peptide markers for CRC by capillary 
electrophoresis coupled to mass spectrometry. 
Setting: Recruitment took place at UHCW, analysis was undertaken by Mosaiques-
diagnostics in Hannover, Germany. Inclusion criteria: Colorectal adenocarcinoma 
and colonic adenoma cases that were confirmed histologically.  Exclusion criteria: 
Cases where colonoscopy was not performed, therefore outcome unknown.  
Method 
Sample collection: During 2017, the FAMISHED database at UHCW was 
examined to identify 12 CRC cases, these were age-matched with 6 colonic 
adenoma cases and 6 normal controls. Sample collection and storage followed the 
method described in Chapter Four. Samples remained frozen using dry ice, whilst 
in transit to the study collaborators in Hannover, Germany (Mosaiques-diagnostics) 
where sample analysis took place in September 2017.  
CE-MS 
CE-MS was introduced in Chapter Two. It is a two-phase technique that separates 
molecules based on their mass-to-charge ratio and demonstrates several advantages 
for peptide detection. Schematics of the sample preparation and CE-MS process are 
shown in figure 6.1 below. CE-MS analysis methodology has been well described 
by previous research groups (247, 370) and has been replicated in this experimental 
work. CE-MS is highly sensitive to small peptides present in urine and unlike other 
techniques such as liquid chromatography (LC), there is no requirement for 
continuous adaptation of conditions for optimal ionisation. This allows automated 
urinalysis which would be ideally suited to a diagnostic tool in the clinical setting.  
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Figure 6.1. Simple schematic of the CE-MS process (adapted with kind permission 
from Mosaiques Diagnostics): 1. The CE electrode is inserted into the urine sample 
applying an electrical field and the sample is introduced into the capillary. 2. 
Analytes are separated according to ionic mobility 3. The capillary outlet is 
introduced to the electrospray ionisation chamber (ESI) 4. The ions produced are 
analysed by mass spectrometry. 
 
 
Sample preparation  
For proteomic analysis 0.7 millilitres (mls) of urine was supplemented with 0.7 mls 
of 2M urea and 10mM NH40H containing 0.02% SDS. To remove proteins of 
higher molecular mass (for example albumin and immunoglobulin G) the sample 
was filtered using a Centrisart ultracentrifugation filter device (20 kDa (kilodalton) 
molecular weight cut-off; (Sartorius, Goettingen, Germany) at 2600xg until 1.1 mls 
of filtrate was obtained. The filtrate was then loaded onto a PD-10 desalting column 
(GE Healthcare, Munich, Germany) and equilibrated in 0.01% NH4OH in HPLC-
grade water to decrease matrix effects by removing urea, electrolytes and salts and 
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also to enrich polypeptides. All samples were lyophilised and suspended in HPLC-
grade water at 40C directly before CE-MS analysis.  
CE-MS analysis  
A P/ACE MDQ capillary electrophoresis system (Beckman Coulter, Fullerton, 
USA) was used coupled to a Micro-TOF (time-of-flight) MS (Bruker Daltonic, 
Bremen, Germany). A solution of 20% acetonitrile (Sigma-Aldrich, Taufkirchen, 
Germany) in HPLC-grade water supplemented with 0.94% formic acid (Sigma-
Aldrich) was used as a running buffer. The ESI sprayer (Agilent Technologies, Palo 
Alto, USA) was grounded and the ion spray interface potential was set between -
4.0 and -4.5 kV. Data acquisition and MS acquisition methods were automatically 
controlled by the CE via contact-close-relays. Spectra were accumulated every 3 
seconds over a range of m/z 350 to 3000.  
CE-MS data processing 
Ion peaks were decluttered using MosaiquesVisu software which uses a 
probabilistic clustering algorithm and is a well-established method (371). Each 
polypeptide is characterised by its mass and migration time. Using reference data 
points the peptides were calibrated using local linear regression to isolate points of 
interest and discard ionic signal intensity that resulted from environmental factors 
(e.g. salt content).  The resulting peak list from each sample analysis characterises 
each polypeptide by it’s a) calibrated molecular mass b) calibrated CE migration 
time and c) normalised signal intensity. Raw peptide data was collated in a 
Microsoft database and disease-specific peptide models were generated using the 
support vector machine (SVM)-based MosCluster software. Classification of 
patient samples is achieved using the SVM-based multi-marker model. Here a 
peptide classifier is constructed, and each sample is given a score expressing the 
similarity of the patients’ peptide profile to that of one identified to be specific to 
the disease. The classifier based test is constructed using an array of biomarkers. In 
general, it is not possible to reduce highly complex disease pathophysiology to a 
single marker (372). In addition, a single peptide marker is highly susceptible to the 
effects of biological variability.  
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Sequencing of peptides 
Urine samples were analysed on a Dionex Ultimate 3000 RSLS nano flow system 
(Dionex, Camberly, UK). Elution was performed on an Acclaim PepMap C18 nano 
column with a linear gradient of 0.1% formic acid as solvent A versus 100% 
acetonitrile as solvent B starting at 5% to 50% over 100 minutes. The sample was 
ionised in positive ion mode using a Proxeon nano spray ESI source (Thermo Fisher 
Hemel, UK) and analysed in an Orbitrap Velos FTMS (Thermo Finnigan, Bremen, 
Germany). Data files were searched against the IPI human non-redundant database 
using the Open Mass Spectrometry Search Algorithm without any enzyme 
specificity. Calculated CE-migration time based on the number of basic amino acids 
was compared to the experimental migration time.  
Statistical analysis 
Estimates of sensitivity and specificity for the SVM-based disease specific peptide 
models are calculated by tabulating the number of correctly classified samples. 
MedCalc 8.1.1.0 (Mariakerke, Beligium) was used to calculate 95% CI’s and ROC 
plot. The area under the ROC curve (AUC) was calculated as it provides a single 
measure of overall accuracy (373). 
Incorporating previous plasma analysis: A previous, small feasibility study using 
CE-MS at Mosaiques-diagnostics established 392 plasma peptides that were 
differentially regulated between CRC (n=18) and normal (n=12) patients. From 
these peptides 143 amino acid sequences and 24 proteins were sequenced. Due to 
the low numbers of samples in this pilot study on urine there was not enough 
statistical power for adjusted p-value statistics. To compensate for this statistical 
limitation it was decided to only select those urinary peptide markers that could be 
corroborated with peptide markers found in plasma.  Urinary peptides were selected 
with significant Wilcoxon rank sum p-values with a frequency distribution of 30% 
in at least one group.  
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Results 
A total of 24 patient urinary samples were analysed: 12 with CRC, 6 with colonic 
adenomas and 6 normal controls (table 6.1). 5 of the CRCs were right sided and 8 
were left sided. Dukes stage for the cancer cases was as follows: Dukes A – 1/12 
(8.3%), Dukes B – 5/12 (41.7%), Dukes C – 6/12 (50%). Four adenoma cases were 
low risk and two were intermediate, all were found in the left colon.  
 Table 6.1. Study population characteristics 
 Median 
age 
[years] 
(sd) 
Male (%) Median 
BMI 
[kg/m2] 
(sd) 
Smoker 
% 
Alcohol 
intake 
[average 
u/wk] 
CRC 70 (9.4) 8/12 
(66.7) 
26.1 (2.0) 41.7 9.5 
Adenoma 75 (4.9) 4/6 (66.7) 27 (3.9) 66.7 6 
Control 67(7.4) 5/6 (83.3) 24.8 (2.9) 0 1.5 
 
CRC peptide markers in urine 
158 urinary peptide marker candidates with significant Wilcoxon p-values were 
detected, i.e. markers that were differently regulated in CRC compared with 
adenoma + control. Using tandem mass spectrometry 52 amino acids were isolated 
from the peptide markers (figure 6.2). The 19 proteins from which the amino acids 
are derived, are shown in table 6.2. The contour plots that contain the raw CE-MS 
data are shown in figure 6.3, here the crude differences in peptide composition 
between the groups can be visualised.  
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Figure 6.2. Identification chain from urinary peptides to proteins  
 
 
 
Table 6.2. Proteins from which the CRC peptide marker candidates in  
urine are derived and number of peptide markers for each protein precursor.  
 
Protein name 
Number of 
peptide 
markers 
Collagen alpha-1(I) chain 22 
Collagen alpha-1(III) chain 7 
Polymeric immunoglobulin receptor 3 
Uromodulin 3 
Clusterin 2 
Collagen alpha-1(II) chain 2 
CD99 antigen 1 
Collagen alpha-1(V) chain 1 
Collagen alpha-1(XI) chain 1 
Collagen alpha-1(XXVI) chain 1 
Collagen alpha-2(I) chain 1 
Collagen alpha-3(IX) chain 1 
Fibrinogen alpha chain 1 
Gelsolin 1 
Heat shock protein beta-1 1 
Protein S100-A9  1 
Sodium/potassium-transporting ATPase 
subunit gamma 
1 
Xylosyltransferase 1 1 
Zyxin 1 
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The most prominent protein was collagen alpha-1(I) chain with 22 corresponding 
peptide markers. Other key proteins are collagen alpha-1(III) with seven 
corresponding peptides, uromodulin (three peptides), polymeric immunoglobulin 
receptor (three peptides), clusterin (two peptides), collagen alpha-1(II) (two 
peptides). There were single peptide occurrences for zyxin, fibrinogen alpha chain, 
gelsolin, protein S100-A9, CD99 antigen, heat shock protein beta-1, 
sodium/potassium-transporting ATPase subunit gamma, xylosyltransferase 1 and 
five other collagen alpha chains. 
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Figure 6.3. Contour plots of the raw CE-MS data for CRC, adenoma and control demonstrating the spectra of urinary polypeptides. 
CE migration time (x axis) is plotted against log molecular weight (y axis). Mean signal intensity is demonstrated by peak height.  
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Performance of a CRC-specific peptide marker model 
Both the complete peptide marker lists for plasma and for urine were screened to 
identify peptides with identical experimental mass, CE migration time and sequence 
identity. Ten peptides fulfilled these criteria. A second method to identify peptide 
markers common to both plasma and urine was also employed in order to 
compensate for the differences in protease composition present due to the different 
composition of each bodily fluid. Overlapping amino acid sequences were assessed 
between the two CRC groups. Frequent overlaps were seen in the collagen alpha-
1(I) chain. This method, of identifying common peptide markers from the same 
linear region highlighted a total of 16 additional CRC urinary peptide marker 
candidates. In total 26 CRC urinary peptide markers were linked to peptide markers 
previously defined in CRC plasma samples. These 26 markers were used to 
generate a SVM-based, CRC specific multidimensional peptide marker panel. The 
complete list of peptide markers is shown in table 6.3.   
Using the SVM-based classification model derived from the 26 surrogate CRC 
peptide markers, it was possible to differentiate the 12 CRC cases from 12 non-
CRC cases with 100% sensitivity and 92% specificity, AUC 0.99 95% CI:0.84-1. 
These results are shown in table 6.4 and the corresponding ROC curve is shown in 
figure 6.4.  
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Peptide 
ID† 
(urine) 
CE-MS 
characteristics 
Distribution in normal 
controls 
Distribution in CRC Amino acid sequence and protein information 
Exp. 
mass 
[Da] 
CE-time 
[min] 
Mean 
(SD) 
Frequency Mean 
(SD) 
Frequency Sequence‡ Protein 
symbol 
Protein name 
5675 911.435 25.8763 161 
(191) 
67 493 (517) 100 DGKTGPpGPA COL1A1 Collagen alpha-
1(I) chain 
13992 1031.43 25.6586 0 (0) 0 31 (51) 42 NGDDGEAGKpG COL1A1 Collagen alpha-
1(I) chain 
17694 1096.48 26.0757 4431 
(4614) 
100 6008 
(3146) 
92 ApGDRGEpGPp COL1A1 Collagen alpha-
1(I) chain 
24502 1200.54 25.0266 3604 
(4173) 
83 10031 
(3864) 
100 KGDAGApGApGSQG COL1A1 Collagen alpha-
1(I) chain 
25893 1223.57 19.3926 894 
(1522) 
67 138 (447) 17 DHEGTHSTKRG FGA Fibrinogen alpha 
chain 
30575 1297.58 27.365 1018 
(1438) 
83 1820 
(1080) 
92 SpGSpGPDGKTGPp COL1A1 Collagen alpha-
1(I) chain 
35339 1378.61 28.822 2018 
(802) 
100 3071 
(923) 
100 ApGDRGEpGPpGPAG COL1A1 Collagen alpha-
1(I) chain 
46649 1563.7 29.4617 42 (94) 33 277 (173) 92 SpGSPGPDGKTGpPGPAG COL1A1 Collagen alpha-
1(I) chain 
46883 1567.73 23.9151 9 (16) 33 0 (0) 0 VQEKQHPVPPPAQN ZYX Zyxin 
51932 1636.74 30.251 890 
(874) 
67 1813 
(1286) 
75 GSpGSpGPDGKTGPpGPAG COL1A1 Collagen alpha-
1(I) chain 
55315 1693.76 23.4788 472 
(1019) 
33 5 (17) 8 PpGPpGKNGDDGEAGKpG COL1A1 Collagen alpha-
1(I) chain 
57265 1732.77 28.1753 2468 
(1401) 
83 3655 
(1435) 
100 WVGTGASEAEKTGAQEL GSN Gelsolin 
57531 1737.78 31.0012 2788 
(1814) 
83 4057 
(851) 
100 DKGEpGGpGADGVPGKDGP COL3A1 Collagen alpha-
1(III) chain 
57537 1737.78 23.7334 8584 
(3818) 
100 6390 
(2046) 
100 NDGAPGKNGERGGpGGpGp COL3A1 Collagen alpha-
1(III) chain 
59645 1779.8 31.1464 321 
(596) 
50 0 (0) 0 GLTGSpGSpGPDGKTGPpGP COL1A1 Collagen alpha-
1(I) chain 
72896 2055.94 25.438 641 
(426) 
100 1474 
(673) 
100 SGEpGApGSKGDTGAKGEpGPVG COL1A1 Collagen alpha-
1(I) chain 
73697 2070.92 25.399 662 
(386) 
100 1134 
(472) 
100 GNSGEpGApGSKGDTGAKGEPGp COL1A1 Collagen alpha-
1(I) chain 
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Table 6.3. CE-MS and sequence characteristics of the 26 CRC peptide marker candidates that were detected by CE-MS in plasma and urine 
and that showed in both biofluids significant differences in their distribution by group wise comparison of CE-MS peptide profiles between CRC 
cases and non-cancer control
73913 2076.95 21.7789 355 
(738) 
50 1252 
(995) 
92 GPpGPpGKNGDDGEAGKpGRpG COL1A1 Collagen alpha-
1(I) chain 
74420 2085.93 22.0672 5831 
(9863) 
33 8401 
(6652) 
67 EGSpGRDGSpGAKGDRGETGPA COL1A1 Collagen alpha-
1(I) chain 
86241 2303 22.2953 44 (80) 33 1 (5) 8 n.i. ---  ---  
87272 2319.07 33.817 0 (0) 0 317 (422) 42 AGppGEAGKPGEQGVpGDLGApGPSG COL1A1 Collagen alpha-
1(I) chain 
90344 2377.1 20.7997 1644 
(1275) 
100 3474 
(1622) 
100 GKNGDDGEAGKPGRpGERGPpGpQ COL1A1 Collagen alpha-
1(I) chain 
93417 2446.09 28.3726 5 (13) 17 185 (185) 75 ADGQpGAKGEpGDAGAKGDAGPpGPAGP COL1A1 Collagen alpha-
1(I) chain 
130747 3359.58 31.8979 657 
(716) 
83 1509 
(769) 
100 pPGADGQPGAKGEpGDAGAKGDAGppGPAGPAGPPGPIG COL1A1 Collagen alpha-
1(I) chain 
165081 4638.1 25.7822 284 
(581) 
50 25 (86) 8 n.i. ---  ---  
177971 6236.91 21.066 1375 
(765) 
83 242 (373) 42 n.i. ---  ---  
* Abbreviations: AA, amino acid; AUC, area under the curve; CE-MS, capillary electrophoresis mass spectrometry; Da, Dalton; n.i., not identified; min, minutes; SD, standard deviation. 
    † Peptide identification number. 
    ‡ Lower case p and m indicates hydroxyproline and oxidized methionine. 
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Table 6.4 Classification of CRC from control using a 26-peptide urinary marker 
test 
 
 
 
 
 *P=0.0001 
Figure 6.4. ROC curve for differentiating CRC from non-CRC using a 26 urinary 
peptide marker model with corresponding AUC, sensitivity and specificity. The 
dotted lines either side of the true result line represent upper and lowert 95% CI’s. 
 
 Result  
AUC 0.99* 95% CI (0.84-1) 
Sensitivity 100 
Specificity 0.92 
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6.5.2 Experiment two: Establishing the role of urinary-derived proteins in 
CRC. 
Setting: Recruitment took place at UHCW and analysis was undertaken at the 
Clinical Sciences Research Laboratories within UHCW. Inclusion criteria: CRC 
cases recruited from experiment one, provided the tumour had been removed and 
was available for analysis. Exclusion criteria: Cases where no tissue specimen was 
available. Cases where patient had undergone chemotherapy, radiotherapy or any 
other cancer-related treatment prior to surgical excision of tumour.  
Method 
Patient characteristic data is shown in table 6.1 in the above section. 
Antibody selection: The raw peptide data for both serum and urine analysis was 
interrogated to establish those with a direct sequence match in MEROPS (an online 
database for the classification of peptidases) and those with the highest number of 
cleavage sites in order to identify a single protein, or ‘antigen’ of interest. Nine 
showed potential, and are listed in table 6.5 together with corresponding antibody 
code:  
Table 6.5 Nine antigens (proteases) which have a link with the raw urinary 
peptide data based on highest number of cleavage sites. 
Target antigen Antibody code 
Cathepsin D ab75852 
Cathepsin E ab36996 
Cathepsin G ab192793 
Kalikrein 14 ab203226 
Meprin alpha ab107548  
Meprin beta ab204886 
MMP3 ab52915 
MMP7 ab205525 
Plasminogen ab174285 
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Secondly, the protease prediction data was reviewed using Proteasix, which is an 
open-source peptide-central tool which can predict the proteases involved in native 
peptide generation. Using this information, the protease selected for investigation 
was MEP1A. The rationale for this was three-fold: Firstly, it is connected to 
thymosin beta-4 which was identified in 4 peptide markers in plasma and has 
observed cleavage sites for MEP1A, as found on MEROPS. Secondly, thymosin 
beta-4 has a known role in CRC and finally, there has already been a link made 
between MEP1A and CRC in the literature.  
 
Preparation of slides: The slides were formalin-fixed and paraffin-embedded at 
UHCW using a standardised protocol.  
Optimising the antibody: The Human Protein Atlas (374) was interrogated, to 
investigate the current guidance on antibody dilutions and anticipated staining 
patterns for MEP1A. This was used as a guide for the serial dilution experiments 
that were conducted to optimise stain concentration.  A MEP1A-specific primary 
antibody (at a dilution of 1:1000; Abcam, UK) was used for all IHC. This is a rabbit 
polyclonal to MEP1A, known to react with human tissue.  
IHC: The method for IHC was carried out in accordance with the standard operating 
procedure documents produced by the UHCW tissue bank. However, consideration 
was made of specific manufacturer instructions regarding optimal dilution and 
antigen retrieval. The combination of primary antibody, dilution and detection 
system were validated on a series of test controls prior to use on the cases. Sections 
(taken from the same patients studied in experiment one), of colonic tumour (n=12) 
and adjacent normal tissue (n=12) were cut from stored blocks located in UHCW 
tissue bank. Each slice was reviewed by a Gastrointestinal Pathologist to ensure 
adequate tissue was collected prior to staining. Sections were cut at 3-4 µm and 
dried overnight in a 560C oven. A Leica polymer detection kit (Leica, UK) was used 
throughout.  
- Pre-labelled slides were washed with distilled water. 
- A hydrophobic pen was used to mark borders around the tissue sections, they 
were then placed in a metal moist chamber. 
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- Endogenous peroxidase activity was blocked using 100 µl/2 drops of Leica 
peroxidase block and left for 5 minutes.     
- Two washes were carried out using Tris-buffered saline (TBS) for five minutes 
each. Sections were then incubated in Leica protein block 100µl for 20 mins, 
this reduces non-specific binding of primary and polymer. 
- The protein block was drained off and a further 2 TBS washes were completed 
at five minutes each. 
- Incubation in MEP1A at 1:800 dilution was then performed as determined by 
prior serial dilutions. Incubation with antibody was performed overnight in the 
fridge at 4
0
C to help reduce the level of background staining. 
- After overnight incubation, sections were washed in TBS for 10 minutes, twice. 
Leica post primary block was then applied to slides using 100µl and incubated 
for 30 minutes, this solution recognises the rabbit immunoglobulins, this step is 
followed by two washes with TBS for 5 minutes each.  
- Sections were then incubated in Leica Novolink polymer solution using 100µl 
to ensure adequate coverage and incubated for 30 minutes followed by two 
washes with TBS for 5 minutes each time. 
- Sections were incubated in Leica diaminobenzidine (DAB) working solution. 
This was constituted using 50µl of DAB chromagen in one ml of Novolink DAB 
substrate. Each slide was covered with two-three drops and left for five minutes, 
reaction with the peroxidase produces a visible brown precipitate at the antigen 
site.  
- This step was followed by a further two washes with TBS for five minutes each 
time. Slides were then rinsed in distilled water and drained off. 
- A counterstain of haematoxylin (brown colour) was applied for 30 seconds and 
slides were again washed in distilled water, followed by incubation in TBS for 
2-3 minutes. Once left to dehydrate they were then ready for viewing.  
- Results were interpreted using a light microscope and Panoramic viewer 
(3DHISTECH Ltd, Hungary), where digitally converted slides were displayed. 
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The 12 CRC and adjacent normal tissue slides were examined by a Gastrointestinal 
Pathologist at UHCW, who provided evaluation of the staining intensity using the 
Allred scoring system, the details of which are in table 6.6.   
 
Table 6.6 Allred scoring system for stain intensity (375) 
 
Results 
Study population characteristics are displayed in table 6.1 in the section above. 
There were 13 cancers from 12 patients (one synchronous cancer case). Tumour 
characteristics are listed in table 6.7 according to Dukes stage. 
Table 6.7. Tumour site and stage 
Case Number Tumour Site Dukes stage TNM 
1* Rectum A T2N0M0 
2 Rectum A T1N0M0 
3 R.  Colon B T3N0M0 
4 R. Colon B T4N0M0 
5 Rectum B T3N0M0 
6 Rectum B T3N0M0 
7 T. Colon B T3N0M0 
8* Caecum C1 T3N2M0 
9 R. Colon C1 T3N1M0 
10 Rectum C1 T2N2M0 
11 Sigmoid C1 T4N1M0 
12 Sigmoid C1 T3N1M0 
13 Rectum C2 T4N2M0 
*Synchronous tumours from same patient 
Score Intensity 
0 Negative (no staining of any nuclei at high magnification) 
1 Weak (only visible at high magnification) 
2 Moderate (readily visible at low magnification) 
3 Strong (strikingly positive at low magnification) 
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Table 6.8 shows the staining score for each case and control. The stain intensity 
scores have been divided into four, corresponding to the tumour tissue, the 
epithelium of the adjacent normal tissue and the stroma in both CRC and normal 
tissue. 
Table 6.8 IHC staining intensity score for MEP1A in CRC compared with normal 
tissue.  
 Tumour stain 
intensity 
Epithelial stain 
intensity 
Stromal stain intensity 
   Tissue                 
type 
 
Case 
number 
 
CRC Normal CRC  Normal 
1 3 2 1 0 
2 1 2 1 0 
3 3 3 3 0 
4 2 2 0 0 
5 3 2 1 0 
6 3 3 3 1 
7 3 2 0 0 
8 3 3 0 0 
9 3 2 1 0 
10 No result 2 0 0 
11 3 3 0 0 
12 3 3 0 0 
13 1 2 0 0 
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Antibody staining of the colonic tissue and adjacent normal tissue using IHC 
resulted in three main observations:  
1. There were a greater proportion of cases with a stain intensity score of 3 
(strong intensity) in the CRC group, compared with the normal group. In 
the CRC group 9/12 (75%) had a score of 3 and 5/13 (38%) in the normal 
group had a score of 3. This difference was not statistically significant 
(z=1.069 p=>0.2). 
2. In 4 (33%) of the CRC cases MEP1A was concentrated in the advancing 
margin of the tumour, 2 of these cases were Dukes B and 2 Dukes C. 
3. 6/13 (46.1%) CRC cases showed stromal staining with MEP1A compared 
with 1/13 (7.7%) of the normal cases. In most cases the stain intensity score 
was 1 in CRC.  
Figure 6.5a-c shows digital images of cancer tissue and adjacent normal tissue with 
the difference in distribution of MEP1A illustrated. MEP1A staining is brown. The 
objective magnification is denoted in brackets. Figure 6.5a clearly shows strong 
epithelial staining in normal tissue compared with the surrounding stroma. In figure 
6.5b strong stromal uptake of MEP1A in the cancer tissue is demonstrated. In the 
low power image in figure 6.5c, there is an accumulation of MEP1A stain seen at 
the advancing border of the cancer, this was observed in a third of cases.  
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Figure 6.5a. Digital image of IHC staining of MEP1A in the normal colonic 
tissue epithelium of case number 6. (x200). There is intense MEP1A (brown) 
staining in the concentric epithelium (circled) compared with low intensity staining 
of the surrounding stroma (arrow) 
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Figure 6.5b Digital image of IHC staining of MEP1A in the CRC tissue of case 
number 6 (x600). The arrow highlights intense MEP1A accumulation (brown stain) 
in the stroma. This is in direct contrast to the reverse appearance seen in figure 
6.5a.  
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Figure 6.5c Digital image of IHC staining of MEP1A in the advancing margin 
of CRC tissue in case number 8.  (x10). Cancer tissue is seen to the left of the line, 
normal tissue is to the right. The deep brown staining at the junction of these tissues 
(arrow) represents MEP1A accumulation in the cancer tissue. 
 
 
6.6 Discussion 
The feasibility of peptide based markers as a diagnostic tool in CRC and the 
subsequent identification of possible target proteins involved in tumourigenesis, 
were explored in this chapter. There have been a number of important findings that 
contribute to the body of evidence on proteomics in the detection of CRC.  
Using CE-MS urinary peptide sequencing, 158 peptide markers were upregulated 
in the CRC samples, compared with control. A classification model based on 26 
peptides common to both the plasma and urine of patients with CRC was proposed.  
In this proof-of-concept study, applying this model demonstrated high sensitivity 
(100%), specificity (92%) and overall test accuracy (AUC 0.99 95% CI 0.84-1) in 
correctly classifying CRC. This indicates the potential of peptide markers in the 
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diagnosis of CRC. In addition, this work is the first to utilise urine for CE-MS 
analysis, proving that it is feasible but also highly practical in the clinical setting 
given that CE-MS is user-friendly and portable. The suitability of urine as a 
diagnostic medium has been emphasised on several occasions. This work should 
stimulate further investigation into the capabilities of CE-MS in CRC detection 
using urine. Furthermore an added advantage of studying peptides, is the ability to 
exploit the gathered peptide data, in order to ascertain the proteins from which the 
peptides derive. Identification of these proteins may provide insight into their role 
in tumour formation and progression. 
The sequenced peptides in this urinary study, were fragments of 19 proteins. The 
most prominent proteins were collagen alpha-1(I) and (III).  Collagen alpha-1 (1) 
and (111) (COL1A1 and COL3A1) are members of the collagen family and are 
mainly expressed in extensible connective tissue such as skin and vessels. They 
have both been linked to CRC. A recent study by Zhang et al found increased 
COL1A1 in CRC tumour tissue and in metastatic lymph tissue and postulate that 
COL1A1 functions as an oncogene in CRC progression and is associated with 
metastatic disease (376). This may be due to the association of COL1A1 with the 
wingless type/planar cell polarity (WNT/PCP) pathway, although more work is 
needed to explore this further. Earlier work by Zou et al also demonstrated 
upregulation of COL1A1 in CRC using LC-MS/MS and its presence was associated 
with poorer survival (377). COL3A1 has also been linked to poorer prognosis in 
CRC, with Wang and colleagues showing upregulation of epithelial COL3A1, 
rather than stromal. Increase in tissue collagen was mirrored with an increase in 
serum COL3A1 also observed (378). To date, however there has not been 
replication of these findings in CRC, and both COL3A1 and COL1A1 have been 
linked to other cancers too, so their significance is still not clear (379-382).   
Further utilisation of sequenced urinary peptide markers to better understand the 
pathology of disease, has been attempted by a small number of groups, but none in 
CRC. This is achieved by determining the presence or absence of target proteins in 
cancer tissue directly by using immunoassay techniques. One such technique that 
can be employed is immunohistochemistry (IHC).   
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IHC is a method of identifying the presence and distribution of antigen proteins in 
the cells of a tissue section, by using an antibody to bind specifically to the antigen 
in question. The immunogenic response to cancer has been well described and IHC 
has been utilised successfully in previous studies of ovarian, lung and prostate 
cancer (383).  
The protein profile in a patient with cancer is, in part, altered by the immune 
response of the host to that cancer. This is demonstrated by the identification of 
autoantibodies specific for a number of intracellular and cell-surface antigens, that 
are detected in the serum of affected patients (250). Identifying antigenic biomarker 
has so far, been under-researched but is a promising area, as the immune system 
can amplify the immune-mediated response making antigenic tumour proteins more 
detectable. 
In view of the advantages discussed, the peptide marker results from experiment 
one were used as a platform to identify their proteins of origin, and establish 
whether they can be linked to the cancer site directly. This may suggest a role in the 
pathology of CRC.  
A single protein called MEP1A, was targeted at the cancer tissue site. Meprin, a 
metalloendopeptidase, is a member of the astacin family and was originally 
discovered in 1986 by Bond et al, as a protease highly expressed at the kidney brush 
border membrane (in mouse models) (384). It was subsequently found in the human 
intestinal membrane by Sterchi et al (385). There are two homologous subunits to 
meprin: alpha and beta.  
Results from the second experiment in this chapter, found that MEP1A stain uptake 
was distributed differently between the CRC and normal tissue. Firstly, there were 
a greater proportion of CRC cases with stromal uptake compared with in normal 
tissue (46.1% and 7.7% respectively). In addition, there was a greater proportion of 
cases with a stain intensity score of strong in the tumour tissue (75%) compared 
with the normal epithelium (38%). This did not hold statistical significance. 
Another striking feature in a third of cases, was the aggregation of MEP1A at the 
advancing margin of the tumour.  
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MEP1A has been linked to a number of cancers including breast and also infections 
of the renal and urinary tract (384, 386). There has been a small body of work 
looking at the role of MEP1A in the pathogenesis of CRC. In 1999 Lottaz et al 
hypothesised that the basolateral secretion of MEP1A by colonic cancer exposed 
the extracellular matrix components and other stromal elements to increased 
proteolytic potential in the vicinity of tumour cells (387). Using IHC and also 
Western Blot they found a differentiated human colon carcinoma cell line 
endogenously expressed MEP1A. In 2011 a group headed by Lottaz again, 
examined stage 3 and 4 CRC and normal tissue and found MEP1A to be differently 
distributed in disease compared with control. In normal tissue they found MEP1A 
in epithelial cells, but in colonic cancer cells the protease was secreted in a non-
polarised way which led to accumulation and activation in the tumour stroma (388). 
They postulate that extracellular proteolytic events may promote tumour 
progression by disrupting physical barriers. MEP1A staining in adenomatous tissue 
and in hepatic metastases was low.  
Another group led by Rosmann in 2002 also found accumulation of MEP1A in the 
colonic tumour stroma and overall more MEP1A in tumour tissue compared with 
control. They postulated that activation of this protease occurred by plasmin and 
plasminogen (389).  More recently, in 2016, Wang et al suggest that MEP1A plays 
a crucial role in CRC carcinogenesis and in particular it is involved in tumour 
migration and invasion. Their study showed elevated MEP1A expression in human 
CRC tissue, they also demonstrated in mice that when you knock-out the expression 
of MEP1A, cell proliferation and invasion was blocked, this supports the theory 
that MEP1A has a negative impact on tumorigenesis and progression (390).  
The findings reported in this chapter, are supportive of the hypothesis that MEP1A 
has a role in the progression of CRC and its presence may signify a more aggressive 
tumour. This may hold importance in future treatment regimes for CRC. The 
presence or absence or MEP1A in the tumour margin may be useful as an indication 
of poorer outcome and thus aid in decisions regarding chemotherapeutic agents by 
providing a role in risk-stratification. This could be established in a follow up study 
linking those with MEP1A in the tumour margin to survival outcome.  
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Limitations 
There were limitations to the work in this experiment. Firstly there are drawbacks 
to peptide marker selection using only adjusted Wilcoxon rank sum p-values. This 
was calculated due to the small sample size. However, this was compensated for by 
restricting the classifier model to only 26 peptide markers that also demonstrated 
association to CRC in plasma as well as urine. Further work involving a case-
control study on a larger patient set is warranted to validate these tentative results 
on a larger scale, to ensure overfitting of data has not occurred. As long-term follow 
up data was not available on these patients, the significance of MEP1A on prognosis 
can only be hypothesised.  
6.6.1 Returning to the research questions initially posed 
1. Do patients with CRC have a different urinary peptidome to controls? 
The results from the first experiment have demonstrated a different urinary 
peptide profile in CRC compared with control. A test based on a combined 
plasma and urinary peptide marker model was trialled and demonstrated that 
CRC could be differentiated from control with a high degree of accuracy AUC 
(0.99), sensitivity (1.00) and specificity (0.92). 
2. Which are the key proteins coded for by the peptide sequences detected in the 
urine of patients with CRC?  
The two most prominent proteins were COL1A1 and COL3A1.  
3. Which corresponding proteins are present at the tumour site and what is their 
role in carcinogenesis? 
Nine proteins of interest were detected (table 6.5). MEP1A was found to have 
stronger stain intensity in the CRC tissue compared with normal tissue. Stromal 
stain uptake was present in CRC but absent in normal tissue. These findings 
support the evidence in the literature of a link between MEP1A and CRC that 
possibly indicates a more aggressive tumour phenotype.  
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6.7 Conclusion 
This pilot study is the first to establish a urinary peptide marker profile for CRC 
which was differentiated from control with a high degree of accuracy and could 
form the basis of a diagnostic test.  
Using an immunoassay, increased MEP1A in CRC tissue was demonstrated when 
compared with normal epithelium and suggests a link with more aggressive tumour 
pathology. This supports the current body of published literature on MEP1A. Based 
on the available research, there are likely to be other proteins with a similar pattern 
of distribution and derivation of a panel of proteins with high tumour and stromal 
uptake may give a more accurate prediction of tumour behaviour. This may have 
important implications for CRC treatment strategies and prognostication. 
Furthermore, the role and activity of a further eight proteases need to be investigated 
in CRC tissue.  
There is huge scope for further work based on the results presented in this chapter, 
this exemplifies the expanse of protein-based work that is required in CRC to better 
understand its link with the proteome.  
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CHAPTER 7: 
Discussion 
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7.1 Introduction 
 
CRC is common and is a significant cause of morbidity and mortality across the 
world. The burden of this disease is rising in the UK. There is a lifetime risk of 1 in 
19 for women, and 1 in 14 for men of developing CRC. Currently, overall five-year 
survival is approximately 60% (391). Five-year survival improves to nearly 90% 
for early stage disease, but unfortunately only the minority of patients present with 
early cancer (9).  In comparison to many other cancers, funding into CRC research 
is high, with Cancer Research UK investing £35 million between 2016-2017 alone 
(392). Despite advances in the biology and genetics of CRC that have been achieved 
as a result of research funding, survival has not substantially improved in the last 
decade. In consideration of these factors, there is a need to re-evaluate how CRC is 
detected to establish areas for improvement and set achievable targets for future 
research.  
 
The overall theme of this thesis was to explore non-invasive methods in the earlier 
detection of CRC. Firstly, the current TWW referral pathway for cases of suspected 
CRC was investigated, to evaluate whether this route to diagnosis was effective and 
improved outcome for patients. Secondly, the use of both urinary VOCs and 
peptides as biomarkers for the detection of CRC, was explored through 
experimental work. The aim was to understand their role in CRC detection and 
evaluate whether they represent a real option in the future for diagnosis of this 
disease.  
 
7.2 The detection of CRC using the TWW referral pathway 
 
The lower GI TWW referral pathway was devised in the year 2000 by the DOH, to 
streamline referrals for suspected CRC. There is increasing emphasis on utilising 
this pathway by NHS England. The National Cancer Strategy has set out ambitious 
aims in reducing cancer incidence and improving mortality rates (5).  
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Despite the drive for increased TWW usage by primary care, there are few measures 
in place for the re-evaluation of this referral pathway against key performance 
indicators. The Government initially strived for ‘greater than 90% of cancer to be 
diagnosed’ using TWW pathways (144). The document reporting this statement has 
since been archived, and a target percentage is not quoted in the latest cancer 
strategy document.  
 
The systematic review and meta-analysis in Chapter Three, was the first to be 
conducted with the aim of filling gaps in knowledge regarding diagnostic rates and 
outcomes for patients investigated via the TWW pathway. This systematic review 
reported a low yield of CRC of 7.7%. However, this was consistent with the cancer 
conversion rate for all cancers referred via any TWW pathway of 7.4%. Perhaps the 
most important finding of this review, was that no improvement in stage at 
diagnosis of CRC in the TWW cohort was found, when compared with stage at 
diagnosis via non-TWW outpatient routes. In the TWW group, 46.7% presented at 
Dukes C or above, in such cases survival drops substantially compared with earlier 
stage disease. This finding suggests that the TWW pathway is not having an effect 
on reducing mortality from CRC. In addition, the majority of patients had no 
significant lower GI pathology diagnosed, with 54.6% of patients found to have a 
normal colonic examination. An increased public awareness and lowering the 
thresholds for referral from primary care, have resulted in an increase in referral 
rates via TWW without an increase in the diagnosis of CRC (295). The latest figures 
from 2016-2017 showed an 8.7% rise in annual referrals overall for the TWW 
pathway (148).  
 
The results of this systematic review indicate that the current triage of outpatients 
with lower GI symptoms is not effective in detecting those with CRC and has low 
sensitivity in detecting those with early stage disease. This raises important 
questions about whether the financial investment and clinical demands of the TWW 
pathway can be justified. Moreover, there is no rationale according to the results of 
this review, that the move to shorten diagnostic timeframes to 28 days is going to 
improve cancer stage or mortality (391).  
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In order to address the disappointing survival figures in the UK in comparison to 
Europe, there has to be a continued focus on improved pre-emptive medicine in 
CRC diagnosis, to increase the proportion of patients presenting at an early stage of 
disease. A symptom-based approach to diagnosis that forms the basis of the TWW 
referral criteria needs to be superseded by better risk stratification. There is 
currently on-going debate into how this is achieved. 
 
One possibility is the use of biomarkers, in combination with symptoms, to target 
more patients earlier in the course of the disease. For example, the most recently 
published NHS England guidance on TWW pathways in CRC has recommended 
the more widespread use of the faecal immunochemical test (FIT) for low-risk 
symptoms (391). This signifies a move to incorporate objective tests more widely, 
but there is a paucity of high quality options.  
 
7.3 Biomarker development  
Current biomarkers used in CRC are RAS and RAF mutation testing and mismatch 
repair gene deficiency. They serve to risk stratify the patient after diagnosis and 
provide predictions of response to certain treatments (393), but there is currently no 
detection-based biomarker in use.  
Devising a new biomarker is challenging. Major difficulties relate to the multitude 
of competing influences on these markers as a result of constant flux in the host and 
environment. The factors influencing biomarkers are shown in figure 7.1 and 
highlight the challenges of developing a disease-specific marker in an environment 
of constant change. 
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Figure 7.1 Schematic of the factors influencing potential biomarkers 
                        
 
 
 
Regardless of their target or intended use, biomarkers must also satisfy a number of 
conditions before they can be considered for clinical practice. Five phases of 
biomarker development have been proposed by Pepe and Barker and are listed in 
figure 7.2 (394).  These five phases emphasise that in order for a biomarker to gain 
widespread use, it needs to be validated in prospective, well-controlled clinical 
studies including patients of varying age, sex and ethnicity and transcending 
multiple health-care sites, where regional variations in patient populations are 
accounted for. Furthermore the process must be tightly standardised at each step. 
Sources of 
variability in 
biomarker 
analysis
Differences in 
methodology
Lack of 
standardised 
sampling and 
storage
Differences 
between case 
and control 
characteristics
Genetic 
differences
Changes in 
inflammatory 
states
Changes in 
metabolic state
Changes 
reflecting 
underlying 
chronic disease
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Figure 7.2 Five phases of biomarker development. As described by Pepe and 
Barker (394). 
 
 
 
An important focus of this thesis was to evaluate some of the latest advances in 
biomarker technology in the detection of CRC, given the uncertainty surrounding 
the role of emerging biomarkers in the diagnostic pathway of CRC. Therefore, 
Chapters Four, Five and Six, explored the use of two novel biomarker groups.  
Urine was the sole medium used for the experimental work due its many 
advantages. Patient satisfaction is high: over 90% of patients agreed to urine 
sampling, this compares to the uptake of the FOBT which is around 60%. It is 
readily available, shows stability in the medium term and reflects the internal 
environment of the body without the need for invasive sampling.  It has been 
postulated that the urinary proteome is less complex than other bodily fluids such 
as blood (369). As a consequence, this may simplify analysis. 
 
Phases of 
biomarker 
development
1. 
Preclinical 
exploratory
2. Clinical 
assay and 
validation
3. 
Retrospective 
longitudinal
5. Prospective 
screening
5. Case 
control
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7.4 VOCs in the detection of CRC 
The use of VOC-based disease detection has gained momentum over the last few 
decades and there has been a plethora of small studies examining the VOC profile 
of a variety of bodily fluids and linking this to disease detection. But there has been 
very little focussed research on the analysis and storage of samples, yet both play a 
crucial role in the validity of the results. Chapter Four provides the first detailed 
account of the salient considerations when analysing VOCs and will act as a 
framework for future researchers. The findings from the work examining the effect 
of storage on VOCs resulted in three key recommendations: 
1. No changes to the environment or sampling methodology should be made 
during an experiment. Minor changes have been demonstrated to confound 
results. 
2. Following sample collection, transfer to -800C storage should occur within 
a minimum of 12 hours. 
3. Samples should be stored at -800C for a maximum of 12 months prior to 
analysis.   
A comprehensive investigation of urinary VOC analysis in the detection of CRC 
was performed in Chapter Five. The results were unique in view of the size of the 
symptomatic population studied, but also because this was the first urinary VOC 
research involving the BCSP population. Analysis utilised machine learning models 
which are currently at the forefront of medical diagnostics research. The results 
indicated a high degree of accuracy in separation of CRC from non-CRC using 
FAIMS (AUC 0.98 95% CI: 0.93-1) in the FOBT positive population. Test accuracy 
dropped considerably when attempts were made to group CRC with other diagnoses 
and compare with different groups (AUC 0.56-0.64). This supports the hypothesis 
that CRC has a unique VOC signature. This is the first study to demonstrate the 
feasibility of urinary VOCs as a screening tool in the BCSP. The results confirm 
that there is potential in an alternative means of CRC detection in this group and 
provides a benchmark for future studies.    
Adenomas represent a pre-malignant process, therefore identification and removal 
prevents cancer development in the majority of CRC cases. This is particularly 
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pertinent to the BCSP population in view of the fact that adenoma detection rates 
are far higher, with around 50% of patients found to have adenomas in the BCSP 
population compared with around 15% in the average population  (340). Using 
FAIMS, CRC was correctly classified from low, intermediate and high risk 
adenomas with test accuracy ranging from 0.83-0.92 (95% CI: 0.66-1).   
GC-IMS, a new analytical instrument in the detection of VOCs for medical 
diagnostics, was also used to investigate the BCSP cohort as a proof of concept 
study. GC-IMS was used to classify CRC cases from control. There was a high test 
accuracy (AUC 0.82 95% CI: 0.67-0.97), sensitivity was 0.80 (0.44-0.97) and 
specificity was also high at 0.83 (0.63-0.95) for correctly classifying cases based 
on VOC profile, this showed consistency with the FAIMS results. 
This is one of only a handful of studies to demonstrate the application of this tool 
in the medical field for diagnostic purposes, and the first to look at CRC. The results 
were promising and should stimulate more interest in its application on further, 
larger-scale studies. Not only did this instrument demonstrate feasibility in 
detecting cancer from control, GC-IMS have several advantages as a clinical tool. 
It is simple to use, meaning specialist training is not required. Also, it is portable, 
thus in theory, could be transported to the clinical area of need for instant analysis. 
Finally, due to the IMS component, it has the technology to isolate and identify the 
chemical compounds within the urine sample. This has the potential to broaden 
current understanding of CRC pathogenesis and provide better encoding of features, 
resulting in more targeted VOC detection.  The chemical library required to perform 
this step is currently in the development stage. 
7.5 Proteomics in the detection of CRC 
There is still currently very little understanding of the influence of proteomics on 
CRC or of the key proteins involved in carcinogenesis (392). In contrast to the high 
expectation, the impact of proteomics over the last two decades has been modest. 
This is mainly due to the unpredictable and complex nature of the proteome, which 
makes it exponentially more difficult to map than the genome (245). 
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The work in Chapter Six produced a number of interesting and promising results. 
The feasibility of urinary peptide markers as a test for CRC was investigated and 
was the first to demonstrate the utility of CE-MS in the peptide profiling of CRC. 
CE-MS is a highly sensitive modality and has several features that are suited to the 
clinical field including ease of use and fast analysis. Both these attributes are 
important in a busy clinical environment, as laboratory-based technology is often 
unable to meet the requirements of a medical setting.  Using a 26-peptide test model, 
classification of CRC from control was high, with AUC 0.99 95% CI: 0.84-1, 
sensitivity was 100% and specificity was 92%., Based on these peptide markers, 
nineteen proteins were sequenced with COL1A1 AND COL1A3 showing 
prominence. In addition, using the raw peptide data to cross-reference with online 
protein databases, nine proteases were highlighted as having a potential link with 
CRC. These were MEP1A, MEP1B, MMP3, Cathepsin, G, Cathepsin E, Cathepsin 
D, Plasminogen, MMP7 and Kallikrein.   
Using IHC, the role of MEP1A in the pathology of CRC was investigated.  The 
results contributed to a small body of evidence on the topic (387-389). There were 
three main findings: 
1. A greater proportion of CRC cases showed strong stain intensity of MEP1A 
compared with the adjacent normal tissue (75% versus 38%), suggesting 
MEP1A has a role in CRC. 
2. In a third of CRC cases, MEP1A was seen to accumulate at the advancing 
margin of the tumour.  
3. 46.1% of CRC cases demonstrated stromal staining with MEP1A compared 
with 7.7% of normal tissue.  
Stromal migration of proteins and the consequent association with more advanced 
disease and resistance to treatment has been described in CRC (395, 396). But it is 
hard to make firm conclusions about this observation as studies have also 
demonstrated heterogeneity within the same tumour. For example, in one study 
patients could be simultaneously classified into multiple subgroups using a 30-gene 
list depending on the region analysed from the same tumour (397). The 
accumulation of MEP1A at the advancing edge of the tumour was an interesting 
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finding, not described before in the literature. One could postulate that this 
reinforces the theory of MEP1A proteolytic activity assisting in tumour cell 
migration into neighbouring structures.    
Overall, the findings support the hypothesis that MEP1A has a role in the 
progression of CRC. Several features seen here may signify a more aggressive 
tumour type and could have implications in treatment regimes and risk –
stratification. More evidence will need to be gained and will be aided by the 
improvements in analysis of formalin-fixed, paraffin-embedded tissues that have 
occurred in recent years.  
The heterogeneity of the CRC proteome is considerable, with differences observed 
depending on the colonic tumour site and whether there are metastases or not (392). 
As mentioned, in research by previous groups, there has been heterogeneity seen 
within different sections from the same tumour specimen (392). It may be that the 
key functionality of proteome mapping in CRC is as an adjunct to other biomarkers 
and further research into a step-wise biomarker panel algorithm would be 
welcomed. In particular, a study combining investigation of other proteins that 
show increased stromal activity in cancer tissue may provide a more accurate 
prediction of tumour behaviour.   
7.6 The future of biomarker research in CRC 
Ultimately, there is a need to integrate with other research communities to share 
strategies and data more effectively. Most studies on biomarker research have been 
undertaken by individual investigators, focussed on single biomarker. This limits 
the strength and generalisability of the results. The current lack of approval and 
integration of biomarkers into clinical practice exemplifies the challenges that have 
already been discussed earlier in this chapter.  
Multi-phase analysis is likely to be the most useful way of utilising biomarkers for 
maximum accuracy, i.e. using a set of biomarkers as part of a diagnostic algorithm 
that takes into account other factors too. This type of analysis will occur via more 
collaboration between groups who have access to different equipment and 
expertise.  
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There has already been a move to utilise FIT more broadly in the TWW population. 
It has been suggested that FIT could be incorporated into a more accurate 
assessment model by utilising other patient factors, such as age, sex, BMI and 
smoking status in predicting likelihood of disease (398). This is an interesting idea 
and challenges the population-based approach to most biomarker tests. This concept 
of risk stratification according to patient characteristics should be investigated by 
groups testing new biomarkers at the outset. It could provide a new level of 
understanding of individual patient risk and also prioritise investigations for those 
deemed at higher risk. Although the TWW pathway risk-stratifies patients 
according to symptoms, age is the only other factor taken into account. Yet, as 
described in Chapter Two other factors, such as diet, medication history and 
smoking status have an important effect on CRC risk.  
Multi-institutional teamwork via participation in collaborative studies heightens 
both analytical and clinical validation, for example, proteomeXchange (399) is a 
consortium, which aims to coordinate mass spectrometry proteomics data. It also 
provide the most economical use of patient samples through standardisation of 
methodology which maximises validity and reduces bias.  
Biomarker collaborative networks are in place, such as the National Cancer Institute 
Early Detection Research Network (400). To date, for CRC they have reported on 
13 biomarkers, 12 of which are proteins. None currently have FDA approval, but 
results have the potential to create greater impact when collaboration occurs. 
Furthermore the Human Protein Atlas project has merged a partnership between the 
public and private sector to share data on tissue distribution and subcellular 
localisation of candidate biomarkers (374). Finally, the Global Alliance for 
Genomics and Health (401) is an international collaboration which provides 
information on genomics data sharing within the ethical, legal and technical 
boundaries. This provides reassurance to researchers who want to share knowledge, 
without compromising restrictions set by their local ethics board. 
A forum for sharing experience and expertise on the analytical instruments used in 
both VOC and peptide analysis would be welcomed. This could include advice 
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when sampling errors occur, encourage the sharing of results and most importantly 
serve to form collaborations between groups.  
Earlier this year, a highly instructive position paper by Lawler and colleagues was 
published. This outlines research gaps and provided recommendations to improve 
outcomes in CRC. This paper was written in collaboration with Bowel Cancer UK 
who have recently created a research initiative to guide upcoming researchers to 
concentrated funding in key areas according to need (392). This approach 
demonstrates a progressive strategy for change.  
In regard to biomarkers, ‘Metaphorically speaking, the ‘water’ is everywhere, but 
little is yet ready to drink’ (402). 
7.7 Recommendations and further research 
There is a lack of widely accepted prognostic and predictive biomarkers in CRC. 
Urine-based biomarkers could revolutionise CRC diagnostics with low cost and 
maximum accessibility. 
The work in this thesis could be expanded further in several ways: 
1. A larger-scale study of the detection of CRC from control. Using urinary 
VOCs from the symptomatic population would provide more robust data on 
the performance of a classifier test and would allow examination of the 
VOC profile by tumour stage, which was not possible in this thesis.  
2. Use GC-IMS to identify the individual chemicals excreted as urinary VOCs 
in CRC and explore their role in carcinogenesis. 
3. Explore the significance of the remaining eight proteins that have been 
implicated here in the pathology of CRC and use IHC to map their 
distribution in cancer tissue compared with control. 
7.8 Limitations 
There are several limitations to discuss. Firstly, the systematic review provided high 
quality evidence summarising the literature on the TWW referral pathway but the 
results, where high heterogeneity were found, must be deliberated with caution. 
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Attempts were made to ascertain the cause of heterogeneity but stratification by 
sample size did not result in any significant reduction.  
There must be consideration of the small sample size in both the VOC and peptide 
biomarker studies. The machine learning algorithms that were used to analyse both 
sets of data always risk the possibility of overfitting of the data. This was minimised 
as much as possible by using a cross-validation technique. Research results must 
demonstrate repeatability and be validated on a larger scale before any strong 
conclusions can be drawn.  
7.9 Final remarks 
There needs to be a culture change from the fragmented approach to elucidating 
diagnostics in CRC.  Large scale studies are required to be conducted where 
possible, in conjunction with research partners. This will enhance recruitment 
numbers, but also diversify the patient population to enable more generalisation of 
results. This is likely to happen through shared databases. Such work has already 
started to happen locally, driven by the FAMISHED research group, whereby co-
ordination between four local trusts has already been set-up with preliminary results 
on VOC analysis within the next 12 months.  
In conclusion, the work in this thesis draws together two key themes in the 
improvement of CRC detection. Firstly, purely symptom- based criteria or results 
of a single biomarker test are not the solution to improving CRC detection. Rather 
a biomarker profile that may be derived from multiple origins, e.g. gaseous, protein 
and genomic, should be incorporated into a risk-stratification algorithm of an 
individual patient, based on key characteristics. Secondly, the recommendation that 
collaboration is essential to validate pilot studies on a large scale and to share 
knowledge on methods and novel results.  
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Appendix 
Appendix 1. Search strategy for the systematic review (Chapter Three) 
 Search strategies for Pubmed MEDLINE  
 
1. ((("Referral and Consultation"[Mesh])) AND "Neoplasms"[Mesh]) AND 
"Waiting Lists"[Mesh]  
 
2. ((((fast track OR rapid OR urgent))) AND ("Referral and 
Consultation"[Mesh])) AND "Neoplasms"[Mesh]  
 
3. ((((((outcomes OR survival OR diagnosis OR detection))) AND 
((gastrointestinal OR colorectal OR oesophageal OR stomach OR duodenal OR 
bowel OR rectal OR CRC))) AND ((TWW OR 2WW OR two week wait OR 
rapid access OR fast track OR urgent referral)))) AND cancer  
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Appendix 2. Quality assessment tool for systematic review (Chapter Three) 
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Appendix 3. Table of patient and Study characteristics for abstract data 
CONFERENCE ABSTRACTS 
       
STUDY ID, YEAR Study 
characteristics  
Population 
characteristics 
Intervention groups Outcomes 
          
ADEOSUN, 2002 Design: Prospective % Women: n/s Intervention group (n= 319): All lower GI 
tww referrals within recruitment period 
1. Cancer conversion rate 
 
Study setting: 
Secondary care 
Median age 
(range): n/s 
2. Cancer stage at 
diagnosis 
 
No. of centres: 1 Recruitment dates: 
1 year (date not 
stated) 
3. Other diagnoses made 
 
Length of follow-
up: n/s 
Total Total sample 
size: 319 
    
4. Adherence to targets 
    Total drop-
out/excluded: n/s 
              
ARYAL, 2003 Design: Prospective % Women: 47 Intervention group (n=50): All newly 
diagnoses CRC within time period 
1. Adherence to targets 
 
Study setting: 
Secondary care 
Median age 
(range): mean 70 
(34-97) 
   
 
No. of centres: 1 Recruitment dates: 
April 2001-July 
2002 
Comparator group (n=41): Routine and 
soon referrals 
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Length of follow-
up: n/s 
Total Total sample 
size: 91 
   
    Total drop-
out/excluded: n/s 
      
BROWNING, 2016 Design: 
Retrospective 
% Women: n/s Intervention group (n=624): All lower GI 
tww referrals within the recruitment 
period 
1. Cancer conversion rate 
 
Study setting: 
Secondary care 
Median age 
(range): n/s 
2. Adherence to targets 
 
No. of centres: 1 Recruitment dates: 
March-October 
2015 
    
 
Length of follow-
up: n/s 
Total Total sample 
size: 624 
   
    Total drop-
out/excluded: n/s 
      
CHODHARY, 2005 Design: Not stated % Women: n/s Intervention group (n= 931): All lower GI 
tww referrals within time frame 
1. Cancer conversion rate 
 
Study setting: 
Secondary care 
Median age 
(range): n/s 
   
 
No. of centres: 1 Recruitment dates: 
Aug 2000-Jul 2003 
    
 
Length of follow-
up: n/s 
Total sample size: 
931 
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    Total drop-
out/excluded: n/s 
      
FLASHMAN, 2001 Design: Not stated % Women: n/s Intervention group (n= 284): All lower GI 
referrals within time frame 
1. Cancer conversion rate 
 
Study setting: 
Secondary care 
Median age 
(range): n/s 
   
 
No. of centres: 1 Recruitment dates: 
1st Jul 2000-31st 
Oct 2000 
   
 
Length of follow-
up: n/s 
Total sample size: 
884 
Comparator group (n= 600): Routine 
lower GI referrals 
   
    Total drop-
out/excluded: n/s 
      
GANDY, 2002 Design: Prospective 
observational study 
% Women: n/s Intervention group (n= 543): All lower GI 
referrals within time frame 
1. Cancer conversion rate 
 
Study setting: 
Secondary care 
Median age 
(range): n/s 
2. Adherence to targets 
 
No. of centres: 1 Recruitment dates: 
Jun 2000-Nov 2001 
Comparator group (n=1961): Non- tww 
lower GI referrals 
   
 
Length of follow-
up: n/s 
Total sample size: 
2504 
   
    Total drop-
out/excluded: n/s 
      
HERIOT, 2001 Design: Prospective  % Women: n/s 1. Cancer conversion rate 
280 
 
 
Study setting: 
Secondary care 
Median age 
(range): n/s 
Intervention group (n= 37): All lower GI 
tww referrals within time frame 
   
 
No. of centres: 1 Recruitment dates: 
3 months (directly 
after tww 
implementation) 
       
 
Length of follow-
up: n/s 
Total sample size: 
37 
       
    Total drop-
out/excluded: n/s 
              
MACDONALD, 2002 Design: Prospective  % Women: n/s Intervention group (N= 50): All lower GI 
tww referrals within time frame 
1. Cancer conversion rate 
 
Study setting: 
Secondary care 
Median age 
(range): n/s 
   
 
No. of centres: 1 Recruitment dates: 
Not stated 
       
 
Length of follow-
up: n/s 
Total sample size: 
50 
       
    Total drop-
out/excluded: n/s 
              
MARTIN, 2016 Design: Prospective  % Women: n/s Intervention group (N= 568): All lower GI 
tww referrals within time frame 
1. Adherence to targets 
 
Study setting: 
Secondary care 
Median age 
(range): n/s 
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No. of centres: 1 Recruitment dates: 
3 months (not 
stated which) 
       
 
Length of follow-
up: n/s 
Total sample size: 
568 
       
    Total drop-
out/excluded: n/s 
              
MASHLAD, 2016 Design: 
Retrospective 
% Women: n/s Intervention group (N= 1000): All lower 
GI tww referrals within time frame 
1. Cancer conversion rate 
 
Study setting: 
Secondary care 
Median age 
(range): n/s 
   
 
No. of centres: 1 Recruitment dates: 
01/12/14-
13/7/2015 
       
 
Length of follow-
up: n/s 
Total sample size: 
1000 
       
    Total drop-
out/excluded: n/s 
              
MIHSSIN, 2001 Design: Prospective  % Women: n/s Intervention group (n= 120): All lower GI 
tww referrals within time frame 
1. Cancer conversion rate 
 
Study setting: 
Secondary care 
Median age 
(range): n/s 
2. Adherence to targets 
 
No. of centres: 1 Recruitment dates: 
1st Jul 2000-31st 
Oct 2000 
       
282 
 
 
Length of follow-
up: n/s 
Total sample size: 
120 
       
    Total drop-
out/excluded: n/s 
              
RASHLEIGH, 2016 Design: 
Retrospective 
% Women: n/s Intervention group (n= 2994): All lower 
GI tww referrals within time frame 
1. Cancer conversion rate 
 
Study setting: 
Secondary care 
Median age 
(range): n/s 
 
 
No. of centres: 1 Recruitment dates: 
2011-2014 
       
 
Length of follow-
up: n/s 
Total sample size: 
2994 
       
    Total drop-
out/excluded: n/s 
              
VIETEN, 2002 Design: Prospective  % Women: n/s Intervention group (n= 420): All lower GI 
tww referrals within time frame 
1. Cancer conversion rate 
 
Study setting: 
Secondary care 
Median age 
(range): n/s 
   
 
No. of centres: 1 Recruitment dates: 
Mar 2000-Dec 
2001 
       
 
Length of follow-
up: n/s 
Total sample size: 
420 
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    Total drop-
out/excluded: n/s 
              
WARWICK, 2002 Design: Audit % Women: n/s Intervention group (n=100): All lower GI 
tww referrals within time frame 
1. Cancer conversion rate 
 
Study setting: 
Secondary care 
Median age 
(range):  (32-82) 
   
 
No. of centres: 1 Recruitment dates: 
Not stated 
       
 
Length of follow-
up: n/s 
Total sample size: 
100 
       
    Total drop-
out/excluded: n/s 
              
WOLOWCZYK, 2003 Design: Audit % Women: n/s Intervention group (n= 335): All lower GI 
tww referrals within the three 
recruitment periods 
1. Cancer conversion 
rate 
 
 
Study setting: 
Secondary care 
Median age 
(range):  n/s 
   
 
No. of centres: 1 Recruitment dates: 
Three 3-month 
periods in each 
year from 2000-
2002 
       
 
Length of follow-
up: n/s 
Total sample size: 
342 
       
    Total drop-
out/excluded: 7 
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Appendix 4. Forest plot for cancer conversion rate in the subset (4a) and abstract (4b) 
groups. 
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Appendix 5. Forest plot of cancer conversion rate for full publications split into low (top 
figure) and high (low figure) study population size.  
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